



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

September 2017 Volume: 14 Issue: 3 [www.tjoddergisi.org](http://www.tjoddergisi.org)

## Clinical Investigations

### ► Spectroscopic analysis of embryo culture media

Embriyo kültür medyasının spektroskopik analizi

Ercan Baştu, Uğur Parlutan, Günay Başar, Harika Yumru, Nima Bavili, Fatih Sağ, Sibel Bulgurcuoğlu, Faruk Buyru; İstanbul, Turkey

### ► Micronuclei frequencies in polycystic ovarian syndrome

Polikistik over sendromunda mikronükleus frekansları

Rengin Karataylı, Ayşe Gül Zamani, Kazım Gezginç, Ebru Tuncez, Sema Soysal, Fikriye Karanfil, Aynur Acar, M. Selman Yıldırım; Konya, Şanlıurfa, İstanbul, Turkey

### ► A marker research for ectopic pregnancy

Ektopik gebelik tanısında yeni belirteç araştırması

Özge Kömürcü Karuserci, Mete Gürol Uğur, Özcan Balat, Seyhun Sucu; Gaziantep, Turkey

### ► Severity of intrahepatic cholestasis of pregnancy

Gebeliğin intrahepatik kolestazının ciddiyeti

Çiğdem Yayla Abide, Fisun Vural, Çetin Kılıççı, Evrim Bostancı Ergen, İlter Yenidede, Ahmet Eser, Oya Pekin; İstanbul, Turkey

### ► Third trimester hemoglobin

Üçüncü trimester hemoglobin

Kazibe Koyuncu, Batuhan Turgay, Yavuz Emre Şükür, Bircan Yıldırım, Can Ateş, Feride Söylemez; Ankara, Turkey

### ► Comparison of obstetrics and neonatal outcome

Obstetrik ve neonatal sonuçların karşılaştırılması

Şükrü Gündüz, Serenat Eriş Yalçın, Gökhan Karakoç, Mehmet Özgür Akkurt, Yakup Yalçın, And Yavuz; İstanbul, Isparta, Ankara, Turkey

### ► First trimester anemia prevalence

İlk trimester anemi prevalansı

Mustafa Öztürk, Özlem Öztürk, Mustafa Ulubay, Emre Karşahin, Taner Özgürtaş, Müfit Yenen, Aytekin Aydın, Fahri Fıratlıgil, Serkan Bodur; İstanbul, Ankara, Kocaeli, Turkey

### ► A new technique for uterine prolapse

Uterin prolaps için yeni bir teknik

İlhan Sanverdi, Çetin Kılıççı, Mesut Polat, Enis Özkaya, Sami Gökhan Kılıç, Merve Dizdar, Ateş Karateke; İstanbul, Turkey, Texas, USA





# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## ■ Owner on the behalf of Turkish Society of Obstetrics and Gynecology

Ateş Karateke

## ■ Editorial Manager

Eray Çalışkan

## ■ Past/Honorary Editor in Chief

Hulusi Bülent Zeyneloğlu

## ■ Editor in Chief

Eray Çalışkan

Bahçeşehir University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: [orcid.org/0000-0002-6799-5909](https://orcid.org/0000-0002-6799-5909)

## ■ Editors

**Bariş Ata**

Koç University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: [orcid.org/0000-0003-1106-3747](https://orcid.org/0000-0003-1106-3747)

**Evrin Erdemoğlu**

Süleyman Demirel Faculty of Medicine, Department of Gynecologic Oncology, Isparta, Turkey

ORCID ID: [orcid.org/0000-0002-5993-6968](https://orcid.org/0000-0002-5993-6968)

**Münire Erman Akar**

Akdeniz University Faculty of Medicine, Department of Obstetrics and Gynecology, Antalya, Turkey

ORCID ID: [orcid.org/0000-0002-3656-3787](https://orcid.org/0000-0002-3656-3787)

**Bülent Haydardedeoğlu**

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Adana, Turkey

ORCID ID: [orcid.org/0000-0001-9873-7454](https://orcid.org/0000-0001-9873-7454)

**Fatma Ferda Verit**

İstanbul Süleymaniye Maternity Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: [orcid.org/0000-0002-7104-4532](https://orcid.org/0000-0002-7104-4532)

**Recep Yıldızhan**

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

ORCID ID: [orcid.org/0000-0002-2841-0453](https://orcid.org/0000-0002-2841-0453)

## ■ Section Editors

**Gürkan Bozdağ**

Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

**Cem Çelik**

Bahçeci Umut IVF Center, İstanbul, Turkey

**Emek Doğer**

Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, Kocaeli, Turkey

**Melih Atahan Güven**

Acıbadem Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

**Hatice Banu Kumbak Aygün**

Acıbadem University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

**Özlem Özdeğirmenci**

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

**Kemal Özerkan**

Uludağ University Faculty of Medicine, Department of Obstetrics and Gynecology, Bursa, Turkey

## ■ English Language Editor

**David Chapman**, Winchester, England

## ■ Statistics Editors

**Murat Api**

Zeynep Kamil Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

**Ayşen Telce Boza**

Vehbi Koç Foundation American Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

## ■ Managing Editors

**Rahime Nida Bayık**

Bahçeşehir University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

**Yiğit Çakıroğlu**

Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, Kocaeli, Turkey

**Kemal Güngördük**

Muğla Sıtkı Koçman University Training and Research Hospital, Clinic of Gynecologic Oncology, Muğla, Turkey



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## Editorial Board

### Remzi Abalı

Namık Kemal University Faculty of Medicine, Department of Obstetrics and Gynecology, Tekirdağ, Turkey

### Aris Antsaklis

University of Athens, Department of Obstetrics and Gynecology, Athens, Greece

### Aydın Arıcı

Yale University, Obstetrics, Gynecology and Reproductive Sciences, Connecticut, USA

### Tayfun Bağış

Acıbadem University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

### Başak Baksu

Şişli Etfal Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

### Eralp Başer

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Gynecologic Oncology, Ankara, Turkey

### Ercan Baştu

İstanbul University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

### Orhan Bükülmez

University of Texas Southwestern Medical Center, Reproductive Endocrinology and Infertility, Dallas, USA

### Sabri Cavkaytar

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Gynecologic Oncology, Ankara, Turkey

### Aylin Pelin Çil

Gazi Public Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

### Cem Dane

Haseki Training and Research Hospital, Clinic of Gynecologic Oncology, İstanbul, Turkey

### Berna Dilbaz

Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Infertility and Family Planning, Ankara, Turkey

### Polat Dursun

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Mehmet Sıddık Evsen

Dicle University Faculty of Medicine, Department of Obstetrics and Gynecology, Diyarbakır, Turkey

### Kazım Gezginç

Necmettin Erbakan University Meram Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

### Çağrı Gülümser

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Haldun Güner

Gazi University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Issam Lebbi

Obstetrics and Gynecology and Fertility Private Clinic; Dream Center, Belvedere, Tunisia

### Giampaolo Mandruzzato

Istituto per l'Infanzia, Burlo Garofolo, Obstetrics and Gynecology, Trieste, Italy

### Charles E. Miller

Edward-Elmhurst Health Hospital, Gynecology; Reproductive Endocrinology and Infertility, The Advanced IVF and Gynecologic Surgery Institute, Naperville, USA

### Ceana H. Nezhat

Northside Hospital Director of Training and Education, Nezhat Medical Center, Endometriosis, Minimally Invasive Surgery, Atlanta, USA

### Batuhan Özmen

Ankara University Faculty of Medicine, Cebeci Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

### Abdullah Karaer

İnönü University Faculty of Medicine, Department of Obstetrics and Gynecology, Malatya, Turkey

### Emre Karaşahin

Gülhane Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

### Taner Kasapoğlu

Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

### Esra Buldan Kılıçdağ

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Ali Kolusarı

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

### Zehra Kurdoğlu

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

### Mehmet Anıl Onan

Gazi University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Halil Gürsoy Pala

University of Health Sciences, Tepecik Training and Research Hospital, Clinic of Obstetrics and Gynecology, Perinatology, İzmir, Turkey

### Federico Prefumo

Local Health District of Garda, Obstetrics, Brescia, Italy

### Walid Saghir

Clemenceau Medical Center and Trad Hospital, Clinic of Obstetrics and Gynecology, Lebanon, UAE



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## Emre Seli

Yale University, Obstetrics, Gynecology and Reproductive Sciences,  
Connecticut, USA

## Silber Sherman

Infertility Center of St. Louis at St. Luke's Hospital; Public Health Service,  
Alaska, USA

## Akın Sivaslıoğlu

Ankara Atatürk Training and Research Hospital, Clinic of Obstetrics and  
Gynecology, Ankara, Turkey

## Fatih Şendağ

Acıbadem University Faculty of Medicine, Department of Obstetrics and  
Gynecology, İstanbul, Turkey

## Alper Tanrıverdi

Adnan Menderes University Faculty of Medicine, Department of Obstetrics  
and Gynecology, Aydın, Turkey

## Ömer Lütfi Tapısız

Etlik Zübeyde Hanım Women's Health Training and Research Hospital,  
Clinic of Obstetrics and Gynecology, Ankara, Turkey

## Ebru Tarım

Başkent University Adana Application and Research Center,  
Department of Obstetrics and Gynecology, Adana, Turkey

## Abdülkadir Turgut

İstanbul Medeniyet University Faculty of Medicine,  
Department of Obstetrics and Gynecology, İstanbul, Turkey

## İlgın Türkçüoğlu

İnönü University Faculty of Medicine, Department of Obstetrics and  
Gynecology, Malatya, Turkey

## Mete Gürol Uğur

Gaziantep University Faculty of Medicine, Department of Obstetrics and  
Gynecology, Gaziantep, Turkey

## Serdar Ural

Penn State Hershey Womens Health Obstetrics and Gynecology,  
Maternal-Fetal Medicine, Pennsylvania, USA

## Yaprak Üstün

Zekai Tahir Burak Women's Health Training and Research Hospital,  
Clinic of Obstetrics and Gynecology, Ankara, Turkey

## Yusuf Üstün

Medicana International Ankara Hospital, Clinic of Obstetrics and  
Gynecology, Ankara, Turkey

## Gazi Yıldırım

Yeditepe University Faculty of Medicine, Department of Obstetrics and  
Gynecology, İstanbul, Turkey

## Contact

Çetin Emeç Bulvarı Hürriyet Caddesi Harbiye Mahallesi 1/13 Öveçler, Ankara, Turkey  
Phone: +90 312 481 06 06 Fax: +90 312 481 28 28 E-mail: editor@tjod.org

All rights are reserved. Rights to the use and reproduction, including in the electronic media, of all communications, papers, photographs and illustrations appearing in this journal belong to the Turkish Journal of Obstetrics and Gynecology. Reproduction without prior written permission of part or all of any material is forbidden. The journal complies with the Professional Principles of the Press.

⊗ The paper used to print this journal conforms to ISO 9706: 1994 standard (Requirements for Permanence). The National Library of Medicine suggests that biomedical publications be printed on acid-free paper (alkaline paper). Reviewing the articles' conformity to the publishing standards of the Journal, typesetting, reviewing and editing the manuscripts and abstracts in English and publishing process are realized by Galenos.



**Publisher**  
Erkan Mor

**Publication Director**  
Nesrin Çolak

**Web Coordinators**  
Eren Arsel  
Soner Yıldırım  
Turgay Akpınar

**Graphics Department**  
Ayda Alaca  
Çiğdem Birinci

**Project Coordinators**  
Eda Koluksa  
Hatice Balta  
Lütfiye Ayhan İrtem  
Melis Kuru  
Zeynep Altındağ

**Finance Coordinator**  
Sevinç Çakmak

## Publisher Contact

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1  
34093 İstanbul, Turkey  
Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27  
E-mail: info@galenos.com.tr/yayin@galenos.com.tr  
Web: www.galenos.com.tr

**Printing at:** Bizim Basım Limited Şirketi  
Litros Yolu 2. Matbaacılar Sitesi ZD1 Topkapı, İstanbul, Turkey  
Phone: +90 (212) 709 75 25  
Printing Date: October 2017  
ISSN: 2149-9322 E-ISSN: 2149-9330  
International scientific journal published quarterly.



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## AIMS AND SCOPE

Turkish Journal of Obstetrics and Gynecology (former Türk Jinekoloji ve Obstetrik Derneği Dergisi) is the official peer-reviewed publication of the Turkish Society of Obstetrics and Gynecology and is published quarterly on March, June, September and December.

It is an independent peer-reviewed international journal printed in English language since 2014 September. Manuscripts are reviewed in accordance with "double-blind peer review" process for both referees and authors.

The target audience of Turkish Journal of Obstetrics and Gynecology includes gynecologists, obstetricians, urogynecologists, reproductive medicine specialists, gynecological oncologists and primary care physicians interested in gynecology practice. It publishes original work on all aspects of obstetrics and gynecology. The aim of Turkish Journal of Obstetrics and Gynecology is to publish high quality original research articles. In addition to research articles, reviews, editorials, letters to the editor and case presentations are also published.

The General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, & Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2016, archived at <http://www.icmje.org/>).

- Turkish Journal of Obstetrics and Gynecology is indexed in PubMed Central (PMC), Web of Science-Emerging Sources Citation Index (ESCI), EBSCO, DOAJ, Index Copernicus, Scopus, CINAHL, Google Scholar, Tübitak/Ulakbim Turkish Medical Database, Turk Medline and Türkiye Citation Index.

### Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supporting a greater global exchange of knowledge.

Open Access Policy is based on rules of Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/>. By "open access" to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution and the only role for copyright in this domain, is given to authors to retain control over the integrity of their work and the right to be properly acknowledged and cited.

This journal is licensed under a Creative Commons 3.0 International License.

### Permission

Permission required for use any published under CC-BY-NC license with commercial purposes (selling, etc.) to protect copyright owner and author rights. Reproduction and reproduction of images

or tables in any published material should be done with proper citation of source providing author names; title of the article; journal's name, year (volume) and page numbers of publication; copyright year of the article.

Financial expenses of the journal are covered by Turkish Society of Obstetrics and Gynecology.

### Subscription Information

Turkish Journal of Obstetrics and Gynecology is distributed free of charge to all physicians, specialists in obstetrics and gynecology field. The access to tables of contents, abstracts and full texts of all articles published since 2003 are free to all readers via the journal's webpage "<http://www.tjoddergisi.org>". Visit the journal's home pages for details of the aims and scope and instruction to authors. Manuscripts can only be submitted electronically through the Journal Agent website (<http://journalagent.com/tjo/>) after creating an account. This system allows online submission and review.

### Instructions for Authors

Instructions for authors page of the journal is available in the journal content and at [www.tjoddergisi.org](http://www.tjoddergisi.org)

### Disclaimer

The statements and opinions expressed contained in the articles of the Turkish Journal of Obstetrics and Gynecology are solely those of the individual authors and contributors not of the Turkish Society of Obstetrics and Gynecology or Galenos Yayınevi.

### Advertising

Enquiries concerning advertisements should be addressed to Editorial Office or Publisher:

### Editorial Office

Editor-in-Chief: Eray Çalışkan, M.D.

Address : Çetin Emeç Bulvarı Hürriyet Caddesi Harbiye Mahallesi 1/13 Öveçler, Ankara - Turkey

Phone : +90 (312) 481 06 06

Fax : +90 (312) 481 28 28

E-mail : [info@tjod.org](mailto:info@tjod.org)

### Publisher

Galenos Yayınevi Tic. Ltd. Şti.

Address : Molla Gürani Mah. Kaçamak Sk. No: 21/1 34093 Fındıkzade, İstanbul - Turkey

Phone : +90 212 621 99 25

Fax : +90 212 621 99 27

E-mail : [info@galenos.com.tr](mailto:info@galenos.com.tr)

The journal is printed on acid-free paper.



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## INSTRUCTIONS FOR AUTHORS

The "Turkish Journal of Obstetrics and Gynecology" is the official publication of the Turkish Society of Obstetricians and Gynecologists. The journal is published quarterly (March, June, September and December) in English and publishes original peer-reviewed articles, reviews, case reports and commentaries in the fields of gynecology, gynecologic oncology, endocrinology and reproductive medicine and obstetrics. The journal gives publication priority to original research articles over case reports. Reviews are considered for publication only if they are prepared by authors who have at least three published manuscripts in international peer-reviewed journals on the topic of the review and these studies should be cited in the review. Otherwise only invited reviews will be considered for peer-review from qualified experts in the area.

The "Turkish Journal of Obstetrics and Gynecology" is a peer-reviewed journal and adheres to the highest ethical and editorial standards. The editors also adhere to the Committee on Publications Ethics (COPE) recommendations (<http://publicationethics.org>).

The journal should be abbreviated as Turk J Obstet Gynecol when referenced.

Turkish Journal of Obstetrics and Gynecology does not charge any article submission or processing charges.

Turkish Journal of Obstetrics and Gynecology is indexed in PubMed Central (PMC), Web of Science-Emerging Sources Citation Index (ESCI), EBSCO, DOAJ, Index Copernicus, Scopus, CINAHL, Google Scholar, Tübitak/Ulakbim Turkish Medical Database, Turk Medline and Türkiye Citation Index.

### Submission of Manuscripts

Turkish Journal of Obstetrics and Gynecology has specific instructions and guidelines for submitting articles. Those instructions and guidelines are readily available on the submission service site. Submit all manuscripts through the journal's web page at [www.tjoddergisi.org](http://www.tjoddergisi.org). New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre. Download the Instructions to Authors for detailed notes on how to prepare your manuscript.

The ORCID (Open Researcher and Contributor ID) number of the correspondence author should be provided while sending the manuscript. A free registration can be done at <http://orcid.org>.

Manuscripts submitted via any other medium will not be evaluated. During the submission please make sure to provide all requested information to prevent any possible delays in the evaluation process. Only those submitted articles are not currently being considered by another journal, or have not been previously published, will be considered for publication in Turkish Journal of Obstetrics and Gynecology. The submitted articles are firstly evaluated over by the non-biased editors. The articles that meet the originality and other requirements of the journal are peer-reviewed by the national or international referees. Acceptance for publication is based on significance, novelty, and quality of the article.

Authors who have any queries regarding the submission process can contact the journal's editorial office:

Çetin Emeç Bulvarı Harbiye Mahallesi Hürriyet Caddesi 1/3 Öveçler/Ankara.

Phone number: +90 (312) 481 06 06

E-mail: [editor@tjod.org](mailto:editor@tjod.org)

### Editorial Policies

All manuscripts will be evaluated for their scientific contribution, originality and content by the editorial board. Only those submitted articles are not currently being considered by another journal, or have not been previously published, will be considered for publication in Turkish Journal of Obstetrics and Gynecology. Authors are responsible for the accuracy of the data presented in their manuscript. The journal retains the right to make appropriate changes on the grammar and language of the manuscript when needed. When suitable the manuscript will be sent to the corresponding author for revision. The manuscript, if accepted for publication, will become the property of the journal and copyright will be taken out in the name of the journal.

### Peer-review

Turkish Journal of Obstetrics and Gynecology is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. These manuscripts then sent for external peer-review, the Editor in Chief assigns Associate Editor. The Associate Editor sends the manuscript to the 3 reviewers internal and external reviewers. The reviewers must review the manuscript in 21 days. Associate Editor recommends decision based on the reviewers' recommendations and sends the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality and reviewer recommendations. If there are any conflicting recommendation of reviewers, Editor-in-Chief can assign a new reviewer. The scientific board guiding the selection of the papers to be published in the journal consists of elected experts of the journal and if necessary, selected from national and international experts in the relevant field of research. All manuscripts are reviewed by the editor, section associate editors and at least three internal and external expert referees. All research articles undergo review by statistics editor as well.

Full text of all articles can be downloaded at the web site of the journal: [www.tjoddergisi.org](http://www.tjoddergisi.org)

### Authorship

The role of authorship in Turkish Journal of Obstetrics and Gynecology is reserved for those individuals who meet the criteria recommended by the International Committee of Medical Journal Editors (ICMJE; <http://www.icmje.org>). Describe each authors' contribution by using ICMJE's criteria: substantial contributions to the conception or design; the acquisition, analysis, or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the study in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The statement about the authors' contributions should be placed in the cover letter. All persons who contributed to the work, but not sufficiently to be authors, must be acknowledged.





# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## INSTRUCTIONS FOR AUTHORS

### Cover Letter

Cover letter to the editors addressing the following points:

- The authors' intent to submit solely to Turkish Journal of Obstetrics and Gynecology.
- Verification that the manuscript is not under consideration elsewhere, and indication from the authors that it will not be submitted elsewhere until a final decision is made by the editors of Turkish Journal of Obstetrics and Gynecology.
- The declaration of transparency from the corresponding author.
- Clinical trial registration, if applicable.
- Institutional review board (IRB) approval or exemption.
- Informed consent.
- Any explanations related to reporting guidelines.
- The statement about the authors' contributions.

### Preparation of Manuscripts

The "Turkish Journal of Obstetrics and Gynecology" follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" (International Committee of Medical Journal Editors - <http://www.icmje.org/>). Upon submission of the manuscript, authors are to indicate the type of trial/research and provide the checklist of the following guidelines when appropriate:

CONSORT statement for randomized controlled trials (Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (<http://www.consort-statement.org/>),

PRISMA for preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (<http://www.prisma-statement.org/>),

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al, for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (<http://www.stard-statement.org/>),

STROBE statement-checklist of items that should be included in reports of observational studies (<http://www.strobe-statement.org/>),

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).

CARE guidelines are designed to increase the accuracy, transparency, and usefulness of case reports. (Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.) (<http://www.care-statement.org/>)

### Human and Animal Studies

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards described in an appropriate version of the 1964 Declaration of Helsinki, as revised in 2013 (<http://www.wma.net/en/30publications/10policies/b3/>). It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. In case of usage of any image media that potentially can expose patients' identity requires obtaining permission for publication from the patients or their parents/guardians. Experimental animal studies should be presented with the disclosure of the appropriateness to the institutional/national/international ethical guides on care and use of laboratory animals.

Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) were followed, as well as specific national laws where applicable.

The editors reserve the right to reject manuscripts that do not comply with the above mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above mentioned requirements.

Authors must provide statement on the absence of conflict of interests between authors and provide authorship contributions and declare if any financial/material support.

### Copyright

The author(s) transfer(s) the copyright to his/her article to the Turkish Journal of Obstetrics and Gynecology effective if and when the article is accepted for publication. The copyright covers the exclusive and unlimited rights to reproduce and distribute the article in any form of reproduction (printing, electronic media or any other form); it also covers translation rights for all languages and countries. For U.S. authors the copyright is transferred to the extent transferable.

After receiving and accept decision for publication, submissions must be accompanied by the "Copyright Transfer Statement". The form is available for download on the journal's manuscript submission and evaluation site. The copyright transfer form should be signed by all contributing authors and a scanned version of the wet signed document should be submitted.

### Manuscript Structure

All manuscripts must be submitted as Microsoft Word (.doc or .docx) files. All manuscript pages (including references, tables, and figure legends) must be double-spaced. Use a standard, 12-point typeface such as Times New Roman. Top, bottom, and side margins should be set at 1 inch. Authors must include the following in the manuscript file:

#### Title Page

A separate title page should list;

-The manuscript title, which should contain no more than a total of 100 characters (counting letters and spaces) and should not be declarative; do not use abbreviations or commercial names in the title.

## INSTRUCTIONS FOR AUTHORS

- A short title of no more than 50 characters, including spaces, for use as a running foot.
- All author name(s), institutional, corporate, or commercial affiliations, and up to two major degree(s).
- Corresponding author's name, address, telephone (including the mobile phone number), fax numbers and e-mail address (the corresponding author will be responsible for all correspondence and other matters relating to the manuscript).

### Precis

The precis is a one-sentence synopsis of no more than 30 words that describes the basic findings of the article. Precis sample can be seen below:

'Using a 45 point questionnaire, we have evaluated the trend of Robotic surgery training in the gynecologic surgery fellowship programs across the nation.'

### Abstract

All manuscripts should be accompanied by an abstract. All information in the abstract should be consistent with the information in the text, tables, or figures. Avoid use of commercial names in the abstract. Original research reports should have a structured abstract of no more than 250 words, using the following headings:

- Objective: Main question, objective, or hypothesis (single phrase starting with, for example, "To evaluate..." or "To estimate." [never start with "To determine."]).
- Materials and Methods: Study design, participants, outcome measures, and in the case of a negative study, statistical power.
- Results: Measurements expressed in absolute numbers and percentages, and when appropriate indicate relative risks or odds ratios with confidence intervals and level of statistical significance; any results contained in the abstract should also be presented in the body of the manuscript, tables, or figures.
- Conclusion: Directly supported by data, along with clinical implications.

Authors from Turkey or Turkish speaking countries are expected to submit a Turkish abstract including subheadings such as "Amaç, Gereç ve Yöntemler, Bulgular, Sonuç". The abstract of Authors whose native language is not Turkish will be provided free of charge translation services into Turkish language.

A structured abstract is not required with review articles and case reports.

### Keywords

Below the abstract provide 3 to 5 keywords. Abbreviations should not be used as keywords. Keywords should be picked from the Medical Subject Headings (MeSH) list ([www.nlm.nih.gov/mesh/MBrowser.html](http://www.nlm.nih.gov/mesh/MBrowser.html)).

Turkish abstracts should have keywords "Anahtar Kelimeler" picked from [www.atifdizini.com](http://www.atifdizini.com) under "Türkiye Bilim Terimleri" link.

Several types of articles can be submitted for publication in Turkish Journal of Obstetrics and Gynecology: Original research, case reports,

systematic reviews, current commentaries, procedures and instruments, and letters. Stated word counts and page limits were shown in Table 1. Copyright transfer forms, the cover letter, and figures do not contribute to the page limits.

Table 1. Manuscript length at a glance

Article type	Abstract Length	Manuscript Word Count*	Maximum Number of Authors	Maximum Number of References <sup>†</sup>
Original Research	250 words	5,500 words (~22 pages) <sup>‡</sup>	NA	30
Case report	150 words	2,000 words (~8 pages)	4	8
Systematic review	300 words	6,250 words (~25 pages)	4	60
Current commentary	250 words	3,000 words (~12 pages)	4	12
Procedure and Instruments	200 words	2,000 words (~8 pages)	4	10
Letters	NA	350 words	4	5

\*Manuscript length includes all pages in a manuscript (ie, title page, abstract, text, references, tables, boxes, figure legends, and appendices). <sup>‡</sup>Suggested limit. <sup>†</sup>The Introduction should not exceed 250 words. <sup>‡</sup>approximately; NA, not applicable.

Original researches should have the following sections;

### Introduction

State concisely the purpose and rationale for the study and cite only the most pertinent references as background. Avoid a detailed literature review in this section.

### Materials and Methods

Describe the research methodology (the patients, experimental animals, material and controls, the methods and procedures utilized, and the statistical method(s) employed) in sufficient detail so that others could duplicate the work. Identify methods of statistical analysis and when appropriate, state the basis (including alpha and beta error estimates) for their selection. Cite any statistical software programs used in the text. Express p values to no more than two decimal places. Indicate your study's power to detect statistical difference.

Address "IRB" issues and participants informed consent as stated above, the complete name of the IRB should be provided in the manuscript. State the generic names of the drugs with the name and country of the manufacturers.

### Results

Present the detailed findings supported with statistical methods. Figures and tables should supplement, not duplicate the text; presentation of data in either one or the other will suffice. Authors should report outcome data as both absolute and relative effects since information presented this way is much more useful for clinicians. Actual numbers and percentages should be given in addition to odds ratios or relative risk. When appropriate, number needed to treat for benefits (NNTb) or harm (NNTh) should be supplied. Emphasize only your important observations; do not compare your observations with those of others.





# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## INSTRUCTIONS FOR AUTHORS

Such comparisons and comments are reserved for the discussion section.

### Discussion

Begin with a description of what your study found in relation to the purpose or objectives as stated in the Introduction. State the importance and significance of your findings to clinicians and actual patient care but do not repeat the details given in the Results section. Limit your opinions to those strictly indicated by the facts in your report. Compare your finding with previous studies with explanations in cases where they differ, although a complete review of the literature is not necessary.

### Study Limitations

Provide information on the limitations of the study. No new data are to be presented in this section. A final summary is not necessary, as this information should be provided in the abstract and the first paragraph of the Discussion. Although topics that require future research can be mentioned, it is unnecessary to state, "Further research is needed."

### Conclusion

The conclusion of the study should be highlighted. The study's new and important findings should be highlighted and interpreted.

### Conflict of Interest

Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research.

The main text of case reports should be structured with the following subheadings:

Introduction, Case Report, Discussion and References.

### References

References are numbered (Arabic numerals) consecutively in the order in which they appear in the text (note that references should not appear in the abstract) and listed double-spaced at the end of the manuscript. The preferred method for identifying citations in the text is using within parentheses. Use the form of the "Uniform Requirements for Manuscripts" (<http://www.icmje.org/about-icmje/faqs/icmje-recommendations/>). If number of authors exceeds seven, list first 6 authors followed by et al.

Use references found published in peer-reviewed publications that are generally accessible. Unpublished data, personal communications, statistical programs, papers presented at meetings and symposia, abstracts, letters, and manuscripts submitted for publication cannot be listed in the references. Papers accepted by peer-reviewed publications but not yet published ("in press") are not acceptable as references.

Journal titles should conform to the abbreviations used in "Cumulated Index Medicus".

### Examples

Journals; Zeyneloglu HB, Onalan G. Remedies for recurrent implantation failure. *Semin Reprod Med* 2014;32:297-305.

Book chapter; Ayhan A, Yenen MC, Dede M, Dursun P, Gultekin M. How to Manage Pre-Invasive Cervical Diseases? An Overview. In: Ayhan A, Gultekin M, Dursun P, editors. *Textbook of Gynaecological Oncology*. Ankara, Turkey: Gunes Publishing; 2010. p. 28-32.

Book; Arici A, Seli E. Non-invasive Management of Gynecologic Disorders. In: Arici A, Seli E (eds). London: Informa Healthcare; 2008.

### Tables and Figures

Tables should be included in the main document after the reference list. Color figures or gray-scale images must be at minimum 300 DPI resolutions. Figures should be submitted in ".tiff", ".jpg" or ".pdf" format and should not be embedded in the main document. Tables and figures consecutively in the order they are referred to within the main text. Each table must have a title indicating the purpose or content of the table. Do not use internal horizontal and vertical rules. Place explanatory matter in footnotes, not in the heading. Explain all abbreviations used in each table in footnotes. Each figure must have an accompanying descriptive legend defining abbreviations or symbols found in the figure. If photographs of people are used, the subjects must be unidentifiable and the subjects must have provided written permission to use the photograph. There is no charge for color illustrations.

### Units of Measurement and Abbreviations

Units of measurement should be in Système International (SI) units. Abbreviations should be avoided in the title. Use only standard abbreviations. If abbreviations are used in the text, they should be defined in the text when first used.

### Revisions

Revisions will be sent to the corresponding author. Revisions must be returned as quickly as possible in order not to delay publication. Deadline for the return of revisions is 30 days. The editorial board retains the right to decline manuscripts from review if authors' response delays beyond 30 days. All reviewers' comments should be addressed a revision note containing the author's responses to the reviewers' comments should be submitted with the revised manuscript. An annotated copy of the main document should be submitted with revisions. The Editors have the right to withdraw or retract the paper from the scientific literature in case of proven allegations of misconduct.

### Accepted Articles

Accepted articles are provided with a DOI number and published as ahead of print articles before they are included in their scheduled issue.

### Journal and Society Web sites:

[www.tjod.org](http://www.tjod.org) (Turkish Society of Obstetrics and Gynecology)

[www.tjoddergisi.org](http://www.tjoddergisi.org) (Turkish Journal of Obstetrics and Gynecology)

## CONTENTS

### Clinical Investigations

- 145** Spectroscopic analysis of embryo culture media for predicting reproductive potential in patients undergoing *in vitro* fertilization  
*In vitro* fertilizasyon hastalarının üreme potansiyelini belirlemede embriyo kültür medyasının spektroskopik analizle incelenmesi  
Ercan Baştu, Uğur Parlatan, Günay Başar, Harika Yumru, Nima Bavili, Fatih Sağ, Sibel Bulgurcuoğlu, Faruk Buyru; İstanbul, Turkey
- 151** Micronuclei frequencies in lymphocytes and cervical cells of women with polycystic ovarian syndrome  
*Polikistik over sendromlu kadınlarda lenfositler ve servikal hücrelerde mikronükleus frekansları*  
Rengin Karataylı, Ayşe Gül Zamani, Kazım Gezginc, Ebru Tuncez, Sema Soysal, Fikriye Karanfil, Aynur Acar, M. Selman Yıldırım; Konya, Şanlıurfa, İstanbul, Turkey
- 156** No increase in free fetal DNA level in ectopic pregnancy: A preliminary study  
*Ektopik gebelik tanısında serbest fetal DNA'nın yeri: Ön hazırlık çalışması*  
Özge Kömürcü Karuserci, Mete Gürol Uğur, Özcan Balat, Seyhun Sucu; Gaziantep, Turkey
- 160** Can we predict severity of intrahepatic cholestasis of pregnancy using inflammatory markers?  
*Enflamatuvar belirteçleri kullanarak gebelik kolestazının ciddiyeti öngörülebilir mi?*  
Çiğdem Yayla Abide, Fisun Vural, Çetin Kılıççı, Evrim Bostancı Ergen, İlder Yenidede, Ahmet Eser, Oya Pekin; İstanbul, Turkey
- 166** Third trimester anemia extends the length of hospital stay after delivery  
*Üçüncü trimesterdeki anemi doğum sonrası hastanede kalış süresini arttırmaktadır*  
Kazibe Koyuncu, Batuhan Turgay, Yavuz Emre Şükür, Bircan Yıldırım, Can Ateş, Feride Söylemez; Ankara, Turkey
- 170** Comparison of bupivacaine and ropivacaine in combination with fentanyl used for walking epidural anesthesia in labor  
*Yürüyen epidural anesteziye fentanil ile kombine kullanılan bupivakain ve ropivakainin karşılaştırılması*  
Şükrü Gündüz, Serenat Eriş Yalçın, Gökhan Karakoç, Mehmet Özgür Akkurt, Yakup Yalçın, And Yavuz; İstanbul, Isparta, Ankara, Turkey
- 176** Anemia prevalence at the time of pregnancy detection  
*Gebeliğin tanısı ile birlikte saptanan anemi prevalansı*  
Mustafa Öztürk, Özlem Öztürk, Mustafa Ulubay, Emre Karaşahin, Taner Özgürtaş, Müfit Yenen, Aytekin Aydın, Fahri Fıratlıgil, Serkan Bodur; İstanbul, Ankara, Kocaeli, Turkey
- 181** A new operation technique for uterine prolapse: Vaginally-assisted laparoscopic sacrohysteropexy  
*Uterin prolaps için yeni bir operasyon tekniği: Vajinal asiste laparoskopik sakrohisteropeksi*  
İlhan Sanverdi, Çetin Kılıççı, Mesut Polat, Enis Özkaya, Sami Gökhan Kılıç, Merve Dizdar, Ateş Karateke; İstanbul, Turkey, Texas, USA

### Case Reports

- 187** Isolated tubal torsion: Successful preoperative diagnosis of five cases using ultrasound and management with laparoscopy  
*İzole tubal torsiyon: Beş olgunun ultrasonografi ile başarılı preoperatif tanısı ve laparoskopi ile yönetimi*  
Erdem Fadiloğlu, Rıza Dur, Erhan Demirdağ, Çağatayhan Öztürk, Şeyma Fadiloğlu, Metin Kaplan, Ömer Lütfi Tapısız; Ankara, Turkey
- 191** Laparoscopic repair of ureter damaged during laparoscopic hysterectomy: Presentation of two cases  
*Laparoskopik histerektomide yaralanan üreterin laparoskopik tamiri: İki olgunun sunumu*  
Murat Api, Ayşen Boza, Semra Kayataş, Barış Boza; İstanbul, Turkey
- 195** Ovarian metastasis of Müllerian adenosarcoma of the cervix with sarcomatous overgrowth  
*Serviksin sarkomatöz gelişim gösteren Müllerian adenosarkomunda over metastazi*  
Meral Koyuncuoğlu, Bahadır Saatli, Nuri Yıldırım; İzmir, Turkey



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## LETTER FROM THE PRESIDENT

Dear Colleagues,

We have learned with great pleasure and gratification that our journal, the Turkish Journal of Obstetrics and Gynecology, has been accepted to PubMed, one of the most respected and renowned medical indexes. I should sincerely emphasize that the tireless struggle and devoted endeavour of the journal editorial board and the editorial manager has an undisputed role in this success. Nevertheless, at least as precious as those efforts, is the role of the invaluable scientific contributions of obstetrics and gynecology physicians to our journal, which cannot go unseen in this achievement. In this context, on behalf of the Turkish Society of Obstetrics and Gynecology board, I congratulate the obstetricians and gynecologists, who contribute their scientific publications to our journal as well as the editorial board and the editorial manager of the Turkish Journal of Obstetrics and Gynecology, and thank them all for their efforts.

Even so, in order for our journal to achieve an even better position and to become a world-renowned and respected women's health journal and so that our country can play a greater role in the scientific environment, we still feel the need for the invaluable scientific support of our esteemed obstetrics and gynecology physicians. We believe that the high-quality papers that our colleagues will submit and the references they make to the articles published in our journal will carry it upwards in the list of women's health journals in the coming years.

I hope that our scientific progress will further accelerate and I would like to remind you about the 16<sup>th</sup> National Gynecology and Obstetrics Congress, which will be held in Antalya on 9-13 May 2018, in order for you to arrange your schedules accordingly, looking forward to being together once again for a great congress.

Sincerely,

Ateş Karateke, Prof. MD

President of TSOG



# TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

## EDITORIAL

Dear Colleagues,

I am glad to announce that our journal "Turkish Journal of Obstetrics and Gynecology" is now indexed in "PubMed Central". It's been 13 years since the publication of the first issue and our journal is evolving and progressing. This is another milestone in the journey of a journal to become an international scientific venue. With the growing numbers of young scientists we will inevitably be in a highly ranked position among the relatively young journals.

Turkish Society of Obstetrics and Gynecology is launching a campaign to decrease preventable maternal deaths in order to reach the goal of less than 10 per 100.000 live births and to decrease the primary cesarean section rate by 10% a year. In order to help our colleagues to improve their capabilities to prevent obstetric hemorrhages, a fresh cadaveric course was held in İstanbul. A total of 150 specialists were trained on the management of obstetric hemorrhage, sepsis, disseminated intravascular coagulation, surgical anatomy, uterine devascularization surgeries to prevent bleeding, tamponades, catheter applications, uterine packing sutures on models and fresh cadavers. Organization of obstetric emergency teams is going on. In order to support this action we are calling for manuscripts conducted on the area of preventing maternal deaths and decreasing cesarean deliveries.

I hope this action will find supporters among you.

**Best wishes,**

**Eray Çalışkan, Editor**



# Spectroscopic analysis of embryo culture media for predicting reproductive potential in patients undergoing *in vitro* fertilization

## *In vitro* fertilizasyon hastalarının üreme potansiyelini belirlemede embriyo kültür medyasının spektroskopik analizle incelenmesi

Ercan Baştu<sup>1</sup>, Uğur Parlattan<sup>2</sup>, Günay Başar<sup>2</sup>, Harika Yumru<sup>1</sup>, Nima Bavili<sup>2</sup>, Fatih Sağ<sup>1</sup>, Sibel Bulgurcuoğlu<sup>1</sup>, Faruk Buyru<sup>1</sup>

<sup>1</sup>Istanbul University Istanbul Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul, Turkey

<sup>2</sup>Istanbul Technical University Faculty of Science and Letter, Department of Physics Engineering, Istanbul, Turkey

### Abstract

**Objective:** To predict the reproductive potential of embryos via Raman spectroscopy evaluation of the spent culture media as well as with a conventional morphologic evaluation.

**Materials and Methods:** Women of reproductive age (n=31) who were treated for unexplained infertility and scheduled for single embryo transfer were invited to participate in this prospective study. After the embryos were removed from the culture, the spent culture media were stored at -80 °C after snap-freezing in liquid nitrogen.

**Results:** Fifteen patients were clinically pregnant, and 16 patients were clinically non-pregnant. Clinical pregnancy was predicted using Raman spectroscopy in 93% (14/15) of clinically pregnant patients, and in 62.5% (10 out of 16) of clinically non-pregnant patients. The sensitivity of the Raman spectroscopic analysis was 93% and the specificity was 62.5%.

**Conclusion:** Metabolomic evaluation of spent embryo culture media is an emerging technique with promising objective results. However, there is clearly room for improvement.

**Keywords:** *In vitro* fertilization, embryo culture media, morphology, Raman spectroscopy

### Öz

**Amaç:** Embriyoların üreme potansiyelini belirlemede kültür medyasını Raman spektroskopik analizle ve süregelen morfolojik değerlendirmeye karşılaştırılmasıdır.

**Gereç ve Yöntemler:** Açıklanamayan infertilite tedavisine göre ve tek embriyo transferi olacak 31 üreme yaşındaki kadın bu prospektif çalışmaya katıldı. Embriyolar kültürden alındıktan sonra, kültür medyası -80 °C'de likit nitrojenle donduruldu.

**Bulgular:** On beş hastada klinik gebelik bulunmuşken, 16 hastada gebelik bulunmamıştır. Klinik gebelik tahmini Raman spektroskopisiyle %93 (14/15), gebe olmayan hastalarda ise %62,5 (10/16) olmuştur. Raman spektroskopik analizin sensitivitesi %93, spesifitesi %62,5 şeklindedir.

**Sonuç:** Embriyo kültür medyasının metabolomik değerlendirmesi objektif sonuçlar doğurabilir. Öte yandan metodun geliştirilmesi ihtiyacı gerekmektedir.

**Anahtar Kelimeler:** *In vitro* fertilizasyon, embriyo kültür medyası, morfoloji, Raman spektroskopisi

Address for Correspondence/Yazışma Adresi: Ercan Baştu, MD,

Istanbul University Istanbul Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul, Turkey

Phone: +90 532 413 41 95 E-mail: ercan.bastu@istanbul.edu.tr ORCID ID: orcid.org/0000-0003-0810-6195

Received/Geliş Tarihi: 26.01.2017 Accepted/Kabul Tarihi: 06.09.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.



**PRECIS:** Metabolomic evaluation of spent embryo culture media is an emerging technique with promising objective results; however, there is clearly room for improvement.

## Introduction

The identification of embryos with the highest potential to implant and establish ongoing pregnancy is the primary aim in human-assisted reproduction. This task is undertaken every day by embryologists worldwide during the treatment of couples that wish to conceive through in vitro fertilization (IVF). The optimal scenario is the transfer of a single embryo that gives rise to a singleton pregnancy. However, even in patients with good prognosis, namely patients aged under 35 years, implantation and the subsequent success rates are well below the expectations of infertile couples undergoing IVF treatment. Therefore, multiple embryo transfer has become clinical routine in IVF clinics worldwide to increase the rate of pregnancies. This approach has consequences such as an increased rate of multiple gestations, which are regarded as high-risk pregnancies<sup>(1)</sup>. Furthermore, the treatment process may cause considerable emotional, financial, and physical distress for couples undergoing IVF treatment because nearly two out of every three IVF cycles do not result in pregnancy<sup>(2)</sup>. The current limitations in the determination of embryos that have the highest implantation potential probably contribute to the low rates of pregnancy during IVF treatment. Hence, improvement of embryo selection has been a “hot research topic” since the beginning of IVF.

Morphology has been a very obvious parameter to assess embryos because it provides a chance for their evaluation from the oocyte stage, all the way to the blastocyst stage. Thus, in the first era of IVF, there was a number of studies that evaluated this parameter and associated morphology with IVF success rates. On the other hand, some researchers stated that the slight increase in pregnancy rates during IVF treatment was most likely a result of better practice in the laboratory than morphologic evaluation<sup>(3)</sup>. Due to the limitations of morphologic evaluation, several researchers investigated adjunctive non-invasive approaches for the assessment of the embryo, such as metabolic parameters<sup>(4)</sup>.

Raman spectroscopy is a vibrational technique that has been used in the field of metabolomics, as well as other techniques such as near-infrared (NIR) spectroscopy, mass spectroscopy, and various others. Raman techniques use a laser to gather vibrational strokes or anti-strokes together with vibrations from the analyzed molecules. Laser-illuminated samples produce scattered light. The amount of light absorbed at a number of vibrational frequencies is then calculated. In the field of metabolomics, one advantage of the Raman technique is that evaluation of liquid samples is straightforward because water gives out weak signals.

The purpose of the present study was to predict the reproductive potential of embryos through Raman spectroscopy evaluation

of the spent culture media, as well as conventional morphologic evaluation. We hypothesized that adding Raman spectroscopy to morphologic evaluation would predict better results than those of conventional morphologic evaluation alone.

## Materials and Methods

### Patients

Women of reproductive age (18 to 35 years) who were treated for unexplained infertility in the Infertility Clinic of İstanbul University Faculty of Medicine (İstanbul, Turkey) were invited to participate in this prospective study. Inclusion criteria for the diagnosis of unexplained infertility were as follows: (1) duration of infertility for >1 year; (2) confirmation of regular menstrual cycle, (2) hysterosalpingogram-confirmed presence of normal tubal patency; (3) normal day-3 hormonal panel of follicle-stimulating hormone and estradiol, and total antral follicle count more than 7 (4); normal semen analysis results according to the 2010 World Health Organization criteria<sup>(5)</sup>; (5) planned to undergo IVF/intracytoplasmic sperm injection (ICSI) treatment; and (6) planned to undergo day-3 embryo transfer. This study was approved by Ethics Committee of İstanbul University Faculty of Medicine (2015) and informed consent was received from all participants.

All patients received the same ovulation stimulation and monitoring protocols as previously described<sup>(5)</sup>. In brief, the patients underwent ovarian stimulation with a conventional gonadotropin-releasing hormone antagonist protocol.

After oocyte retrieval, cumulus complexes were isolated in the embryology laboratory and mechanically stripped. Afterwards, oocytes were put into separate 50 mL of culture (Sagew, Quinn's advantage protein plus cleavage medium, Cooper Surgical, Inc., Trumbull, CT, USA). The same culture was used in all embryos. Conventional ICSI was used in all patients according to our laboratory's process. After the presence of fertilization was identified on day-2 and day-3, as assessed by morphologic evaluation, developed embryos were put into separate 50 mL of culture until the cleavage stage. Throughout the study, standard tri-gas incubators that provided a 5% oxygen environment were used and all embryos were cultured in separate media.

### Morphologic evaluation

Grade-1 embryos were transferred and analyzed according to the morphologic classification as established by Depa-Martynow et al.<sup>(6)</sup>. Grade-1 was considered as embryos with  $\geq 7$  blastomeres similar in shape and with <20% of cytoplasmic fragmentation.

### End-point

Clinical pregnancy was the primary outcome of the study, which was defined as the presence of a fetal heartbeat using vaginal ultrasound at 6 weeks of amenorrhea.

## Study design

After the embryos were removed from the culture and prepared for transfer, the spent culture media were loaded into separate labeled cryovials (Nunc Intermed, Kamstrup, Denmark), and stored at  $-80^{\circ}\text{C}$  after snap-freezing in liquid nitrogen. Cryovials were shipped on dry ice to the Raman Spectroscopy Laboratory at Istanbul Technical University (Istanbul, Turkey).

## Raman spectroscopy

The thirty-one samples of 31 patients that were shipped to the Raman Spectroscopy Laboratory for measurement were kept at room temperature for a few minutes and then poured into custom-designed disk-shaped sample cells. The liquid samples were filled in a volumetric cylinder with a diameter of 1.6 mm and length of 6 mm. These cells allowed small volumes with a reservoir of 30  $\mu\text{L}$  and consequently resulted in a long optical path for Raman scattering. The samples were exposed to a single longitudinal mode, 785 nm diode laser, whose output power was 100 mW. Inelastically-scattered photons were collected with a lens (scattering in 1800 geometry) and then focused into the 100- $\mu\text{m}$  entrance slit of a spectrograph with another lens. The inserted photons were dispersed with a grating (600 l/mm) according to the wavelengths in the spectrograph and were imaged on a charge-coupled device (CCD) camera.

The spectra to be formed on the CCD camera, which were the multiple images of the entrance slit, were registered. Measurements were performed sequentially over 10 minutes. After a cleaning procedure, a distilled water spectrum was measured as background before every measurement in the same sample cell. A toluene spectrum was measured after every spent culture measurement in order to check laser stability and to have a reference for Raman calibration.

## Spectral and statistical analyses


The Raman spectra were preprocessed using homemade software written on MATLAB and Simulink software (Mathworks, Natick, MA, USA). The spectral analysis preprocess steps are summarized in Figure 1. In brief, the spectra were first cleaned of unwanted cosmic ray peaks. After calibration of the wavenumbers, water spectra were subtracted from the embryo culture measurements as background correction. The residual fluorescence background profile of each spectrum was corrected using a third order polynomial and normalized to their maximum intensity.

Band component analysis was applied on the preprocessed spectra for 815-1065  $\text{cm}^{-1}$  and 1140-1500  $\text{cm}^{-1}$  regions using Gaussian line profiles. The bands were statistically analyzed in view of the pregnancy rates. Each band was tested using the Mann-Whitney U test. Only the band ratio of 900/940  $\text{cm}^{-1}$  was statistically significant ( $p < 0.5$ ) (Figure 2).

Principal component analysis (PCA) together with quadratic discriminant analysis (QDA) were applied to the measurements for regions containing 900 and 940  $\text{cm}^{-1}$  bands. The numbers of variables were picked as low as possible because PCA is affected


by low sample numbers. The analysis was performed for a partial region of the spectra between 890 and 950  $\text{cm}^{-1}$  where the most significant bands found in the band component analysis were located. The first two principal components were used as inputs for QDA analysis. A leave-one-out cross validation was applied to the QDA classifiers in order to obtain the best model. Receiver operating characteristic (ROC) analysis was performed on the QDA classifiers to test the accuracy of the analysis and to find a cut-off value between the two groups.

A sample size calculation was not conducted a priori because previous studies reported no significant differences between groups that were analyzed with conventional morphology and spectroscopic methods<sup>(7)</sup>.



**Figure 1.** Raman spectral analysis procedure for embryo culture samples

ROC: Receiver operating characteristic, PCA: Principal component analysis, LDA: Linear discriminant analysis



**Figure 2.** Receiver operating characteristic analysis was made for the band area of 900/940  $\text{cm}^{-1}$ . The faint lines show the 95% confidence interval

## Results


Thirty-one spent embryo culture media from 31 patients who met the inclusion criteria of the study were preprocessed.

The averages of Raman spectra were calculated for the pregnant and non-pregnant groups. The average spectra are demonstrated in Figure 3 for group comparison. The spectra show no clear distinction but was shifted for better visualization between the samples of patients whose embryos developed to pregnancy or not.


The similarity between the groups described above underscores the need for sophisticated statistical methods such as Raman spectral analysis. We applied QDA after PCA for the region between 890 and 950  $\text{cm}^{-1}$ . The score plot of this analysis is shown in Figure 4. Each discriminant line is a parabola that maximizes the between-group distance and minimizes the within-group distance because QDA is a discriminant analysis method that uses second order polynomial function.

The accuracy of PCA-QDA analysis was tested with an additional ROC analysis. The curve obtained from the analysis is shown in Figure 5. ROC analysis was performed and a threshold of 0.4007 (band area ratio) was found. This curve shows that the optimal specificity and sensitivity of this accuracy ROC analysis was 80.25% and 87.50%, respectively.

Fifteen patients were clinically pregnant, and 16 patients were clinically non-pregnant (Table 1). Clinical pregnancy was predicted using Raman spectroscopy in 93% (14/15) of clinically pregnant patients, and in 62.5% (10 out of 16) of clinically non-pregnant patients. The sensitivity of the Raman spectroscopic analysis was 93% and the specificity was 62.5%.




**Figure 3.** Raman spectra of two selected samples are demonstrated. The corresponding spectra of embryos that developed to pregnancy were manually shifted for better visualization



**Figure 4.** Quadratic discriminant analysis on the band area ratios obtained from band component analysis of the Raman spectra of 31 samples. Discriminant lines were calculated using home-made software that minimizes within-group distances and maximizes between-group distances

QDA: Quadratic discriminant analysis



**Figure 5.** Receiver operating characteristic analysis was performed and a threshold of 0.4007 was found

ROC: Receiver operating characteristic

**Table 1.** Clinical pregnancy rates according to conventional morphologic evaluation and Raman spectra analysis

	Patients predicted to be pregnant according Raman spectra, n (%)	Patients predicted to be non-pregnant according Raman spectra, n (%)
Clinically pregnant patients, n (%)	14 (93)	1 (7)
Clinically non-pregnant patients, n (%)	6 (37.5)	10 (62.5)

## Discussion

The present study identified that adding Raman spectroscopic analysis of spent embryo culture media revealed that this approach may predict clinical pregnancy as an adjunct to morphologic evaluation.

Currently, conventional morphologic evaluation is the most commonly used approach in assessing embryo quality worldwide. It has been used since the beginning of IVF, first as a tool to explain embryo development<sup>(8)</sup>, and then to select the embryo with the highest implantation transfer potential<sup>(9-13)</sup>. Morphologic evaluation is based on the embryologist; therefore, embryo scores can vary considerably because it is still a somewhat subjective matter<sup>(14)</sup>.

Metabolomics is an emerging “omics” science that has evolved from proteomics, genomics and transcriptomics. It systematically analyzes the inventory of metabolites. These metabolites are representatives of functional phenotypes at a cellular level. Within this context, researchers focused on the composition of the culture media. The subsequent step was the metabolomic analysis of what embryos use from the culture media and release during their development and to understand if there was a correlation with successful or unsuccessful implantation to the maternal uterus<sup>(15)</sup>.

Seli et al.<sup>(16)</sup> documented the first proof-of-concept study, which correlated the metabolome of the spent embryo culture media with embryo viability using Raman spectroscopy. The mean spectrum of embryos that did not implant was compared with the mean spectrum of embryos that implanted successfully. In a study by Scott et al.<sup>(17)</sup>, the mean spectrum was validated by analyzing spent embryo culture from a different IVF center that used a different type of culture. Further studies with either Raman and/or NIR spectroscopy argued that the metabolomic profile of the spent embryo culture media was a parameter that was independent of embryo morphology<sup>(18-24)</sup>. The present study is in line with these findings and shows that metabolomic evaluation of spent embryo culture media alone can predict reproductive potential as efficiently as conventional morphologic evaluation of the embryo.

Interestingly, despite the promise of metabolomic evaluation, the use of Raman spectroscopy and/or other techniques such as NIR and mass spectroscopy have limited clinical presence. There are a few potential explanations for these limitations. Currently, the equipment used for these spectroscopic techniques are expensive and require dedicated specialists. Moreover, prompt results are needed during embryo transfer in clinical practice and the applicable information gathered from spectroscopic techniques still requires time. If we look specifically at Raman spectroscopy for the purpose of metabolomic evaluation, it provides weak signal intensity, which may be a drawback when sample concentrations are low. Enhancement methods such as surface-enhanced Raman spectroscopy (SERS) or resonance Raman spectroscopy (RRS) can be used to overcome this limitation. On the other hand, RRS may damage the sample and produce broad background in the

spectra; therefore, it may shield information from the spectra. Although SERS suffers from repeatability, it is a developing method and may be useful for future studies. However, it is important to note that even with the aforementioned drawbacks, Raman spectroscopy alone still produced results that were comparable to conventional morphologic evaluation in the present study. Hence, if these drawbacks were to be overcome in future studies, metabolomic evaluation could provide a more objective approach to the current morphologic evaluation and possibly result in becoming a more accurate technique with increased reproductive outcomes.

## Study Limitations

A limitation of the study was its small sample size. We wanted to create an ideal design by only including single embryo transfer. Due to the financial aspects of IVF treatment and psychological burden, single embryo transfer is only occasionally feasible. Also, Raman spectroscopy equipment use and evaluation of embryo culture media required time to give results that could be utilized in routine clinic practice.

## Conclusion

Existing embryo assessment relies heavily on the morphologic evaluation of the embryo by an embryologist. Furthermore, this subjective method does not provide sufficient specificity or sensitivity to produce desirable pregnant rates for patients receiving IVF treatment. Metabolomic evaluation of spent embryo culture media is an emerging technique with promising objective results. However, there is clearly room for improvement in the exact spectroscopic technique used for metabolomic evaluation. Moreover, it has to be adequately validated. Hence, this approach still remains experimental and its application has not translated into the clinical setting. Further randomized control trials with improved spectroscopic techniques are needed to document the potential benefit from the use of metabolomic evaluation alone or as an adjuvant approach to the conventional morphologic evaluation.

## Acknowledgement

We would like to thank David F. Chapman, BSc, for editing the language of the manuscript. This research received funding from the Scientific Research Projects Coordination Unit of İstanbul University (grant number: 22501).

## Ethics

**Ethics Committee Approval:** This study was approved by Ethics Committee of İstanbul University Faculty of Medicine (2015).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Concept: E.B., G.B., Design: E.B., F.B., Data Collection or Processing: H.Y., S.B., Analysis or Interpretation: N.B., U.P., Literature Search: F.S., E.B., Writing: E.B., U.P.



**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** This research received funding from the Scientific Research Projects Coordination Unit of İstanbul University (grant number: 22501).

## References

- Multiple gestation pregnancy. The ESHRE Capri Workshop Group. *Hum Reprod* 2000;15:1856-64.
- Centers for Disease Control and Prevention ASfRM, Society for Assisted Reproductive Technology. 2013 Assisted Reproductive Technology Fertility Clinic Success Rates Report. In. Atlanta (GA): US Dept of Health and Human Services, 2015.
- WHO. WHO laboratory manual for the examination and processing of human semen. Geneva, Switzerland, 2010.
- Botros L, Sakkas D, Seli E. Metabolomics and its application for non-invasive embryo assessment in IVF. *Mol Hum Reprod* 2008;14:679-90.
- Bastu E, Mutlu MF, Yasa C, Dural O, Nehir Aytan A, Celik C, et al. Role of Mucin 1 and Glycodelin A in recurrent implantation failure. *Fertil Steril* 2015;103:1059-64.e2.
- Depa-Martynow M, Jedrzejczak P, Pawelczyk L. Pronuclear scoring as a predictor of embryo quality in in vitro fertilization program. *Folia Histochem Cytobiol* 2007;45(Suppl 1):S85-9.
- Vergouw CG, Heymans MW, Hardarson T, Sfountouris IA, Economou KA, Ahlstrom A, et al. No evidence that embryo selection by near-infrared spectroscopy in addition to morphology is able to improve live birth rates: results from an individual patient data meta-analysis. *Hum Reprod* 2014;29:455-61.
- Edwards RG, Purdy JM, Steptoe PC, Walters DE. The growth of human preimplantation embryos in vitro. *Am J Obstet Gynecol* 1981;141:408-16.
- Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. *Hum Reprod* 2011;26:1270-83.
- Desai NN, Goldstein J, Rowland DY, Goldfarb JM. Morphological evaluation of human embryos and derivation of an embryo quality scoring system specific for day 3 embryos: a preliminary study. *Hum Reprod* 2000;15:2190-6.
- Hill GA, Freeman M, Bastias MC, Rogers BJ, Herbert CM, Osteen KG, et al. The influence of oocyte maturity and embryo quality on pregnancy rate in a program for in vitro fertilization-embryo transfer. *Fertil Steril* 1989;52:801-6.
- Montag M, Liebenthron J, Köster M. Which morphological scoring system is relevant in human embryo development? *Placenta* 2011;32(Suppl 3):S252-6.
- Racowsky C, Vernon M, Mayer J, Ball GD, Behr B, Pomeroy KO, et al. Standardization of grading embryo morphology. *Fertil Steril* 2010;94:1152-3.
- Baxter Bendus AE, Mayer JF, Shipley SK, Catherino WH. Interobserver and intraobserver variation in day 3 embryo grading. *Fertil Steril* 2006;86:1608-15.
- Gardner DK, Lane M, Stevens J, Schoolcraft WB. Noninvasive assessment of human embryo nutrient consumption as a measure of developmental potential. *Fertil Steril* 2001;76:1175-80.
- Seli E, Sakkas D, Scott R, Kwok SC, Rosendahl SM, Burns DH. Noninvasive metabolomic profiling of embryo culture media using Raman and near-infrared spectroscopy correlates with reproductive potential of embryos in women undergoing in vitro fertilization. *Fertil Steril* 2007;88:1350-7.
- Scott R, Seli E, Miller K, Sakkas D, Scott K, Burns DH. Noninvasive metabolomic profiling of human embryo culture media using Raman spectroscopy predicts embryonic reproductive potential: a prospective blinded pilot study. *Fertil Steril* 2008;90:77-83.
- Ahlstrom A, Wikland M, Rogberg L, Barnett JS, Tucker M, Hardarson T. Cross-validation and predictive value of near-infrared spectroscopy algorithms for day-5 blastocyst transfer. *Reprod Biomed Online* 2011;22:477-84.
- Hardarson T, Ahlstrom A, Rogberg L, Botros L, Hillensjo T, Westlander G, et al. Non-invasive metabolomic profiling of Day 2 and 5 embryo culture medium: a prospective randomized trial. *Hum Reprod* 2012;27:89-96.
- Kirkegaard K, Svane AS, Nielsen JS, Hindkjaer JJ, Nielsen NC, Ingerslev HJ. Nuclear magnetic resonance metabolomic profiling of Day 3 and 5 embryo culture medium does not predict pregnancy outcome in good prognosis patients: a prospective cohort study on single transferred embryos. *Hum Reprod* 2014;29:2413-20.
- Seli E, Bruce C, Botros L, Henson M, Roos P, Judge K, et al. Receiver operating characteristic (ROC) analysis of day 5 morphology grading and metabolomic Viability Score on predicting implantation outcome. *J Assist Reprod Genet* 2011;28:137-44.
- Seli E, Vergouw CG, Morita H, Botros L, Roos P, Lambalk CB, et al. Noninvasive metabolomic profiling as an adjunct to morphology for noninvasive embryo assessment in women undergoing single embryo transfer. *Fertil Steril* 2010;94:535-42.
- Vergouw CG, Botros LL, Roos P, Lens JW, Schats R, Hompes PG, et al. Metabolomic profiling by near-infrared spectroscopy as a tool to assess embryo viability: a novel, non-invasive method for embryo selection. *Hum Reprod* 2008;23:1499-504.
- Vergouw CG, Kieslinger DC, Kosteljk EH, Botros LL, Schats R, Hompes PG, et al. Day 3 embryo selection by metabolomic profiling of culture medium with near-infrared spectroscopy as an adjunct to morphology: a randomized controlled trial. *Hum Reprod* 2012;27:2304-11.





# Micronuclei frequencies in lymphocytes and cervical cells of women with polycystic ovarian syndrome

## Polikistik over sendromlu kadınlarda lenfositler ve servikal hücrelerde mikronükleus frekansları

Rengin Karataylı<sup>1</sup>, Ayşe Gül Zamani<sup>2</sup>, Kazım Gezginç<sup>3</sup>, Ebru Tuncez<sup>4</sup>, Sema Soysal<sup>5</sup>, Fikriye Karanfil<sup>6</sup>, Aynur Acar<sup>7</sup>, M. Selman Yıldırım<sup>2</sup>

<sup>1</sup>Konya Private Selçuklu Hospital, Clinic of Obstetrics and Gynecology, Konya, Turkey

<sup>2</sup>Necmettin Erbakan University Meram Faculty of Medicine, Department of Medical Genetics, Konya, Turkey

<sup>3</sup>Necmettin Erbakan University Meram Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

<sup>4</sup>Şanlıurfa Pediatric Disease Hospital, Clinic of Medical Genetics, Şanlıurfa, Turkey

<sup>5</sup>Necmettin Erbakan University Meram Faculty of Medicine, Department of Medical Education and Informatics, Konya, Turkey

<sup>6</sup>University of Health Sciences, Konya Training and Research Hospital, Clinic of Obstetrics and Gynecology, Konya, Turkey

<sup>7</sup>İstanbul Bilim University Faculty of Science, Department of Molecular Biology and Genetics, İstanbul, Turkey

### Abstract

**Objective:** The aim of this study was to determine micronucleus (MN) frequencies in exfoliated cervical cells and peripheral blood lymphocytes of women with polycystic ovarian syndrome (PCOS).

**Materials and Methods:** Fifteen patients with PCOS and 11 healthy control patients were included in the study. Cervical smears and peripheral blood were collected from all patients. Specimens were analyzed for MN frequencies and compared between the groups. In addition to MN, other nuclear anomalies connected with both genotoxicity and cytotoxicity were evaluated.

**Results:** The MN frequencies in cervical smear and peripheral blood lymphocytes were compared in patients with PCOS and normal controls. There was no statistically significant difference between the groups regarding micronucleus frequency in peripheral blood lymphocytes ( $p=0.239$ ). The mean MN scores in exfoliated cervical cells of patients with PCOS and normal controls were  $1.19 \pm 0.57$  and  $0.74 \pm 0.34$ , respectively. The difference regarding micronucleus frequencies in cervical cells was statistically significant between the groups ( $p=0.032$ ).

**Conclusion:** Although study group is small, our study results support that there is an increased micronucleus frequency in cervical exfoliated cells of PCOS patients; this is a determinant of genetic hazard in the disease.

**Keywords:** Micronucleus tests, polycystic ovarian syndrome, cervical smears, lymphocytes, genotoxicity tests

### Öz

**Amaç:** Bu çalışmanın amacı, polikistik over sendromlu (PKOS) kadınların eksfoliyatif servikal hücrelerinde ve periferik kan lenfositlerinde mikronükleus (MN) frekanslarını belirlemektir.

**Gereç ve Yöntemler:** PKOS'li 15 hasta ve 11 sağlıklı kontrol hastası çalışmaya dahil edildi. Tüm hastalardan servikal smearleri ve periferik kan toplandı. Numuneler, MN frekansları açısından analiz edildi ve gruplar arasında karşılaştırıldı. Hem MN sıklığı, hem de genotoksitesite ve sitotoksitesite bağlı diğer nükleer anomaliler değerlendirildi.

**Bulgular:** Servikal smear ve periferik kan lenfositlerinde MN frekansları PKOS hastaları ve normal kontrollerde karşılaştırıldı. Periferik kan lenfositlerinde MN frekansı açısından gruplar arasında istatistiksel olarak anlamlı fark yoktu ( $p=0.239$ ). PKOS hastalarının eksfoliyatif servikal hücrelerindeki ortalama MN skorları ve normal kontrollerinki sırasıyla  $1.19 \pm 0.57$  ve  $0.74 \pm 0.34$  idi. Servikal hücrelerdeki MN frekansları istatistiksel olarak gruplar arasında anlamlıydı ( $p=0.032$ ).

**Sonuç:** Çalışma grubu küçük olmasına rağmen çalışma sonuçlarımız, PKOS hastalarının eksfoliyatif hücrelerinde, hastalıkta genetik tehlikenin belirleyicisi olan MN sıklığının arttığını desteklemektedir.

**Anahtar Kelimeler:** Mikronükleus testleri, polikistik over sendromu, servikal yaymalar, lenfositler, genotoksitesite testleri

Address for Correspondence/Yazışma Adresi: Sema Soysal, MD,

Necmettin Erbakan University Meram Faculty of Medicine, Department of Medical Education and Informatics, Konya, Turkey

Phone: +90 332 223 66 02 E-mail: semasoysal@hotmail.com ORCID ID: orcid.org/0000-0002-2636-5740

Received/Geliş Tarihi: 25.07.2017 Accepted/Kabul Tarihi: 16.09.2017

This study was presented at the 11<sup>th</sup> National Gynaecology and Obstetric Congress as a poster.

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

**PRECIS:** By using micronucleus (MN) genotoxicity tests, we determined MN frequencies in exfoliated cervical cells and peripheral blood lymphocytes of women with polycystic ovarian syndrome.

## Introduction

Polycystic ovarian syndrome (PCOS) is a common endocrinopathy in women and it is characterized by chronic oligoanovulation and clinical/biochemical hyperandrogenism. Its prevalence is reported to be around 3.5-10% regarding diagnostic criteria<sup>(1)</sup>.

Micronucleus (MN) is cytoplasmic chromatin condensations that appear as small nuclei, which are secondary to chromosomal fragmentation at the anaphase stage of cell division. MN is one of the established genotoxicity biomarkers in human erythrocytes, lymphocytes, reticulocytes, and exfoliated mucosa cells. Spontaneous or baseline MN frequencies in cultured human lymphocytes and exfoliated cells provide an index of accumulated genetic damage occurring during the life span of these cells. An increased frequency of MN is used as a measure to detect clastogenicity and aneugenicity. MN presence in cells reflects structural and/or numerical chromosomal aberrations arising during mitosis<sup>(2)</sup>. The genetic basis of PCOS has been investigated in several studies, and there is evidence of the presence of multiple gene polymorphisms, oxidative stress, and environmental factors in the background<sup>(3,4)</sup>. In patients with PCOS, increased oxidative stress and decreased antioxidant capacity have been reported, and those were all reported to be related to genetic damage in PCOS<sup>(5)</sup>.

Yesilada et al.<sup>(6)</sup> reported that the MN frequency in peripheral blood lymphocytes of women with PCOS was increased. In our study, we aimed to investigate the micronuclei frequency both in peripheral lymphocytes and cervical squamous cells of patients with PCOS in order to demonstrate genetic damage, also in cervical smears.

## Materials and Methods

The study was conducted Necmettin Erbakan University Meram Faculty of Medicine, Department of Gynecology, and Department of Medical Genetics between January 2012 and August 2012. Fourteen patients with PCOS and 11 controls with similar age and body mass index were recruited. PCOS was diagnosed using the Rotterdam criteria established in 2003. Patients with diseases related to hyperandrogenism such as hyperprolactinemia, Cushing's disease, androgen-secreting tumors, and late-onset congenital adrenal hyperplasia were all excluded by their medical history and specific tests. All participants answered a modified version of the questionnaire of the Commission for Protection against Environmental Mutagens and Carcinogens<sup>(7)</sup>. Information about contraceptive methods used, histories of sexually-transmitted diseases, and the patients' habits (smoking, drug use and numbers of sexual partners) were obtained. None of the patients included in the study had any systemic disease or history of smoking.

Patients with multiple partners, abnormal cervical cytology results or history of genital warts were excluded from the study. All patients in the study had at least one negative smear test previously.

Informed consent was taken from all patients and the study was approved by Necmettin Erbakan University Meram Faculty of Medicine Research Ethics Committee (approval number: 2012/21).

## Sampling and scoring of exfoliated cervical cells

Exfoliated cervical cells were collected using brushes and transferred to Falcon tubes containing 0.9% serum physiologic for MN tests. The material was centrifuged and the supernatant was discarded, leaving the exfoliated cells in the pellet. Cells were treated with hypotonic solution for 5 min. They were then treated twice with 5 mL of freshly prepared cold methanol: acetic acid (3:1). Drops of the material were placed on cold damp slides and allowed to dry. Samples were stained using 5% Giemsa for 5 minutes.

The slides were analyzed and 1000 epithelial cells were counted at a magnification of 1000 x (objective = 100 x with eyepiece = 10 x). Micronuclei were determined according to the criteria of Stich and Rosin<sup>(8)</sup>. Within the samples, only separate cells, without overlapping or folding, were analyzed. Micronuclei were counted if the structures had regular borders and were located inside the cytoplasm, with an intensity of staining less than or equal to that of the main nucleus and a size less than two-thirds of the size of the main nucleus (Figure 1a). The frequency of cells with micronucleus, binucleated cells (BNC), and cells with buds were reported as results.

## Sampling and scoring of peripheric blood lymphocytes

Heparinized blood samples were obtained. Lymphocyte cultures were performed for each subject and incubated for 72 h at 37 °C. According to the cytokinesis-block human lymphocyte MN test, cytochalasin-B (Sigma) was added after 44 hours into the final concentration of 3 Gg/mL<sup>(9,10)</sup>. After a total of 72 h culture, cells were harvested. First, they were treated with prewarmed hypotonic solution (0.075 M KCl) for a few minutes at room temperature and then resuspended twice in cold fresh fixative (methanol:glacialacetic acid, 3:1). Fixed cells were dropped on clean slides. After air drying the slides, they were stained using 5% Giemsa for 5 min. For each sample, 1000 BNC were observed to assess the frequencies of MN (Figure 1b). The cells scored for MN had to be clearly seen as binucleate. The number of MN in each binucleate cell was scored<sup>(8)</sup>. MN were accepted only when (i) they were separated from the main nuclei, but included within the corresponding cytoplasm, (ii) they had a chromatin structure similar to that of the main nuclei, (iii) they were coplanar to the main nuclei<sup>(11)</sup>, and (iv) they were no greater than one third the volume of the main nuclei<sup>(10,12)</sup>.

### Statistical Analysis

Statistical analysis was performed using SPSS for Windows, version 18.0 (SPSS Inc., USA). Continuous variables are expressed as mean  $\pm$  standard deviation. Student's t-test was used to analyze statistical differences. The level of  $p < 0.05$  was considered statistically significant.


### Results

The mean age in PCOS group was  $29.3 \pm 5.2$  years (range, 19-39 years), and in the control group it was  $27.9 \pm 5.1$  years (range, 21-35 years). The mean gravidity and parity in the PCOS group were  $1.7 \pm 1.4$  (range, 1-5) and  $1.3 \pm 1.1$  (range, 1-4) respectively, whereas they were  $2.5 \pm 1.2$  (range, 0-4) and  $1.8 \pm 1.2$  (range, 0-4) in the control group. There were no statistically significant differences between the groups regarding age, gravidity, and parity. The body mass indices were  $25.1 \pm 3.4$  kg/m<sup>2</sup> (range, 21-31 kg/m<sup>2</sup>) in the PCOS group and  $23.8 \pm 2.8$  kg/m<sup>2</sup> (range, 21-28 kg/m<sup>2</sup>) in the control group, respectively, without any statistical significance ( $p = 0.147$ ). The mean interval of coits was  $4.7 \pm 3.6$  in the PCOS group, whereas it was  $5.1 \pm 3.1$  in the control group; the difference was not statistically significant between the groups. The study results are summarized in Table 1. The MN frequency

in the peripheral blood lymphocytes of women with PCOS was  $10.93 \pm 6.5$  (per 1000 cells), whereas it is  $8.4 \pm 3.8$  (per 1000 cells) in the control group. There was no statistically significant difference between the groups regarding MN frequency in peripheral blood lymphocytes ( $p = 0.239$ ). On the other hand, the MN frequency in cervical exfoliated cells was  $1.19 \pm 0.57$  (per 1000 cells) in PCOS group, whereas it is  $0.74 \pm 0.34$  (per 1000 cells) in the control group. The difference regarding MN frequency in cervical cells was statistically significant between the groups ( $p = 0.032$ ). In addition, other cellular discrepancies such as BNC and budding cells were  $1.08 \pm 0.27$  (per 1000 cells) and  $0.10 \pm 0.08$  (per 1000 cells) in the PCOS group, respectively, and  $0.81 \pm 0.23$  (per 1000 cells) and  $0.06 \pm 0.06$  (per 1000 cells) in the the control group. The difference between the groups regarding BNC was statistically significant ( $p = 0.016$ ), whereas the difference concerning budding cells was not statistically significant ( $p = 0.147$ ) (Table 2).

### Discussion

PCOS, a common endocrinopathy among reproductive age women, is accepted to be associated with metabolic syndrome. It is also associated with severe long-term hazards such as type-2 diabetes, cardiovascular diseases, and endometrial



**Figure 1.** Micronucleus (arrow) in exfoliated cervical cell (a) and peripheral blood lymphocyte (b)

**Table 1.** Mean age, mean gravidity, mean parity and duration of sexual life in patients with polycystic ovarian syndrome and the control group

	PCOS group	Control group	p
Mean age (years) (mean + SD)	$29.3 \pm 5.2$ (19-39)	$27.9 \pm 5.1$ (21-35)	0.428
Mean gravidity (mean + SD)	$1.7 \pm 1.4$ (1-5)	$2.5 \pm 1.2$ (0-4)	0.148
Mean parity (mean + SD)	$1.3 \pm 1.1$ (1-4)	$1.8 \pm 1.2$ (0-4)	0.333
Duration of sexual life (mean + SD)	$4.8 \pm 3.6$ years	$5.1 \pm 3.1$ years	0.778

<sup>a</sup>Duration of sexual life in years from initial coitus;  $p < 0.05$   
PCOS: Polycystic ovarian syndrome, SD: Standard deviation

**Table 2.** Average and standard deviation of the number of cells with micronuclei, binucleated cells, broken egg cells, and cells with buds

Anomalies	PCOS group	Normal controls	p
PBL MN frequency (mean ± SD)	10.93±6.5	8.4±3.8	0.239
ECC MN frequency (mean ± SD)	0.74±0.34	1.19±0.57	0.032*
BNC (mean ± SD)	1.08± 0.27	0.81±0.23	0.016*
BC (mean ± SD)	0.10±0.08	0.06±0.06	0.147

p&lt;0.05; \*there is a statistically significant difference

PCOS: Polycystic ovarian syndrome, PBL: Peripheric blood lymphocytes, MN: Micronucleus, SD: Standard deviation, ECC: Exfoliated cervical cells, BNC: Binucleated cells, BC: Cells with buds

cancer. Nowadays, PCOS and its relation with cancer is of special interest in scientific research. Oxidative stress due to an imbalance between the generation of reactive oxygen species and antioxidant defense has been investigated in the etiology of cancer development<sup>(13,14)</sup>. The imbalance between pro-oxidants and antioxidants has been proposed to be associated with reproductive diseases such as endometriosis, PCOS, and unexplained infertility. In the literature, there are various reports about increased oxidative stress and related comorbidity in patients with PCOS<sup>(5,15,16)</sup>. It is known that proteins, lipids, and DNA are exposed to damage as a result of oxidative stress. Moreover, in a study by Simic<sup>(14)</sup>, it was defined that oxidative stress was linked to chromosomal breakage and carcinogenesis. Zuo et al.<sup>(17)</sup> reported that variable oxidative stress in PCOS, instability of genes, and DNA mutations increased the risk and potentially contributed to the pathogenesis of gynecologic cancers. Deepika et al.<sup>(18)</sup> reported that serum malondialdehyde levels of oxidative stress markers showed a positive correlation with MN in patients with PCOS.

There are also studies about the increased oxidative stress markers in patients with PCOS and this mechanism has been accepted to be related to mutagenesis in these patients<sup>(5,15)</sup>. Some investigators reported a positive correlation between oxidative stress and lipid peroxidation and genotoxicity<sup>(16-18)</sup>. This type of damage can lead to chromosomal losses and rearrangements. MN are DNA-containing particles that occur during mitosis and result from unrepaired DNA double-strand breaks, leading to chromatin fragments or whole chromosomes being distributed incorrectly. Therefore, the MN test shows genetic damage that cells accumulate throughout life. At the molecular level, this kind of DNA damage could be silenced tumor suppressor genes and activated oncogenes. It could then initiate cancer development by adding epigenetic changes<sup>(17-19)</sup>. In our study, there was no statistically significant difference between the groups regarding MN frequency in peripheral blood lymphocytes (p=0.239). It is suggested that genetic abnormalities are present in women with PCOS. In previous studies, the micronuclei frequency in the peripheral lymphocytes of patients with PCOS was reported to be increased<sup>(6,20-23)</sup>.

On the other hand, the MN frequency in cervical exfoliated cells was statistically significant between the groups (p=0.032). This study is the first to report on the genomic instability in cervical

exfoliated cells of patients with PCOS. In the systematic review by Chittenden et al.<sup>(24)</sup>, it was shown that women with PCOS were more likely to develop endometrial cancer. It has recently been reported that there may exist an association between PCOS and breast cancer and PCOS and ovarian cancer<sup>(25-27)</sup>.

Cervical cancer is a significant health problem especially in developing countries. For prevention, early detection and treatment of preinvasive lesions that could progress to cervical cancer is very important. It has been shown exfoliated cervical cells of patients with moderate and severe dysplasia are observed with significantly higher frequency of MN compared with healthy women<sup>(28)</sup>. It may be suggested that the evaluation of the frequency of MN in exfoliated cervical cells may be helpful in establishing cervical cancer risk<sup>(29)</sup>.

### Study Limitations

Although the research has reached its aims, there were some unavoidable limitations. First, we had difficulty finding financial support for this research. For this reason, this study was conducted in a limited number of patients. Such studies should be carried out in wider series. Because of the same reason, we could not apply any additional test in assessing genotoxicity.

### Conclusion

According to our study results, although the study sample was small, there is a genomic instability in cervical exfoliated cells of women with PCOS. This study stands as the first in the literature concerning cervical cytology and genomic instability. Patients with PCOS should be followed up for cervical cancer with more frequent intervals than healthy women.

### Ethics

**Ethics Committee Approval:** The study was approved by Necmettin Erbakan University Meram Faculty of Medicine Research Ethics Committee (approval number: 2012/21).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: R.K., K.G., F.K., Concept: R.K., A.G.Z., Design: R.K., A.G.Z., Data Collection or Processing: R.K., K.G., F.K., Analysis or Interpretation: A.G.Z., E.T., A.A., Literature Search: S.S., M.S.Y., Writing: S.S., M.S.Y.



**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support. The remaining materials of previous studies were used for this study.

## References

1. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab* 2000;85:2434-8.
2. Fenech M, Holland N, Zeiger E, Chang WP, Burgaz S, Thomas P, et al. The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells--past, present and future. *Mutagenesis* 2011;26:239-45.
3. Barber TM, Franks S. Genetics of polycystic ovary syndrome. *Front Horm Res* 2013;40:28-39.
4. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. *Endocr Rev* 2005;26:251-82.
5. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. *Fertil Steril* 2003;80:123-7.
6. Yesilada E, Sahin I, Ozcan H, Yildirim IH, Yologlu S, Taskapan C. Increased micronucleus frequencies in peripheral blood lymphocytes in women with polycystic ovary syndrome. *Eur J Endocrinol* 2006;154:563-8.
7. Carrano AV, Natarajan AT. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. *Mutat Res* 1988;204:379-406.
8. Stich HF, Rosin MP. Quantitating the synergistic effect of smoking and alcohol consumption with the micronucleus test on human buccal mucosa cells. *Int J Cancer* 1983;31:305-8.
9. Slavotinek A, McMillan TJ, Steel CM. A comparison of micronucleus frequency and radiation survival in lymphoblastoid cell lines. *Mutagenesis* 1993;8:569-75.
10. Tomanin R, Ballarin C, Nardini B, Mastrangelo G, Sarto F. Influence of smoking habit on the frequency of micronuclei in human lymphocytes by the cytokinesis block method. *Mutagenesis* 1991;6:123-6.
11. Eastham AM, Atkinson J, West CM. Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines. *Int J Radiat Biol* 2001;77:295-302.
12. Ozkal P, Ilgin-Ruhi H, Akdogan M, Elhan AH, Kaçar S, Sasmaz N. The genotoxic effects of hepatitis B virus to host DNA. *Mutagenesis* 2005;20:147-50.
13. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. *Proc Natl Acad Sci U S A* 1995;92:5258-65.
14. Simic MG. DNA markers of oxidative processes in vivo: relevance to carcinogenesis and anticarcinogenesis. *Cancer Res* 1994;54(Suppl):1918-23.
15. Bayram F, Kocer D, Ozsan M, Muhtaroglu S. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. *Gynecol Endocrinol* 2012;28:497-501.
16. Mayer C, Schmezer P, Freese R, Mutanen M, Hietanen E, Obe G, et al. Lipid peroxidation status, somatic mutations and micronuclei in peripheral lymphocytes: a case observation on a possible interrelationship. *Cancer Lett* 2000;152:169-73.
17. Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. *Oxid Med Cell Longev* 2016;2016:8589318.
18. Deepika ML, Nalini S, Maruthi G, Ramchander V, Ranjith K, Latha KP, et al. Analysis of oxidative stress status through MN test and serum MDA levels in PCOS women. *Pak J Biol Sci* 2014;17:574-7.
19. Chandra Mohan KV, Bhuvaneswari V, Abraham SK, Nagini S. Dose-dependent protection by tomato against 7,12-dimethylbenz(a) anthracene-induced genotoxicity and oxidative stress in mice. *J Med Food* 2003;6:169-73.
20. Subapriya R, Kumaraguruparan R, Abraham SK, Nagini S. Protective effects of ethanolic neem leaf extract on N-methyl-N'-nitro-N-nitrosoguanidine-induced genotoxicity and oxidative stress in mice. *Drug Chem Toxicol* 2004;27:15-26.
21. Hamurcu Z, Bayram F, Kahriman G, Dönmez-Altuntas H, Baskol G. Micronucleus frequency in lymphocytes and 8-hydroxydeoxyguanosine level in plasma of women with polycystic ovary syndrome. *Gynecol Endocrinol* 2010;26:590-5.
22. Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF. Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. *Mutat Res* 2008;639:55-63.
23. Nersesyan A, Martirosyan A, Parsadanyan G, Zalinyan G. Chromosomal aberrations level in peripheral blood lymphocytes of women with polycystic ovary syndrome. *J BUON* 2006;11:477-80.
24. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. *Reprod Biomed Online* 2009;19:398-405.
25. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: is there a link? *Gynecol Endocrinol* 2005;20:200-8.
26. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. *Eur J Endocrinol* 2002;147:717-25.
27. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. *Ann Intern Med* 2000;132:989-93.
28. Chakrabarti RN, Dutta K. Micronuclei test in routine smears from uterine cervix. *Eur J Gynaecol Oncol* 1988;9:370-2.
29. Nersesyan AK. Possible role of the micronucleus assay in diagnostics and secondary prevention of cervix cancer: a minireview. *Tsitol Genet* 2007;41:64-6.





# No increase in free fetal DNA level in ectopic pregnancy: A preliminary study

## Ektopik gebelik tanısında serbest fetal DNA'nın yeri: Ön hazırlık çalışması

Özge Kömürcü Karuserci, Mete Gürol Uğur, Özcan Balat, Seyhun Sucu

Gaziantep University Faculty of Medicine, Department of Obstetric and Gynecology, Gaziantep, Turkey

### Abstract

**Objective:** The aim of this study was to diagnose ectopic pregnancy in the early period by measuring cell-free fetal DNA (cffDNA) levels in maternal blood using spectrophotometry.

**Materials and Methods:** Thirty patients with ectopic pregnancy and 30 patients with first trimester intrauterine pregnancy were enrolled in this prospective controlled study. cffDNA levels in maternal serum were measured using spectrophotometry.

**Results:** There were no differences between the two groups in terms of cffDNA absorbance levels.

**Conclusion:** Spectrophotometry is not suitable for measuring cffDNA levels to diagnose ectopic pregnancies in the early period. Practical and cost-effective methods should be found or larger patient series should be investigated.

**Keywords:** Ectopic pregnancy, free fetal DNA, spectrophotometry

### Öz

**Amaç:** Ektopik gebelik tanısının erken dönemde spektrofotometrik yöntemle anne kanından serbest fetal DNA (cffDNA) ölçülerek konulmasıdır.

**Gereç ve Yöntemler:** Bu prospektif kontrollü çalışmada 30 adet ektopik gebelik tanısı almış hasta ile 30 adet ilk trimester intrauterin gebe cffDNA değerleri açısından spektrofotometrik yöntem kullanılarak karşılaştırıldı.

**Bulgular:** İki grup arasında cffDNA absorbans değerleri bakımından anlamlı fark bulunmadı.

**Sonuç:** Spektrofotometrik yöntemle cffDNA ölçümü ucuz ve basit bir yöntem olmasına rağmen ektopik gebeliğin erken tanısında yararlı bulunmamıştır. Polimeraz zincir reaksiyonu ya da daha hassas sitogenetik araştırmalar kullanılabilir; ancak maliyet etkinliği açısından uygun olmayabilir.

**Anahtar Kelimeler:** Ektopik gebelik, serbest fetal DNA, spektrofotometre

**PRECIS:** We have measured free fetal DNA level to diagnose ectopic pregnancy not to need repeat tests.

### Introduction

Ectopic pregnancy is complication of pregnancy with high morbidity and mortality rates, which is why early and precise diagnosis is very important. The current administration for diagnosis of ectopic pregnancy includes serial serum beta human chorionic gonadotropin ( $\beta$ -hCG) levels and transvaginal ultrasound<sup>(1)</sup>. However, it may not be possible to distinguish between intrauterine or extrauterine pregnancy in 8-31% of cases at the first examination<sup>(2)</sup>. Thus, several checks for  $\beta$ -hCG level and ultrasound monitoring are required for diagnosis

and management decisions. Another marker could be used in diagnosis and management. To date, many researchers have worked on this subject and reported a range of new markers that could be used in this issue.

In recent years, cell-free nucleic acids have been studied for use as potential candidate biomarkers for numerous conditions, especially in gynecologic cancers, ovarian and endometrial diseases, obstetric disorders such as preeclampsia<sup>(3)</sup>, fetal aneuploidy, intrauterine fetal demise, and abortus<sup>(4)</sup>. Furthermore, concentration of cell-free nucleic acids in serum of patients undergoing *in vitro* fertilization

(IVF) or embryo culture could give information about IVF outcomes<sup>(5)</sup>.

In this preliminary study, we aimed to measure and compare cell-free fetal DNA (cffDNA) expression in the maternal circulation among women with intrauterine and ectopic pregnancies using spectrophotometry for cheap, easy, early, and precise diagnosis with only one blood test.

## Materials and Methods

This study was performed with 30 patients with ectopic pregnancy and 30 women with first trimester singular pregnancies without any medical problems serving as controls who were admitted to the Gaziantep University Faculty of Medicine, Department of Obstetric and Gynaecology. The ectopic pregnancy group was named as group 1 and the control group was named as group 2. An acceptance form was signed all volunteer pregnant women. This study was approved by the Gaziantep University Local Ethics Committee (approval number: 05/2011-16).

Diagnostic criteria of ectopic pregnancy were; irregular  $\beta$ -hCG increase, ectopic implantation of pregnancy or diffuse fluid in the pouch of Douglas and abdomen, as determined using transvaginal ultrasound.


We took 8-10 cc blood samples from the intrauterine pregnancy group and ectopic pregnancy group, which were then placed in two 15 cc Falcon tubes and sent to the laboratory within two hours and centrifuged at 2480 rpm for 10 minutes. The supernatant with its pellet was then separated to another Falcon tube and centrifuged at 3600 rpm for 20 minutes. Finally, the supernatant was separated into 3 Eppendorf tubes (1.5 cc) with its pellet and kept at -80 °C until required for analysis. These materials were thawed for analysis and DNA absorption measurements were made using a Tetra Spectrophotometer, Model: T80+UV/VIS Spectrophotometer.

## Statistical Analysis

Data were analyzed using SPSS 13.0. The independent t-test, independent Levene's test, and Mann-Whitney U test were used when appropriate. Statistical significance was considered as  $p < 0.05$ .

## Results

The average age of both groups was  $24.9 \pm 4.8$  years (range, 16-36 years). The mean age of the ectopic pregnancy group was  $25.3 \pm 4.5$  years (range, 16-35 years). The mean age of the intrauterine pregnancy group was  $24.4 \pm 5.1$  years (range, 18-36 years). There was no statistically significant difference in terms of age between the two groups ( $p = 0.776$ ). The average weight of the both groups was  $67.7 \pm 11.5$  kg (range, 45-92 kg). There was no statistically significant difference in terms of weight ( $p = 0.968$ ), height ( $p = 0.507$ ), body mass index ( $p = 0.873$ ) and hemoglobin levels ( $p = 0.741$ ) between the two groups. The sociodemographic data of the groups are listed in Table 1 and Table 2.  $\beta$ -hCG levels were higher than in the control group



**Figure 1.** Beta human chorionic gonadotropin levels of two groups  
hCG: Human chorionic gonadotropin

**Table 1.** Sociodemographic data of ectopic pregnancy group (group 1)

Variables	n/Total* (%)
Mother's education status	
Illiterate	2/30 (6.7%)
Literate	4/30 (13.3%)
Primary school graduate	4/30 (13.3%)
Secondary school graduate	9/30 (30%)
High school graduate	8/30 (26.7%)
University graduate	3/30 (10%)
Husband's education status	
Illiterate	0/30 (0%)
Literate	3/30 (10%)
Primary school graduate	5/30 (16.7%)
Secondary school graduate	9/30 (30%)
High school graduate	10/30 (33.3%)
University graduate	3/30 (10%)
Mother's job	
Housewife	21/30 (70%)
Working	9/30 (30%)
Husband's job	
Self-employment	18/30 (60%)
Employee	8/30 (26.7%)
Officer	4/30 (13.3%)
Social security	
No	4/30 (13.3%)
Yes	26/30 (86.7%)
Mother's chronic disease	
No	28/30 (93.3%)
Yes	2/30 (6.7%)

\*: Abnormal values in both groups

and this was statistically significant ( $p<0.001$ ) (Figure 1). There were no differences between the two groups with respect to DNA absorbance levels ( $p=0.647$ ) (Figure 2).

## Discussion

It is crucial to diagnose ectopic pregnancies in the earliest possible time because this interval of suspicion but uncertainty can cause dangerous conditions such as internal bleeding and future infertility<sup>(6)</sup>. Less than 50% of tubal ectopic pregnancies could be diagnosed at the first examination of patients<sup>(7,8)</sup>. We performed this research in the hope of identifying a new marker that could identify this important illness as early as possible. Therefore, we measured cffDNA

**Table 2.** Sociodemographic data of intrauterine pregnancy group (group 2)


Variables	n/Total* (%)
Mother's education status	
Illiterate	1/30 (3.3%)
Literate	1/30 (3.3%)
Primary school graduate	5/30 (16.7%)
Secondary school graduate	8/30 (26.7%)
High school graduate	8/30 (26.7%)
University graduate	6/30 (20%)
Husband's education status	
Illiterate	0/30 (0%)
Literate	1/30 (3.3%)
Primary school graduate	8/30 (26.7%)
Secondary school graduate	10/30 (33.3%)
High school graduate	10/30 (33.3%)
University graduate	1/30 (3.3%)
Mother's job	
Housewife	19/30 (63.3%)
Working	7/30 (23.3%)
Husband's job	
Self-employment	21/30 (70%)
Employee	8/30 (26.7%)
Officer	1/30 (3.3%)
Social security	
No	1/30 (3.3%)
Yes	29/30 (96.7%)
Mother's chronic disease	
No	26/30 (86.7%)
Yes	4/30 (13.3%)

\*: Abnormal values in both groups

absorbance using spectrophotometry, but we could not find a difference between intrauterine pregnancy and ectopic pregnancy groups in terms of cffDNA absorbance. We also found that the cffDNA values did not increase with increasing hCG values. This is a valuable result because it showed that the amount of the cffDNA could not give information about the week or settlement of the pregnancy. A previous study also reported that cffDNA was not suitable as a marker for pregnancy complications, but it was suitable for the diagnosis of aneuploidies<sup>(9)</sup>.

Researchers are looking for many new markers to shorten the diagnosis time of ectopic pregnancy and reduce the possibility of tubal rupture. Previous studies researched placental (pregnancy-associated plasma protein A, human placental lactogen, inhibin A, activin A, vascular endothelial growth factor) and non-placental markers (glycodelin and vascular endothelial growth factor) for the diagnosis of ectopic pregnancy<sup>(10,11)</sup>. Our study is the second regarding cffDNA in ectopic pregnancy. There is only one more study about cffDNA measurements in ectopic pregnancies. In that study, Lazar et al.<sup>(12)</sup> investigated free DNA quantities using polymerase chain reaction (PCR) analysis of sex-determining region Y (SRY) between ectopic and intrauterine pregnancies. SRY was found in 15 ectopic pregnancies and 14 intrauterine pregnancies. Mean fetal free DNA quantity in ectopic pregnancies has been found higher than in intrauterine pregnancies ( $p<0.005$ ). This result is significant but PCR is an expensive and long-term method; therefore, it is not suitable for ectopic pregnancy.

Measurement of the amount of nucleic acids is an essential tool in molecular biology that uses quantities of DNA solutions ranging from 1 pg/ $\mu$ L to 50 mg/mL<sup>(13)</sup>. A previous study measures the DNA quantity of *Enterobacter* from intestinal



**Figure 2.** DNA absorbance levels of two groups

\*Values that are abnormally high but not statistically significant between the two groups

flora at 260 nm, but they used PCR at the beginning to extract genomic DNA<sup>(14)</sup>. We tried to measure cffDNA from maternal blood using spectrophotometry only. The reason that we found no meaningful result could be due to the fact that cffDNA in the blood of patients with ectopic pregnancy does not reach meaningful levels, different from intrauterine pregnancies, or that spectrophotometry only is insufficient without extracting cffDNA. Nevertheless, we foresee diagnosing ectopic pregnancy in the earliest period by measuring cffDNA with an easy, fast, and inexpensive method so we can use it in daily routine.

### Study Limitations

Spectrophotometry to measure cffDNA is a cheap method, but it may not be intensive enough or we need larger patient groups for searching.

### Conclusion

In conclusion, this pilot study may lead to other studies about cffDNA measurement for ectopic pregnancy in larger patient groups using spectrophotometry or any other easy, fast and cheap method.

The measurement of concentrations of cffDNA seems to be a promising tool for early diagnosis of ectopic pregnancy, but evaluation of the technique would be necessary. Spectrophotometry method is not suitable for measuring cffDNA levels to diagnose ectopic pregnancies in the early period. Practical and cost-effective methods should be found or larger patient series should be investigated for using cffDNA in the early diagnosis of ectopic pregnancy.

### Ethics

**Ethics Committee Approval:** This study was approved by the Gaziantep University Local Ethics Committee (approval number: 05/2011-16).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: Ö.K.K., M.G.U., Concept: Ö.K.K., M.G.U., Design: Ö.B., Data Collection or Processing: Ö.K.K., Analysis or Interpretation: M.G.U., Literature Search: S.S., Writing: Ö.K.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Barnhart KT. Clinical practice-Ectopic pregnancy. *N Engl J Med* 2009;361:379-87.
2. Condous G, Okaro E, Bourne T. The conservative management of early pregnancy complication: a review of literature. *Ultrasound Obstet Gynecol* 2003;22:420-30.
3. Zeybek YG, Günel T, Benian A, Aydın K, Kaleli S. Clinical evaluations of cell-free fetal DNA quantities in pre-eclamptic pregnancies. *J Obstet Gynaecol Res* 2013;39:632-40.
4. Clark-Ganheart CA, Fries MH, Leifheit KM, Jensen TJ, Moreno-Ruiz NL, Ye PP, et al. Use of cell-free DNA in the investigation of intrauterine fetal demise and miscarriage. *Obstet Gynecol* 2015;125:1321-9.
5. Traver S, Assou S, Scalici E, Haouzi D, Al-Edani T, Belloc S, et al. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. *Hum Reprod Update* 2014;20:905-23.
6. Rajendiren S, Dhiman P. Biomarkers of Ectopic Pregnancy-Present and Future. In: Darwish A (ed). *Contemporary gynecologic practice*. India: Intech; 2015:2.
7. Robson SJ, O'Shea RT. Undiagnosed ectopic pregnancy: a retrospective analysis of 31 'missed' ectopic pregnancies at a teaching hospital. *Aust N Z J Obstet Gynaecol* 1996;36:182-5.
8. Munro KI, Horne AW, Duncan WC, Critchley HOD. Features associated with time to diagnosis and management of ectopic pregnancy. *Scot Med J* 2008;53:49.
9. Bauer M, Hutterer G, Eder M, Majer S, Leshane E, Johnson KL, et al. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. *Prenat Diagn* 2006;26:831-6.
10. Daponte A, Pournaras S, Zintzaras E, Kallitsaris A, Lialios G, Maniatis AN, et al. The value of a single combined measurement of VEGF, glycodelin, progesterone, PAPP-A, HPL, and LIF for differentiating between ectopic and abnormal intrauterine pregnancy. *Hum Reprod* 2005;20:3163-6.
11. Rausch M, Barnhart KT. Serum biomarkers for detecting ectopic pregnancy. *Clin Obstet Gynecol* 2012;55:418-23.
12. Lazar L, Nagy B, Ban Z, Nagy GR, Papp Z. Presence of cell-free fetal DNA in plasma of women with ectopic pregnancies. *Clin Chem* 2006;52:1599-601.
13. Gallagher SR, Desjardins PR. Quantitation of DNA and RNA with absorption and fluorescence spectroscopy. *Curr Protoc Hum Genet* 2007.
14. Yang JL, Wang MS, Cheng AC, Pan KC, Li CF, Deng SX. A simple and rapid method for extracting bacterial DNA from intestinal microflora for ERIC-PCR detection. *World J Gastroenterol* 2008;14:2872-6.



# Can we predict severity of intrahepatic cholestasis of pregnancy using inflammatory markers?

## Enflamatuvar belirteçleri kullanarak gebelik kolestazının ciddiyeti öngörülebilir mi?

Çiğdem Yayla Abide<sup>1</sup>, Fisun Vural<sup>2</sup>, Çetin Kılıççı<sup>1</sup>, Evrim Bostancı Ergen<sup>1</sup>, İlter Yenidede<sup>1</sup>, Ahmet Eser<sup>1</sup>, Oya Pekin<sup>1</sup>

<sup>1</sup>University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

<sup>2</sup>University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

### Abstract

**Objective:** To investigate the association of inflammatory markers with severity of intrahepatic cholestasis of pregnancy (ICP).

**Materials and Methods:** This retrospective case-control study was conducted with 229 pregnant women, 84 with ICP, and 145 age-matched healthy pregnant women. Patients were categorized as mild ICP ( $<40 \mu\text{mol/L}$ ) and severe ICP ( $\geq 40 \mu\text{mol/L}$ ) with regard to serum bile acids. Inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV), and red blood cell distribution width (RDW) were compared between the groups.

**Results:** Patients with ICP had significantly decreased RDW and increased white blood cell counts (WBC), MPV and PLR, but no significant changes in NLR. The comparison of mild and severe cases with regard to NLR, PLR, WBC, and RDW was similar ( $p>0.05$ ). MPV levels were significantly increased in severe group ( $p<0.05$ ).

**Conclusion:** WBC, MPV, and PLR were the inflammatory markers significantly increased, and RDW was significantly reduced in ICP. MPV was the marker that significantly increased with the severity of disease. The use of inflammatory markers in the assessment of perinatal outcomes needs further studies.

**Keywords:** Cholestasis, inflammation, mean platelet volume, platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio

### Öz

**Amaç:** Gebeliğin intrahepatik kolestazının (GİK) ciddiyeti ile enflamatuvar belirteçler arasındaki ilişkiyi incelemektir.

**Gereç ve Yöntemler:** Bu retrospektif olgu-kontrol çalışması 84 GİK'li ve 145 yaş uyumlu sağlıklı gebe olan 229 gebe kadın üzerinde gerçekleştirilmiştir. Hastalar serum safra asit düzeylerine göre, hafif GİK ( $<40 \mu\text{mol/L}$ ) ve ciddi GİK ( $\geq 40 \mu\text{mol/L}$ ) olarak kategorize edilmiştir. Çalışmamızda bu iki grup arasında enflamatuvar belirteçler olan nötrofil-lenfosit oranı (NLO), platelet-lenfosit oranı (PLO), ortalama platelet hacmi (MPV) ve kırmızı kan hücreleri dağılım genişliği (RDW) karşılaştırılacaktır.

**Bulgular:** GİK hastalarında RDW azalmış, beyaz kan hücresi (WBC), MPV, ve PLO artmıştır, ancak NLO'da önemli bir değişiklik izlenmemiştir. Hafif ve ciddi GİK grupları arasında karşılaştırma sonucunda NLO, PLO, WBC ve RDW benzer bulunmakla beraber MPV seviyesi ciddi grupta anlamlı olarak yüksek tespit edilmiştir ( $p<0,05$ ).

**Sonuç:** GİK hastalarında WBC, MPV, PLO anlamlı olarak artan, RDW ise anlamlı olarak azalan enflamatuvar belirteçlerdir. MPV ise hastalığın ciddiyeti ile birlikte artış gösteren bir belirteçtir. GİK hastalarında bu enflamatuvar belirteçlerin perinatal sonuçlarla ilişkisini incelemek için ise daha fazla çalışmaya ihtiyaç vardır.

**Anahtar Kelimeler:** Kolestaz, enflamasyon, ortalama platelet hacmi, platelet-lenfosit oranı, nötrofil-lenfosit oranı

Address for Correspondence/Yazışma Adresi: Çiğdem Yayla Abide, MD,

University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Phone: +90 506 601 56 00 E-mail: cigdemabide@gmail.com ORCID ID: orcid.org/0000-0001-5437-7987

Received/Geliş Tarihi: 27.05.2017 Accepted/Kabul Tarihi: 16.09.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.



**PRECIS:** This paper investigated the hematological inflammatory markers in mild and severe cases of intrahepatic cholestasis of pregnancy. Mean platelet volume was significantly increased in severe intrahepatic cholestasis of pregnancy.

## Introduction

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease seen during pregnancy, with a changing prevalence worldwide<sup>(1,2)</sup>. The etiology and pathogenesis of ICP are multifactorial. Environmental factors, nutritional deficiencies, hormonal changes, and genetic variations have been found to be responsible for ICP<sup>(3,4)</sup>. It presents most often in the form of pruritus in the second and third trimesters of pregnancy, with elevated serum aminotransferases and/or elevated serum bile acid levels ( $\geq 10 \mu\text{mol/L}$ )<sup>(5)</sup>. ICP can be differentiated from other types of liver diseases unique to pregnancy that share similar laboratory abnormalities such as preeclampsia, acute fatty liver of pregnancy, and hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome<sup>(1,6,7)</sup>. In addition, other skin diseases that cause high transaminase levels in pregnancy must be excluded. After delivery, the symptoms of ICP usually resolve within 48 hours, with laboratory abnormalities normalizing within 2-8 weeks<sup>(8,9)</sup>.

Bile acid levels can affect perinatal outcomes and are related to an increased risk of iatrogenic preterm delivery, spontaneous preterm delivery, meconium-stained amniotic fluid (MSA), and sudden intrauterine death of the fetus<sup>(8,10-12)</sup>. In the severe ICP group, the incidence of complications is higher than in the mild group<sup>(8)</sup>. Unfortunately, ultrasonography, cardiotocography, fetal movements, and Doppler ultrasonography cannot predict fetal death; there is no perfect test or prognostic marker available to predict fetal outcome<sup>(8,13,14)</sup>.

Recent studies demonstrated the prognostic role of inflammatory markers in both cardiovascular diseases and malignancies<sup>(15,16)</sup>, but few studies have been performed with ICP. The neutrophil-to-lymphocyte (NLR) ratio, platelet-to-lymphocyte (PLR) ratio, mean platelet volume (MPV), and red blood cell distribution width (RDW) are hematologic inflammatory markers. One important pathogenesis responsible for the occurrence of ICP is inflammation; however, it is not known which mechanism initiates this inflammation<sup>(17)</sup>. Recently, NLR has been found to be a promising diagnostic marker in ICP<sup>(18)</sup>. To the best of our knowledge, no studies have investigated the roles of PLR and RDW in ICP. Therefore, we aimed to evaluate the role of inflammatory markers, which are readily available and easily calculated parameters, in the severity of ICP.

## Materials and Methods

This retrospective case-control study was conducted at Zeynep Kamil Women and Children's Health Training and Research Hospital, Istanbul. Patients with ICP who delivered their babies in this hospital from January 2013 to January 2016 were enrolled in this study. All data were obtained from hospital files and our computer database. This study was approved by the Zeynep

Kamil Women and Children's Health Training and Research Hospital Local Ethics Committee (approval number: 136).

The term ICP was used if the serum bile acid level was  $\geq 10 \mu\text{mol/L}$  with pruritus that could not be explained by any other condition. A total of 102 women with ICP were enrolled in this study. The exclusion criteria were: patients with incomplete data, fetal congenital anomalies, multiple pregnancies, chronic/acute liver disease (Wilson's disease, cholecystitis, primary sclerosing cholangitis, primary biliary cirrhosis, alpha-1-antitrypsin deficiency, symptomatic cholelithiasis, cytomegalovirus, Epstein-Barr virus, autoimmune hepatitis, or acute fatty liver of pregnancy), and HELLP syndrome. A total of 84 singleton pregnancies were included in this research.

The patients with ICP were categorized into two groups according to their serum bile acid levels: mild ( $<40 \mu\text{mol/L}$ ,  $n=53$ ) and severe ( $\geq 40 \mu\text{mol/L}$ ,  $n=31$ ). The control group was selected from age-matched healthy women who had singleton deliveries on the same day as that of patient's with ICP. All gestational age-matched controls complied with the exclusion criteria ( $n=145$ ).

Serum bile acids were evaluated using an enzymatic assay with intra and inter-assay precisions of 3% and 4%, respectively, [Diasyme Total Bile Acids (TBA) kit; Diasyme Diagnostic Laboratories, USA] and a Cobas C501 (Roche, USA). A blood analyzer (Cell-Dyn 3700; Abbott, USA) was used to determine the complete blood cell count (CBC). The CBC inflammatory markers measured were white blood cell counts (WBC), platelets, NLR, PLR, MPV, and RDW.

Perinatal death was defined as mortality from over 24 weeks' gestation until 7 days postpartum. A low Apgar score was defined as a score of below 7 at 5 minutes. The main outcome of the measures was the association of the inflammatory factors (WBC, NLR, PLR, MPV, and PDW) with the severity of ICP.

## Statistical Analysis

The statistical analysis was performed using the Statistical Package for the Social Sciences for Windows version 18 (SPSS Inc., Chicago, IL, USA). A  $p$  value of less than 0.05 was accepted as being statistically significant, and all measurements were performed within a 95% confidence interval. The results of the study are expressed as means, standard deviations, and percentages. According to the data distribution, comparisons were made using Student's  $t$ -test, ANOVA, or the chi-square ( $\chi^2$ ) test, when appropriate. A post-hoc least significant difference test was used after the ANOVA analysis. Relationships between the data were evaluated using Pearson's correlations.

## Results

The comparison between the patients with ICP ( $n=84$ ) and controls ( $n=145$ ) showed similar ages ( $28 \pm 5.5$  vs.  $28.1 \pm 5.2$

years,  $p>0.05$ ) and gravidities ( $2.1\pm1.3$  vs.  $2.3\pm1.2$ ,  $p>0.05$ ). The ICP group showed significantly decreased gestational weeks at delivery ( $36.2\pm2.3$  vs.  $39.1\pm1.4$  weeks,  $p<0.001$ ) and birth weights ( $2899\pm623.3$  g vs.  $3373\pm413.9$  g,  $p<0.001$ ) when compared with the healthy controls. The comparison of the characteristic findings of the patients with mild and severe ICP is presented in Table 1. The majority of patients (77.3% mild ICP vs. 74.1% severe ICP) were overweight/obese and aged younger than 35 years (79.2% mild ICP vs. 70.9% severe ICP), respectively. The women with mild and severe ICP exhibited similar characteristics with regard to educational status, chronic disease history, and previous ICP history ( $p<0.05$ ). Table 2 presents the laboratory findings; with the exception of serum bile acid levels, the women with mild and severe ICP had similar findings.

**Table 1.** The basal characteristics of mild (n=53) and severe (n=31) intrahepatic cholestasis of pregnancy

	Mild ICP	Severe ICP
Age <35 years	42 (79.2%)	22 (70.9%)
BMI (overweight/obese) (kg/m <sup>2</sup> )	41 (77.3%)	23 (74.1%)
Nulliparity	33 (62.5%)	11 (35.4%)
Abortion	17 (32%)	8 (25.8%)
Education (primary school)	38 (71.6%)	26 (83.8%)
Prior ICP	4 (7.5%)	2 (6.4%)
IVF pregnancy	3 (5.8%)	2 (6.4%)
Progesterone use in pregnancy	13 (22.6%)	5 (16.1%)

ICP: Intrahepatic cholestasis of pregnancy; BMI: Body mass index; IVF: *In vitro* fertilization

**Table 2.** The comparison of the laboratory findings between patients with mild and severe intrahepatic cholestasis of pregnancy

	Mild ICP (n=53)	Severe ICP (n=31)	p†
Hemoglobin (g/dL)	11.1±1.1	11.0±1.1	0.757
Hematocrit (%)	34.0±4.1	34.1±3.0	0.895
Alkaline phosphatase (ng/mL)	259±391.2	249±102.0	0.899
Lactate dehydrogenase (U/L)	24.3±71.0	25.0±51.0	0.648
Gamaglutamyl transferase (U/L)	27.7±28.7	23.8±14.5	0.518
AST (U/L)	135.1±139.2	144.8±173.1	0.773
ALT (U/L)	134.1±133.5	94.3±96.4	0.133
Bile acids (μmol/L)	20.5±7.6	78.9±50.0	<0.001
Fibrinogen (mg/dL)	54±105.0	52.0±128.0	0.743

†P value is obtained by t-test (Levene test used for homogeneity of variances)

ICP: Intrahepatic cholestasis of pregnancy; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase

Serum bile acids were positively and significantly correlated with PLR ( $r=0.343$ ,  $p=0.003$ ), but the correlations of bile acids with WBC ( $r=-0.062$ ), neutrophils ( $r=-0.198$ ), lymphocytes ( $r=-0.112$ ), MPV ( $r=0.08$ ), RDW ( $r=-0.174$ ), and NLR ( $r=-0.110$ ) were statistically non-significant ( $p>0.05$ ). Serum bile acids were negatively significantly correlated with gestational age at delivery ( $r=-0.390$ ,  $p<0.001$ ) and birth weight ( $r=-0.252$ ,  $p=0.02$ ), and PLR was negatively correlated with gestational age at delivery ( $r=-0.254$ ,  $p=0.003$ ).

The comparison of the obstetric outcomes in the women with mild and severe ICP is given in Table 3. The percentages of those having male fetuses, low Apgar scores, fetal distress, MSA, preeclampsia, perinatal/neonatal mortality, gestational diabetes, Rh isoimmunization, and abortus imminence were similar between the women with mild and severe ICP. However, the gestational age at delivery and time of diagnosis were earlier in the severe group ( $p<0.05$ ). In addition, the cesarean section rate was significantly increased in the severe group ( $p<0.05$ ).

Table 4 shows the comparison of the inflammatory markers between the normal and ICP groups. Overall, the inflammatory markers were significantly increased in the ICP group, including WBC, MPV, and PLR ( $p<0.05$ ), and neutrophils, lymphocytes, and RDW were significantly decreased in the ICP group ( $p<0.05$ ). However, NLRs were similar between the normal and ICP groups.

**Table 3.** The comparison of obstetric outcomes in mild (n=53) and severe (n=31) intrahepatic cholestasis of pregnancy

Mean ± SD	Mild ICP	Severe ICP
Gestational age at diagnosis	(33.5±2.8)	(30.8±4.7)†
Gestational age at delivery	(36.7±1.2)	(35.3±3.2)†
Birth weight (g)	(2975±568)	(2733±653)
Cesarean rate n (%)	29 (54.7%)	26 (83.6%)†
n (%) Male fetus	20 (37.7%)	11 (35.4%)
Fetal distress	2 (3.7%)	4 (12.9%)
Low Apgar score	1 (1.9%)	2 (6.4%)
Meconium stained amniotic fluid	2 (3.8%)	3 (9.6%)
Perinatal mortality	0 (0%)	1 (3.2%)
Neonatal mortality	1 (1.9%)	1 (3.2%)
Neonatal intensive care unit	10 (19%)	9 (29%)
Preeclampsia	7 (13.2%)	2 (6.4%)
Gestational diabetes	13 (24.5%)	4 (12.9%)
Rh isoimmunization	8 (15%)	4 (12.9%)
Hyperemesis gravidarum	1 (1.9%)	1 (3.2%)
Abortus imminence	7 (13.2%)	4 (12.9%)

P values were obtained using chi-square test or the t-test as appropriate (†significant at  $p<0.05$  level)

ICP: Intrahepatic cholestasis of pregnancy; SD: Standard deviation

Table 5 presents the comparison of the inflammatory markers in the healthy controls and women with mild and severe ICP. The RDW ( $p=0.128$ ) and WBC ( $p=0.535$ ) values were similar between the women with mild and severe ICP. MPV was significantly increased in the severe ICP group when compared with controls and the mild ICP group ( $p<0.05$ ). Despite the fact that PLR was increased and RDW was decreased in patients with ICP, they were not significantly changed between the mild and severe groups. MPV was the marker that significantly increased in the severe group.

## Discussion

ICP is a liver disease of pregnancy that increases fetal mortality; therefore, early diagnosis and assessment of the severity of the disease is an important task. In this study, we aimed to investigate the associations between the readily available, but newly defined, inflammatory markers, NLR, PLR, MPV, and RDW, with the severity of ICP. The present study found that the

inflammatory markers were significantly increased in patients with ICP, and that MPV increased with the severity of ICP.

Fetal distress, premature delivery, perinatal asphyxia, and intrauterine fetal death may all occur in patients with ICP<sup>(2,8,19)</sup>, and increased bile acid levels are thought to be the cause of these complications<sup>(20)</sup>. Consistent with previous studies, we observed lower birth weights and more preterm deliveries among patients with ICP<sup>(11,21-23)</sup>. However, there were no significant differences found in maternal age, parity, diabetes history, history of chronic systemic disease, preeclampsia or maternal hepatitis B and C infections in the women with mild and severe ICP, which was consistent with the study by Kawakita et al.<sup>(24)</sup>. Some studies found similar cesarean section rates<sup>(12,25,26)</sup>, in contrast to others<sup>(20,27)</sup>. In our study, cesarean rates were higher with severe ICP. Some authors found an increased MSA risk in the ICP group when compared with controls<sup>(8,28,29)</sup>, but some authors did not support these findings<sup>(27)</sup>. In addition, some previous studies reported an increased MSA risk in the severe ICP group when compared with the mild group<sup>(26,27)</sup>, but conflicting results have been reported<sup>(29)</sup> in the literature. Also in our study, we didn't find an increased MSA risk in the severe group when compared with the mild group. Fetal asphyxia in the newborns of patients with ICP has been reported frequently in the literature<sup>(30,31)</sup>. Overall, the characteristics of these patients show wide variations, and the findings are inconsistent in the literature<sup>(30)</sup>.

Previous studies about ICP and inflammation suggested that ICP was an inflammatory process, and that perinatal outcomes were related to inflammation<sup>(18,31-33)</sup>. Bile acids are thought to be related to inflammation, and they directly affect hepatocytes and stimulate the secretion of proinflammatory mediators, which causes neutrophil accumulation, extravasation, and activation<sup>(17)</sup>. Prior studies used the hematologic markers WBC<sup>(18)</sup>, MPV<sup>(31,32)</sup>, and NLR<sup>(18)</sup> as inflammatory markers in ICP. However, as far as we know, no studies have investigated the relationships between ICP and PLR and RDW. Therefore, to the best of our knowledge, this paper is the first to determine the associations between ICP and all CBC inflammatory markers. The results showed that serum bile acids were positively and significantly correlated with PLR ( $r=0.343$ ,  $p=0.003$ ), and the ICP group had a significantly increased PLR and significantly

**Table 4.** The comparison of hematologic indices between control and intrahepatic cholestasis of pregnancy group

Hematologic parameters	ICP (n=84)	Control (n=145)	p <sup>†</sup>
Hemoglobin (g/dL)	11.0±1.1	10.0±1	0.11
Hematocrit (%)	34.1±3.7	34.3±3	0.66
Platelet (10 <sup>3</sup> /mm <sup>3</sup> )	249±80	246±69	0.81
White blood cell count (10 <sup>3</sup> /mm <sup>3</sup> )	17449±3932	10333±2259	<0.001
Neutrophil (10 <sup>3</sup> /mm <sup>3</sup> )	7.2±2.2	7.9±1.9	0.04
Lymphocyte (10 <sup>3</sup> /mm <sup>3</sup> )	1.8±0.5	2.0±0.5	0.01
MPV (fL)	9.2±2.6	8.2±1.2	0.004
RDW (%)	15.1±2.7	17.1±3.4	<0.001
NLR	4.1±1.7	4.0±1.4	0.77
PLR	145±64	125±43	0.02

<sup>†</sup>P value is obtained by t-test (Levene test used for homogeneity of variances)

ICP: Intrahepatic cholestasis of pregnancy, MPV: Mean platelet volume, RDW: Red blood cell distribution width, NLR: Neutrophil-to-lymphocyte ratio, PLR: Platelet-to-lymphocyte ratio

**Table 5.** The comparison of inflammatory markers

	Control (n=145)	Mild ICP (n=53)	Severe ICP (n=31)	p <sup>†</sup>
WBC (10 <sup>3</sup> /mm <sup>3</sup> )	10.360±2300	15.000±3670	21.4±4419	<0.001
Platelet (10 <sup>3</sup> /mm <sup>3</sup> )	246±68.0	242±72.3	261±93.6	0.525
MPV (fL)	8.2±1.2	8.7±1.9	10.1±3.4	>0.001
RDW (%)	17.1±3.4	15.5±2.6	14.3±2.8	>0.001
NLR	4.0±1.4	4.3±1.7	3.8±1.5	0.312
PLR	125.4±43.0	144.0±61.0	147.0±69.0	0.06

<sup>†</sup>P value is obtained by ANOVA test (post-hoc least significant difference is used for subgroup analysis)

WBC: White blood cell count, MPV: Mean platelet volume, RDW: Red blood cell distribution width, NLR: Neutrophil-to-lymphocyte ratio, PLR: Platelet-to-lymphocyte ratio

decreased RDW ratio when compared with the controls. Despite the increased PLRs and decreased RDWs in the patients with ICP, they were not significantly changed in severe ICP.

Kirbas et al.<sup>(18)</sup> found significantly higher mean WBC and NLR values and a lower lymphocyte count in their severe ICP group than in controls, and NLR was found to be even higher in patients with mild ICP. They also found a significant association between fasting TBA levels and NLR<sup>(18)</sup>. However, we found that neutrophil and lymphocyte counts were significantly decreased in patients with ICP; NLRs were similar between the normal and ICP group. Platelets in the blood vary in size, with the granules and adhesion molecules of the platelets increasing when they become larger and play an active role in homeostasis<sup>(34)</sup>. MPV, which is the most frequently used platelet size measurement, is also an index of platelet activation<sup>(34)</sup>. Platelets release thrombin, which plays a role in inflammation<sup>(34)</sup> and angiogenesis<sup>(35)</sup>, and a high platelet volume allows greater coagulability and fibrinolysis<sup>(36)</sup>. However, there is a limited number of studies about the relationship between MPV and the severity of ICP, and the relationship between MPV and perinatal outcomes, even though an MPV increase can be seen in patients with ICP<sup>(31,32)</sup>. Kebapcilar et al.<sup>(31)</sup> investigated the relationship between coagulation parameters and low 5-minute Apgar scores in both patients with ICP and normal pregnancies. In addition, Oztas et al.<sup>(32)</sup> reported higher MPVs in patients with ICP when compared with a control group, with an increased preterm delivery likelihood just after exceeding an MPV of 11.2 fL. In our study, MPV was significantly increased in women with ICP cases compared with healthy controls. Moreover, apart from the PLR and WBC, the MPV levels increased in the severe group.

### Study Limitations

The main limitation of this study was its retrospective design, but despite this methodologic limitation, this research investigated all of the available hematologic inflammatory parameters. It confirmed prior data that inflammatory markers are significantly increased in patients with ICP. Despite the significant changes in the inflammatory markers in patients with ICP, only MPV was significantly increased with the severity of the disease. These results suggest that MPV may be a valuable marker in patients with severe ICP, but large scale studies are needed to confirm this result.

### Conclusion

Based on the results of this study, the inflammatory markers were significantly increased in patients with ICP. PLR, WBC, and MPV were all significantly increased, whereas the RDW was significantly decreased in ICP. MPV was related to the severity of disease and might be a valuable marker for ICP disease severity in the future.

### Ethics

**Ethics Committee Approval:** This study was approved by the Zeynep Kamil Women and Children's Health Training and

Research Hospital Local Ethics Committee (approval number: 136).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: Ç.Y.A., F.V., O.P., Ç.K., Concept: Ç.Y.A., F.V., Design: Ç.Y.A., F.V., Data Collection or Processing: Ç.Y.A., E.B.E., İ.Y., A.E., O.P., Analysis or Interpretation: Ç.Y.A., F.V., E.B.E., Literature Search: Ç.Y.A., İ.Y., Ç.K., Writing: Ç.Y.A., F.V.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. *J Hepatol* 2000;33:1012-21.
2. Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. *Ann Hepatol* 2006;5:202-5.
3. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. *Obstet Gynecol Clin North Am* 2010;37:269-82.
4. Heinonen S, Kirkinen P. Pregnancy outcome with intrahepatic cholestasis. *Obstet Gynecol* 1999;94:189-93.
5. Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Pruritus may precede abnormal liver function tests in pregnant women with obstetric cholestasis: a longitudinal analysis. *BJOG* 2001;108:1190-2.
6. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. *Hepatology* 2006;43:723-8.
7. Geenes V, Williamson C. Liver disease in pregnancy. *Best Pract Res Clin Obstet Gynecol* 2015;29:612-24.
8. Brouwers L, Koster MP, Page-Christiaens GC, Kemperman H, Boon J, Evers IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. *Am J Obstet Gynecol* 2015;212:100.e1-e7.
9. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. *World J Gastroenterol* 2009;15:2049-66.
10. Diken Z, Usta IM, Nassar AH. A Clinical Approach to Intrahepatic Cholestasis of Pregnancy. *Am J Perinatol* 2014;31:1-8.
11. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. *Hepatology* 2014;59:1482-91.
12. Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. *PLoS One* 2012;7:e28343.
13. Asulyman OM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. *Am j obstet Gynecol* 1996;175:9957-60.
14. Oztekin D, Aydal I, Oztekin O, Okcu S, Borekci R, Tinar S. Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy. *Arch Gynecol Obstet* 2009;280:975-9.



15. Nunez J, Nunez E, Bodi V, Sanchis J, Minana G, Mainar L, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. *Am J Cardiol* 2008;101:747-52.
16. Zhang WW, Liu KJ, Hu GL, Liang WJ. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. *Tumour Biol* 2015;36:8831-7.
17. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. *Am J Pathol* 2011;178:175-86.
18. Kirbas A, Biberoglu E, Daglar K, Iskender C, Erkaya S, Dede H, et al. Neutrophil-to-lymphocyte ratio as a diagnostic marker of intrahepatic cholestasis of pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2014;180:12-5.
19. Garcia-Flores J, Cañamares M, Cruceyra M, Garicano A, Espada M, Lopez A, et al. Clinical value of maternal bile Acid quantification in intrahepatic cholestasis of pregnancy as an adverse perinatal outcome predictor. *Gynecol Obstet Invest* 2015;79:222-8.
20. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. *Hepatology* 2004;40:467-74.
21. Roncaglia N, Arreghini A, Locatelli A, Bellini P, Andreotti C, Ghidini A. Obstetric cholestasis: outcome with active management. *Eur J Obstet Gynecol Reprod Biol* 2002;100:167-70.
22. Puljic A, Kim E, Page J, Esakoff T, Shaffer B, LaCoursiere DY, et al. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. *Am J Obstet Gynecol* 2015;212:667.e1-5.
23. Kondrackiene J, Kupcinskas L. Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. *World J Gastroenterol* 2008;14:5781-8.
24. Kawakita T, Parikh LI, Ramsey PS, Huang CC, Zeymo A, Fernandez M, et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. *Am Obstet Gynecol* 2015;213:570.e1-e8.
25. Friberg AK, Zingmark V, Lyndrup J. Early induction of labor in high-risk intrahepatic cholestasis of pregnancy: what are the costs? *Arch Gynecol Obstet* 2016;294:709-14.
26. Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi M, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. *Am J Perinatol* 2008;25:341-5.
27. Wikstrom Shemer E, Marschall HU, Ludvigsson J, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. *BJOG* 2013;120:717-23.
28. Blackwell SC, Wolfe HM, Redman ME, Hassan SS, Berry SM, Treadwell MC, et al. Relationship between meconium staining and amniotic fluid volume in term pregnancies. *Fetal Diagn Ther* 2002;17:78-82.
29. Sargin Oruç A, Seçkin B, Özcan N, Özyer S, Uzunlar Ö, Danişman N. Role of postprandial bile acids in prediction of perinatal outcome in intrahepatic cholestasis of pregnancy. *J Obstet Gynaecol Res* 2014;40:1883-9.
30. Sentilhes L, Verspyck E, Pia P, Marpeau L. Fetal death in a patient with intrahepatic cholestasis of pregnancy. *Obstet Gynecol* 2006;107:458-60.
31. Kebapcilar AG, Taner CE, Kebapcilar L, Bozkaya G. High mean platelet volume, low-grade systemic coagulation, and fibrinolytic activation are associated with pre-term delivery and low APGAR score in intrahepatic cholestasis of pregnancy. *J Matern Fetal Neonatal Med* 2010;23:1205-10.
32. Oztas E, Erkenekli K, Ozler S, Ersoy AO, Kurt M, Oztas E, et al. Can routine laboratory parameters predict adverse pregnancy outcomes in intrahepatic cholestasis of pregnancy? *J Perinat Med* 2015;43:667-74.
33. Biberoglu E, Kirbas A, Daglar K, Kara O, Karabulut E, Yakut HI, et al. Role of inflammation in intrahepatic cholestasis of pregnancy. *J Obstet Gynaecol Res* 2016;42:252-7.
34. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. *Thromb Res* 1983;32:443-60.
35. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. *Proc Natl Acad Sci U S A* 2006;103:855-60.
36. Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med* 1999;340:115-26.





# Third trimester anemia extends the length of hospital stay after delivery

## Üçüncü trimesterdeki anemi doğum sonrası hastanede kalış süresini arttırmaktadır

Kazibe Koyuncu, Batuhan Turgay, Yavuz Emre Şükür, Bircan Yıldırım, Can Ateş, Feride Söylemez

Ankara University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

### Abstract

**Objective:** To assess the relationship between maternal third trimester anemia and hospital stay after delivery.

**Materials and Methods:** In this retrospective cross-sectional study, 695 women aged 18-42 years were included between January 2016 and June 2016. Obstetric outcomes and fetal outcomes were measured. Statistical analysis was performed using SPSS, version 19.0 (SPSS, Chicago, Illinois).

**Results:** The prevalence of anemia in this study was 15.2%. The study population was divided into three groups according to hemoglobin (Hb) levels. Group 1 consisted of patients with Hb <8.5 g/dL, group 2 Hb 8.5-11 g/dL, and group 3 Hb >11 g/dL. Higher levels of Hb were associated with shorter stay in hospital (p=0.028). In binary comparison, no significant difference was observed between groups 2 and 3, whereas it was statistically different from group 1. Fetal weight (p=0.562), neonatal intensive care unit admission (p=0.596), APGAR score 1<sup>st</sup> (p=0.674) and 5<sup>th</sup> minute (p=0.876), type of delivery (p=0.831), and gestational age (p=0.798) were not statistically different between the groups; however, hospitalization time was significantly different (p=0.028).

**Conclusion:** Maternal anemia in the third trimester prolongs hospitalization time after delivery. Anemia effects pregnancy and the fetus in the postpartum period in addition to the prenatal period.

**Keywords:** Anemia, hospitalization, third trimester

### Öz

**Amaç:** Üçüncü trimester anemisi ile doğum sonrası hastanede yatış süresi arasındaki ilişkinin değerlendirilmesidir.

**Gereç ve Yöntemler:** Bu retrospektif kesitsel çalışmaya, 18-42 yaşları arasında 695 kadın, Ocak 2016 ve Haziran 2016 tarihleri arasında dahil edildi. Obstetrik ve fetal sonuçlar değerlendirildi. İstatistiksel analiz, SPSS 19,0 versiyonu kullanılarak yapıldı (SPSS, Chicago, Illinois).

**Bulgular:** Bu çalışmadaki anemi prevalansı %15,2 olarak bulundu. Çalışma popülasyonu hemogloblin (Hb) değerlerine göre üç gruba ayrıldı. Grup 1'e Hb değerleri 8,5 altında olan hastalar, grup 2'ye Hb değeri 8,5-11 arasında olan hastalar, grup 3'e ise Hb değeri 11'in üzerinde olan hastalar dahil edildi. Hb değerlerinin yüksek olması hastanede kalış süresini kısaltmaktadır (p=0,028). İkili karşılaştırmalarda grup 2 ve 3 arasında anlamlı fark saptanmazken, grup 1 ile diğer iki grup arasında anlamlı fark saptanmıştır. Fetal ağırlık (p=0,562), yenidoğan yoğunbakım yatışı (p=0,596), APGAR 1. dakika (p=0,674), 5. dakika değeri (p=0,876), doğum şekli (p=0,831) ve doğum zamanı (p=0,798) arasında istatistiksel olarak anlamlı fark saptanmadı, ancak hastanede kalma süresi açısından karşılaştırıldığı gruplar arasında anlamlı fark saptandı (p=0,028).

**Sonuç:** Üçüncü trimesterde maternal anemi doğumdan sonra hastanede yatış süresini uzatmaktadır. Anemi gebelik ve fetüs prenatal dönemin yanı sıra postnatal dönemde de etkilemektedir.

**Anahtar Kelimeler:** Anemi, hastanede kalış süresi, üçüncü trimester

Address for Correspondence/Yazışma Adresi: Kazibe Koyuncu, MD,

Ankara University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Phone: +90 505 372 81 24 E-mail: kazibekkoyuncu@gmail.com ORCID ID: orcid.org/0000-0001-9070-3962

Received/Geliş Tarihi: 09.08.2017 Accepted/Kabul Tarihi: 04.09.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

**PRECIS:** In this study, we have assessed the relationship between maternal third trimester anemia and hospital stay after delivery.

## Introduction

Maternal anemia remains an important public health problem in under-developed and developing countries like ours. The Centers for Disease Control and Prevention suggested that anemia should be defined as hemoglobin levels of less than 11 g/dL (hematocrit less than 33%) in the first and third trimesters and less than 10.5 g/dL (hematocrit less than 32%) in the second trimester<sup>(1)</sup>. The prevalence of anemia among pregnant women seems to differ between countries and even between regions of a country. It is estimated that half of all pregnant worldwide women are anemic<sup>(2)</sup>. The anemia prevalence in different regions of Turkey were reported between 27% and 88%, on an average 50%<sup>(3)</sup>.

Anemia is a physiologic result of pregnancy, and to some extent, it may be necessary. The absence of physiologic anemia has been suggested to be associated with stillbirth<sup>(4,5)</sup>. Maternal anemia may have a significant impact on fetal outcome in terms of preterm birth and infant deaths<sup>(6)</sup>. The relationship between low birth weight, preterm birth, small for gestational age, perinatal mortality, neonatal mortality, gestational diabetes, preeclampsia, and mode of delivery according to maternal anemia status has been shown in the literature, yet it is not precisely concluded<sup>(4)</sup>. However, the impact of severity of anemia on obstetric outcomes is controversial. Several studies suggest that only severe anemia leads to poor obstetrics outcomes<sup>(7)</sup>.

The aim of our study was to identify the impact of third trimester hemoglobin values on perinatal outcomes and type and time of delivery.

## Materials and Methods

The retrospective cross-sectional study was conducted in the obstetrics out-patient clinic in a university-based hospital between January 2016 and April 2016. All data of women who were referred for routine third trimester follow-up were recorded. The inclusion criteria were as follows: age between 18 and 45 years, singleton pregnancy, iron supplementation started around 18<sup>th</sup> gestational week, gestational age between 28 and 40 weeks during the study period, and at least one complete blood count during the third trimester. The exclusion criteria were history of preterm delivery, elevated risk pregnancy, previous uterine surgery including cesarean section, multiple gestation, any type of chronic systemic disease, and not receiving iron supplementation.

All analyzed data were obtained from the patients' charts and medical records. Patients were divided into three groups: group 1 consisted of patients with Hb <8.5 g/dL, group 2 comprised patients with Hb 8.5- 11 g/dL, and group 3 constituted patients with Hb >11 g/dL. The main outcome measures were perinatal and neonatal outcome parameters such as gestational age at

delivery, mode of delivery, birth weight and APGAR scores, type of delivery, and duration of hospitalization. Ethics committee approval and informed consent were not taken as it is a retrospective study.

## Statistical Analysis

Statistical analysis was performed using SPSS, version 19.0 (SPSS, Chicago, Illinois). Due to the normal distribution of all data, ANOVA test was used for the determination of differences between the three groups. The independent sample t-test was used for to determine differences between the two sexes. Categorical data were assessed using the chi-square test.  $P < 0.05$  was considered statistically significant.

## Results

A total of 695 pregnant women were assessed for eligibility. Among those, 265 patients were excluded due to being lost to follow-up ( $n=97$ ), multiple pregnancy ( $n=13$ ), not receiving iron supplementation ( $n=92$ ), presence of chronic disease ( $n=73$ ). As a result, 433 patients were included in the final analyses. The mean third trimester hemoglobin level was  $11.98 \pm 5.44$  mg/dL (7-15.2 mg/dL). Anemia prevalence in our study population was 15.2%. The characteristics of the study population are presented in Table 1.

Table 2 represents the comparison of perinatal outcome measures between groups 1, 2, and 3. The only parameter that showed a statistically significant difference between the groups was the duration of hospitalization. The duration of hospitalization was significantly longer in group 1 than in groups 2 and 3 ( $p=0.028$ ).

## Discussion

The aim of our study was to identify the impact of third trimester hemoglobin values on perinatal outcomes and type and time of delivery. According to the results, severe anemia during the third trimester results in increased duration of hospitalization. Otherwise, it has no adverse effects on outcomes.

Anemia during the third trimester of pregnancy is defined as Hb less than 11 g/dL or hematocrit less than 33% by the CDC<sup>(1)</sup> and its prevalence can differ between populations and

**Table 1.** Characteristics of the study population

	Mean $\pm$ SD	Minimum	Maximum
Age (year)	28.80 $\pm$ 5.36	18	42
BMI (kg/m <sup>2</sup> )	27.2 $\pm$ 3.21	22	31
Gestational age (weeks)	38 $\pm$ 2.31	27	41
Parity	1.39 $\pm$ 0.93	1	4
Hemoglobin (mg/dL)	11.98 $\pm$ 1.35	7	15.2
SD: Standard deviation, BMI: Body mass index			

**Table 2.** Comparison of hemoglobin values between the three groups (maternal third trimester hemoglobin level groups as lower 8.5 mg/dL, between 8.5 and 11 mg/dL, upper 11 mg/dL)

	Group 1 (n=24)	Group 2 (n=87)	Group 3 (n=322)	Significance p
Birth weight, grams <sup>a</sup>	3357.5±256	3203.7±152	3110.4±203	0.562
Newborn hospitalization, n (%) <sup>b</sup>	0 (0)	7 (8.07)	18 (5.59)	0.596
Gestational age at birth, weeks <sup>a</sup>	38.2±6	38.3±4	38.5±2	0.798
APGAR 1 <sup>st</sup> minute <sup>a</sup>	7.6±1.5	7.7±2.14	7.5±1.78	0.510
APGAR 5 <sup>th</sup> minute <sup>a</sup>	9.2±0.23	9.1±0.14	9.0±0.71	0.876
Mode of delivery, n (%) <sup>b</sup>				
Vaginal <sup>b</sup>	13 (54.1)	46 (52.8)	172 (53.4)	0.831
Cesarean section <sup>b</sup>	11 (45.8)	43 (47.1)	150 (46.5)	
Hospital stay, days <sup>a</sup>	5.2±1.2	2.5±1.1	2.8±1.4	0.028*

\*The significance stems from the differences between group 1 and 2 (p=0.024) and group 1 and group 3 (p=0.043) (<sup>a</sup>Compared using one-way ANOVA test, <sup>b</sup>Compared using chi-square test)

geographic regions. In our study, the prevalence of anemia was found as 15.2% during the third trimester of pregnancy. Although different anemia prevalences have been reported from various parts of our country, the prevalence of third trimester anemia in our study was similar to that reported from a large maternity hospital in our city<sup>(7)</sup>. Both the prevalence from our study and the other study seem to be lower than other parts of the country. This situation might be due to higher socioeconomic status resulting in appropriate follow-up during pregnancy and proper iron replacement therapy. Furthermore, grand-multiparity was rare in our study population and multiparity is also a risk factor for anemia in pregnant women<sup>(8)</sup>.

According to the results obtained from our study, severe third trimester anemia is associated with longer hospital stay after delivery. The main reason for longer hospitalization is postpartum anemia treatment, either by transfusion or intravenous iron supplementation<sup>(9)</sup>. Lin et al.<sup>(10)</sup> reported that every 1-U decrease in hemoglobin level extended the median length of hospital stay by 1.5 days among anemic general medical inpatients. Also, it has been reported that anemia increased the 30-day unplanned readmission rate in addition to extending hospital stay<sup>(11)</sup>.

Iron supplementation may be preventive for adverse effects of anemia<sup>(12,13)</sup>. A recent Cochrane review Peña-Rosas et al.<sup>(13)</sup> concluded that women with anemia were at greater risk of having low-birth-weight infants. On the contrary, Scholl et al.<sup>(14)</sup> suggested a subdivision of anemia according to etiology and gestational age and reported that third trimester anemia due to iron deficiency had no correlation with low birth weight. In addition, some other studies concluded that after adjusting for confounders, anemia was not relevant to poor neonatal outcomes because these relationships were a result of poverty or low socioeconomic status<sup>(14)</sup>. In our study, we also failed to show a significant impact of anemia on neonatal outcomes such as birth weight, APGAR scores at first and

fifth minutes, and neonatal intensive care unit admission. As local clinical policy, we clamp the cord 1-3 minutes after birth and this may be the reason for the neonatal results obtained from our study.

Sehgal et al.<sup>(15)</sup> reported that anemia did not affect the mode of delivery in nulliparous pregnant women. Mild anemia seems to be inconclusive for estimating mode of delivery<sup>(15)</sup>. Van Bogaert<sup>(16)</sup> also suggested no effect of anemia during first trimester of pregnancy on the mode of delivery. Our results were also in accordance with these studies. In the present study, we excluded patients with previous uterine surgery to identify the effect of anemia on the mode of delivery. However, we found no significant effect of anemia on the mode of delivery. In addition, the indications for cesarean section did not differ between the groups.

One of the strengths of our study was the standardized follow-up and management protocol for each patient. Also, neonatal results were obtained from a single center. The strict inclusion and exclusion criteria to create a homogenous study population add credence to our results.

### Study Limitations

The main limitations of our study were the retrospective design and small number of patients included. However, the present study was conducted in a tertiary referral center and we excluded high-risk patients. Hence, it was not possible to include more patients in such a study using strict inclusion criteria, conducted in a single center.

### Conclusion

Anemia during the third trimester extends the length of hospital stay in the postpartum period. However, it does not seem to affect neonatal outcomes and mode of delivery. Prevention and/or treatment of anemia before delivery can shorten the duration of hospital stay. Prospective studies in large cohorts are needed to clarify the exact effects of mild and severe anemia on perinatal and neonatal outcomes.

## Ethics

**Ethics Committee Approval:** Retrospective study.

**Informed Consent:** Retrospective study.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: F.S., Y.E.Ş., Concept: B.T., Design: K.K., Data Collection or Processing: B.Y., Analysis or Interpretation: C.A., Literature Search: K.K., B.T., Writing: K.K., Y.E.Ş.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

- Centers for Disease Control (CDC). CDC criteria for anemia in children and childbearing-aged women. *MMWR Morb Mortal Wkly Rep* 1989;38:400-4.
- United Nations. Administrative Committee on Coordination. Subcommittee on Nutrition. and International Food Policy Research Institute. Second report on the world nutrition situation: a report compiled from information available to the ACC/SCN.1992, Geneva, Switzerland. Washington DC: United Nations International Food Policy Research Institute.
- Pekcan G, Karaagaoglu N. State of nutrition in Turkey. *Nutr Health* 2000;14:41-52.
- Stephansson O, Dickman PW, Johansson A, Cnattingius S. Maternal hemoglobin concentration during pregnancy and risk of stillbirth. *JAMA* 2000;284:2611-7.
- Lone FW, Qureshi RN, Emanuel F. Maternal anemia and its impact on perinatal outcome. *Trop Med Int Health* 2004;9:486-90.
- Sifakis S, Pharmakides G. Anemia in pregnancy. *Ann N Y Acad Sci* 2000;900:125-36.
- Karaoglu L, Pehlivan E, Egri M, Deprem C, Gunes G, Genc MF, et al. The prevalence of nutritional anemia in pregnancy in an east Anatolian province, Turkey. *BMC Public Health* 2010;10:329.
- Sehgal R, Kriplani A, Vanamail P, Maiti L, Kandpal S, Kumar N. Assessment and comparison of pregnancy outcome among anemic and non-anemic primigravida mothers. *Indian J Public Health* 2016;60:188-94.
- Yildiz Y, Özgü E, Unlu SB, Salman B, Eyi EG. The relationship between third trimester maternal hemoglobin and birth weight/length; results from the tertiary center in Turkey. *J Matern Fetal Neonatal Med* 2014;27:729-32.
- Lin RJ, Evans AT, Chused AE, Unterbrink ME. Anemia in general medical inpatients prolongs length of stay and increases 30-day unplanned readmission rate. *South Med J* 2013;106:316-20.
- Aban M, Güngören A, Uyar H, Yilmaz N. Grand Multipar Kadınlardaki Riskler. *Perinatoloji Dergisi* 1991;5:20-2.
- Preziosi P, Prual A, Galan P, Daouda H, Boureima H, Hercberg S. Effect of iron supplementation on the iron status of pregnant women: consequences for newborns. *Am J Clin Nutr* 1997;66:1178-82.
- Pena-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev* 2015;CD004736.
- Scholl TO, Hediger ML, Fischer RL, Shearer JW. Anemia vs iron deficiency: increased risk of preterm delivery in a prospective study. *Am J Clin Nutr* 1992;55:985-8.
- Sehgal R, Kriplani A, Vanamail P, Maiti L, Kandpal S, Kumar N. Assessment and comparison of pregnancy outcome among anemic and non-anemic primigravida mothers. *Indian J Public Health* 2016;60:188-94.
- Van Bogaert LJ. Anemia and pregnancy outcomes in a South African rural population. *J Obstet Gynaecol* 2007;27:755.



# Comparison of bupivacaine and ropivacaine in combination with fentanyl used for walking epidural anesthesia in labor

## Yürüyen epidural anesteziye fentanil ile kombine kullanılan bupivakain ve ropivakainin karşılaştırılması

Şükrü Gündüz<sup>1</sup>, Serenat Eriş Yalçın<sup>2</sup>, Gökhan Karakoç<sup>3</sup>, Mehmet Özgür Akkurt<sup>2</sup>, Yakup Yalçın<sup>4</sup>, And Yavuz<sup>2</sup>

<sup>1</sup>University of Health Sciences, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Clinic of Anesthesiology, İstanbul, Turkey

<sup>2</sup>Süleyman Demirel University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Perinatology, Isparta, Turkey

<sup>3</sup>University of Health Sciences, Ankara Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

<sup>4</sup>Isparta City Hospital, Clinic of Gynecologic Oncology, Isparta, Turkey

### Abstract

**Objective:** Effective pain relief during labor is essential to reduce maternal and perinatal morbidity arising due to pain-induced maternal sympathetic activation, and to avoid unnecessary cesarean sections performed due to maternal anxiety. Walking epidural analgesia on labor reveals lower pain scores, leading to higher maternal satisfaction with better cardiovascular and pulmonary physiology. Despite the extensive use and relative safety of bupivacaine, newer drugs such as ropivacaine have been developed as alternative agents to decrease the risk for cardiac and central nervous system toxicity.

**Materials and Methods:** One hundred women who requested epidural analgesia in active labor were randomly allocated into two groups; one group received 20 mL of ropivacaine 0.125% with fentanyl 50 µg and the other received 20 mL of bupivacaine 0.125% with fentanyl 50 µg. The efficacy of analgesia, adverse effects, and obstetric and neonatal outcomes of both groups were compared.

**Results:** There were no differences between the two study groups in the measured obstetric and neonatal outcomes. The onset time, duration of analgesia, and sensory levels were similar between the groups. Visual analog pain scale scores did not differ between the groups before analgesia or at any of the subsequent evaluation periods.

**Conclusion:** Both ropivacaine and bupivacaine provide equivalent labor analgesia with high maternal satisfaction and tolerable adverse effects in the clinically used dose range. No adverse obstetric or neonatal outcomes were observed in either group. Therefore, either drug is a reasonable choice for labor analgesia and can be used without jeopardizing the safety of the mother and fetus.

**Keywords:** Bupivacaine, epidural, fentanyl, labor, ropivacaine

### Öz

**Amaç:** Doğum sırasında etkin ağrı giderimi, ağrının neden olduğu maternal sempatik aktivasyon nedeniyle ortaya çıkan maternal ve perinatal morbiditeyi ve anne kaygısı nedeniyle uygulanan gereksiz sezaryen oranlarını azaltmak için önemlidir. Doğumda yürüyen epidural analjezi uygulanması daha iyi kardiyovasküler ve pulmoner fizyoloji ile anne memnuniyetine yol açan daha düşük ağrı skorları ortaya koyar. Bupivakainin yaygın kullanımı ve görece emniyetine rağmen, ropivakain gibi yeni ilaçlar, kardiyak ve merkezi sinir sistemi toksisitesi riskini azaltmak için alternatif ajanlar olarak geliştirilmiştir.

**Gereç ve Yöntemler:** Aktif doğumda epidural analjezi isteyen 100 kadın randomize olarak iki gruba ayrıldı; bir gruba 20 mL ropivakain %0,125 + fentanil 50 µg ve diğer gruba 20 mL %0,125 bupivakain ile fentanil 50 µg verildi. Her iki grupta analjezi etkinliği, yan etkiler, obstetrik ve neonatal sonuçlar karşılaştırıldı.

**Bulgular:** Obstetrik ve neonatal sonuçlar açısından iki çalışma grubu arasında fark yoktu. Başlangıç yaşı, analjezi süreleri ve duyu seviyeleri gruplar arasında benzerdi. Görsel analog ağrı skalası skorları, analjezi öncesi veya sonraki değerlendirme periyodlarının herhangi birinde gruplar arasında fark göstermedi.

**Sonuç:** Hem ropivakain hem de bupivakain, klinik olarak kullanılan doz aralığında yüksek anne memnuniyeti ve tolere edilebilen yan etkiler ile eşit analjezik etkinlik sağlamıştır. Her iki grupta istenmeyen obstetrik ve neonatal sonuç gözlenmemiştir. Bu nedenle, anne ve fetüsün güvenliğini tehlikeye atmadan, her iki ilaç da doğum analjezisi için makul bir seçenek olarak değerlendirilebilir.

**Keywords:** Bupivakain, epidural, fentanil, doğum, ropivakain

Address for Correspondence/Yazışma Adresi: Serenat Eriş Yalçın, MD,

Süleyman Demirel University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Perinatology, Isparta, Turkey

Phone: +90 535 025 36 92 E-mail: serenateris@hotmail.com ORCID ID: orcid.org/0000-0002-6465-325X

Received/Geliş Tarihi: 05.06.2017 Accepted/Kabul Tarihi: 21.06.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.



**PRECIS:** Ropivacaine and bupivacaine seem to be equiopotent at clinically used concentrations and can both be reasonable choices for labor analgesia.

## Introduction

Labor pain is reported to be one of the most severe pains that have ever been evaluated<sup>(1,2)</sup>. In a previous study, 41% of women considered it as the worst experience that they had ever had. Fear of labor pain seems one of the most important reasons for the tendency to cesarean section<sup>(2)</sup>. Additionally, pain-induced maternal sympathetic activation in labor compromises fetal oxygenation. Therefore, effective pain relief during labor is essential to reduce maternal and perinatal morbidity and to avoid unnecessary cesarean sections performed due to maternal anxiety<sup>(3)</sup>.

Walking epidural analgesia on labor reveals lower pain scores, leading to higher maternal satisfaction with better cardiovascular and pulmonary physiology<sup>(3)</sup>. The ideal drugs to be used for labor analgesia should have a long duration of action with minimum motor blockade, limited placental transfer, and no significant adverse effects on the mother and fetus<sup>(4,5)</sup>. Bupivacaine is the most commonly used drug for this purpose. Despite the extensive use and relative safety of bupivacaine, newer drugs such as ropivacaine and levobupivacaine have been developed as alternative agents to decrease the risk for cardiac and central nervous system toxicity. Another advantage of these drugs is less motor blockade compared with bupivacaine<sup>(6)</sup>. The addition of opioids to these local anesthetics such as sufentanil or fentanyl is preferable due to their dose minimizing and adverse-effect-reducing properties<sup>(7)</sup>. The purpose of the current study was to compare the effects on obstetric and neonatal outcomes between ropivacaine and bupivacaine in combination with fentanyl used in walking epidural analgesia.

## Materials and Methods

This prospective randomized controlled trial was conducted at a tertiary center during a one-year period. The study was approved by the Cerrahpaşa University Local Ethics Committee (approval number: P20/1999). Written consent for participation was obtained prior to recruitment into the study.

Women aged 18-35 years, classified as American Society of Anesthesiologists score I and II who requested epidural analgesia in active labor with cervical dilatation 3-4 cm, and uterine contractions  $\geq 3/10$  minutes between 37-41 weeks' gestational age with a singleton pregnancy in the vertex position were enrolled in this study.

Women with high risk pregnancies as defined by the obstetrician such as severe preeclampsia, insulin-dependent diabetes mellitus, multiple pregnancies or with any contraindications to epidural techniques such as coagulopathies, spinal deformities, local infections, and any sensitivity to the drug were excluded. The patients were randomized 1:1 to each treatment arm, with stratification based on parity. One hundred participants

who met the above mentioned criteria were allocated into two groups. Group R received 20 mL of ropivacaine 0.125% with fentanyl 50 µg, and group B received 20 mL of bupivacaine 0.125% with fentanyl 50 µg.

No sedative premedication was given to the participants. After intravenous prehydration with 500 mL 0.09% NaCl solution, a 16-gauge Touhy needle was placed in the patients at the level of L3-4 or L4-5 interspaces via a midline approach under complete aseptic conditions. The loss of resistance technique was used to identify the epidural space. After monitoring any aspirate of blood or cerebrospinal fluid via the catheter, a 3 mL test dose of the study medication was administered. If there were no signs of an intravascular or intrathecal injection for the following 5 minutes, the remaining dose of the selected medication was administered. The catheter was inserted about 3-4 cm into the epidural space and securely fixed. After the insertion, patients were placed in the supine position with left uterine displacement.

Vital parameters of the mother such as heart rate, blood pressure, respiratory rate, and maternal saturation were recorded before and every 15 minutes after the injection. Onset of analgesia was evaluated as the time after injection until the first painless contraction occurred. The effectiveness of the epidural block was evaluated using a visual analog pain scale (VAS) (VAS: 0 to 10, with 0 being no pain and 10 being the worst imaginable pain). An additional dose of 5 mL of the analgesic solution was injected whenever the parturient had VAS  $\geq 3$  during labor. The sensory level was assessed using the pinprick method. Preservation of motor function was determined using the modified Bromage scale in both legs (0: no paralysis, full flexion of knees and feet, 1: inability to raise the extended leg and ability to move knees and feet; 2: inability to move knees but ability to move feet; 3: inability to flex ankle joints, complete motor blockade of lower limbs). Maternal adverse effects during the procedure such as nausea, vomiting, pruritus, bradycardia, trembling, and hypotension were recorded.

Fetal wellbeing and uterine contractions were monitored using cardiotocography. For the comparison of uterine activity, a 30-minute postinjection period was taken into account. The duration of the first and second stages of labor, and mode of delivery were recorded. Neonatal welfare was assessed using Apgar scores at 1 and 5 minutes. Maternal satisfaction about labor analgesia was determined after 24 hours on a four-point scale.

## Statistical Analysis

Data were analyzed using IBM SPSS 22.0 software (SPSS Inc., IBM, Chicago, Illinois, USA), and descriptive data are expressed as mean  $\pm$  standard deviations and frequencies. The Mann-Whitney U test, Student's t-test, and chi-square test were

used for comparisons. A probability (p) value of  $<0.05$  was considered significant.

## Results

The enrolled 100 women were assigned to either the ropivacaine group (group R) (n=50) or the bupivacaine group (group B) (n=50). The demographic characteristics were similar between the two groups. Maternal and fetal hemodynamic data were also comparable (Table 1).

Maternal adverse effects (nausea and pruritus) were seen in both groups (group B: 20%, group R: 10%; group B: 10%, group R: 20%, respectively). Trembling was only seen in two patients of group R. There were no cases of motor blockade in either group.

The onset time, duration of analgesia, and sensory levels were similar between the groups. VAS scores did not differ between

the groups before analgesia or at any of the subsequent evaluation periods. Ten parturients in group R and 11 in group B required an additional bolus of 5 mL after 2-3 hours (Table 2).

Maternal satisfaction with labor analgesia was mostly defined as excellent in both groups and no significant difference was observed between the groups (Table 2).

Obstetric characteristics and outcomes are shown in Table 3. Four parturients in each group required cesarean section and one parturient required forceps application in group B. No significant difference was found between the groups when assessed for uterine activity.

Twenty percent of patients in group B and 28% in group R required local anesthesia for closure of the episiotomy wound.

There were no differences between the two study groups in the measured neonatal outcomes (Table 3).

**Table 1.** Demographic characteristics of the patients and data of maternal and fetal hemodynamic parameters

	Ropivacaine (n=50)	Bupivacaine (n=50)	p
Age (year)	23.62±3.86	22.58±3.03	0.695
Height (cm)	161.9±4.86	162.86±4.11	0.288
Weight (kg)	64.06±6.96	63.9±5.67	0.515
Parity (n)			-
Primiparae	32	32	
Multiparae	18	18	
ASA group (n)			-
I	34	40	
II	16	10	
Maternal heart rate			
Before analgesia	89.3±4.6	90.1±5.8	0.784
Fifteen minutes after injection	81.4±5.9	80.2±6.9	0.685
Thirty minutes after injection	86.1±7.4	84.5±6.4	0.832
Maternal respiratory rate			
Before analgesia	16.18±0.74	16.22±0.61	0.771
Fifteen minutes after injection	12.24±0.47	12.16±0.37	0.351
Thirty minutes after injection	12.08±0.37	12.22±0.41	0.450
Maternal systolic blood pressure			
Before analgesia	116.76±9.65	117.94±8.37	0.515
Fifteen minutes after injection	104.06±9.53	104.96±9.39	0.635
Thirty minutes after injection	110.50±8.22	112.20±8.64	0.316
Maternal diastolic blood pressure			
Before analgesia	74.40±6.03	74.28±5.80	0.919
Fifteen minutes after injection	70.24±5.98	70.18±6.07	0.960
Thirty minutes after injection	74.47±6.11	73.36±5.77	0.912
Fetal heart rate			
Before analgesia	143.02±12.59	144.68±10.37	0.474
Fifteen minutes after injection	139.22±15.68	139.62±16.19	0.900
Thirty minutes after injection	139.86±10.32	142.02±9.88	0.288

Data are given as mean ± standard deviations or frequencies

ASA: American Society of Anesthesiologists

## Discussion

Epidural analgesia has become a widely-used technique for providing pain relief in labor. Nowadays, there is an increase in the number of the epidural drugs. The most recent literature focuses on new enantiomers such as ropivacaine, which have reduced risk of cardiotoxicity compared with bupivacaine<sup>(7)</sup>. In our comparison of these two agents in the present study, no motor blockade was observed and maternal satisfaction rates were similar with tolerable adverse effects. In addition, no obstetric or neonatal adverse effects were observed.

Some previous studies claimed that epidurals prolonged labor, and increased oxytocin requirements and instrumental and operative delivery rates<sup>(8,9)</sup>. This was explained as motor block in perineal and abdominal muscles caused by epidural local anesthetics, which may cause abnormal internal rotation of the fetal head leading to dystocia<sup>(9)</sup>.

In a meta-analysis, it was suggested that the type of epidural analgesia might influence spontaneous vaginal delivery rates. Analgesia combined with low-dose opioid and local anesthetic has been asserted to result in lower rates of instrumental deliveries<sup>(10,11)</sup>. Some investigators suggested that ropivacaine was associated with an increased rate of spontaneous vaginal delivery compared with bupivacaine due to a reduction in motor block<sup>(12)</sup>. Lv et al.<sup>(7)</sup> reported in their meta-analysis of 10 impact studies that ropivacaine was associated with less motor blockade but a higher incidence of instrumental delivery. Halpern et al.<sup>(13)</sup> showed that the rate of motor block was more frequent in the bupivacaine group but the incidence of spontaneous vaginal delivery was similar regardless of whether ropivacaine or bupivacaine were used for labor analgesia. There

are conflicting results in the literature in the comparison of these two local anesthetics regarding the mode of delivery. In the current study, the vaginal spontaneous labor rate was high and there was no significant difference between the groups in regard to operative delivery.

It is assumed that ropivacaine has a greater selectivity for sensory fibers than motor fibers due to its lower lipophilic capacity compared with bupivacaine. Accordingly, it is less likely to cause motor blockade and neurotoxicity<sup>(4,6)</sup>. There were no cases of motor blockade in either group in our study. This could be related to the use of very low and titrated concentrations of a local anesthetic through the addition of opioids. It may also account for our high spontaneous vaginal delivery rate. Higher concentrations of local anesthetic may be the reason of increased motor blockade and instrumental delivery rates in previous studies.

Lee et al.<sup>(14)</sup> reported that bupivacaine was associated with prolongation in the first stage of labor. This may result from higher concentrations of initiated analgesia with a 0.25% solution, which triggers motor block, leading to elongation of labor. In contrast, other comparative studies using these local anesthetics in a range of 0.075-0.125% found no differences in the durations of the first or second stages of labor, similar to our results<sup>(15,16)</sup>.

Our findings regarding neonatal outcomes were comparable with the literature<sup>(4,13-16)</sup>. There were no significant differences in the indicators of neonatal wellbeing between the two groups. In a study conducted by Writer et al.<sup>(12)</sup>, lower neurologic and adaptive capacity scores with bupivacaine versus ropivacaine were found. We did not assess this outcome due to the conflicting results about its reliability in newborn evaluations<sup>(17)</sup>.

**Table 2.** Effectiveness of analgesics in both groups and pain assessment using the 0-10 visual analogue scale

	Ropivacaine (n=50)	Bupivacaine (n=50)	p
The onset time of analgesia (minute)	11.18±1.41	11.54±2.21	0.335
The duration of analgesia (minute)	123.56±19.45	130.30±19.65	0.478
Initial pain score before injection	8.30±0.67	8.12±0.62	0.171
Fifteen minutes after injection	0.42±0.92	0.20±0.80	0.209
Thirty minutes after injection	0.06±0.24	0.08±0.34	0.735
One hour after injection	0.04±0.19	0.02±0.14	0.562
Two hours after injection	0.38±0.72	0.30±0.61	0.553
Three hours after injection	4.14±1.06	3.96±0.75	0.333
Need for additional dose (%)	20	22	0.120
Maternal satisfaction of patients for labor analgesia (n)			
Excellent	40	39	
Good	8	8	
Unsatisfactory	2	2	
Terrible	-	1	

Data are given as mean ± standard deviations or percentages

**Table 3.** Obstetric characteristics and data of obstetric and neonatal outcomes

	Ropivacaine (n=50)	Bupivacaine (n=50)	p
Gestational weeks	39.42±0.60	39.60±0.90	0.195
Initial cervical dilatation (cm)	4.66±0.49	4.47±0.57	0.081
Initial cervical effacement (%)	68.70±8.31	66.50±9.16	0.212
Duration of first stage (minute)	130.31±60.60	150.93±100.55	0.227
Duration of second stage (minute)	35.20±9.00	38.22±13.10	0.192
Duration of labor (minute)	165.52±63.20	189.16±106.37	0.189
Need for oxytocin augmentation (%)	72	80	0.348
Mode of delivery (%)			
Normal vaginal delivery	92	90	0.726
Instrumental delivery	0	2	0.314
Cesarean section	8	8	0.999
Need for episiotomy (%)	56	60	0.685
The number of uterine contractions <sup>a</sup>	4.46±0.86	4.48±0.88	0.909
The duration of uterine contractions <sup>a</sup> (second)	68.40±19.72	66.10±19.25	0.557
Montevideo unit <sup>a</sup>	208.40±56.33	197.60±57.55	0.345
Apgar score			
At 1 minute	8.35±0.93	8.10±1.09	0.232
At 5 minute	9.50±0.68	9.22±0.72	0.062
Abnormal arterial blood gases	2	4	0.557
Required mask ventilation	10	12	0.626
Incidence of respiratory distress	4	2	0.557
Required tracheal intubations	0	0	-
Required NICU admission	4	2	0.557

Data are given as mean ± standard deviations or percentages

<sup>a</sup>Assessment of uterine activity in a 30-minute postinjection period

NICU: Neonatal intensive care unit

Shokry et al.<sup>(18)</sup> compared two groups receiving 0.125% bupivacaine and 0.2% ropivacaine, each with fentanyl 100 µg and found a non-significant faster onset of action and significantly shorter duration of analgesia in the ropivacaine group. In contrast, Chora and Hussain<sup>(4)</sup> showed significantly faster onset of analgesia in the bupivacaine group and longer duration in the ropivacaine group. Unlike these, the onset and duration of analgesia for both groups was comparable in current study, consistent with the research of Beilin et al.<sup>(19)</sup>. Bawdane et al.<sup>(20)</sup> recorded similar pain scores, sensory levels, and overall maternal satisfaction between the two groups, as we observed. Although ropivacaine is suggested to be less potent than bupivacaine<sup>(21)</sup>, they appear to be equipotent at clinically used concentrations.

### Study Limitations

The limitation of the current study is its small sample size in both groups, further research should be organized with large sample groups.

### Conclusion

Overall, both ropivacaine and bupivacaine can provide equivalent labor analgesia with high maternal satisfaction and tolerable adverse effects in the clinically used dose range. A combination with opioids is preferable considering their dose lowering effect. No adverse obstetric or neonatal outcomes were observed in either group in the current study. Therefore, from a clinical perspective, either drug is a reasonable choice for labor analgesia and can be used without jeopardizing the safety of the mother and fetus.

### Ethics

**Ethics Committee Approval:** The study was approved by the Cerrahpaşa University Local Ethics Committee (approval number: P20/1999).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: Ş.G., Concept: Ş.G., G.K., Design: Ş.G., Data Collection or Processing: Ş.G., Analysis or Interpretation: Ş.G., S.E.Y., A.Y., Literature Search: M.Ö.A., Y.Y., G.K., Writing: Ş.G., S.E.Y., A.Y.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Beigi NM, Broumandfar K, Bahadoran P, Abedi HA. Women's experience of pain during childbirth. *Iran J Nurs Midwifery Res* 2010;15:77-82.
2. Yerby M, Page L. Pain in Childbearing: Key Issues in Management. In: Tindall B, (ed). Sydney; 2000:17-42.
3. Rao ZA, Choudhri A, Naqvi S, Ehsan-Ul-Haq. Walking epidural with low dose bupivacaine plus tramadol on normal labour in primipara. *J Coll Physicians Surg Pak* 2010;20:295-8.
4. Chora I, Hussain A. Comparison of 0.1% Ropivacaine-Fentanyl with 0.1% Bupivacaine-Fentanyl Epidurally for Labour Analgesia. *Advances in Anesthesiology* 2014;2014:237034.
5. Ezberci M, Zencirci B, Öksüz H, Güven MA. Effects of General and Epidural Anaesthesia in Newborn's Stres Hormones, Blood Gases, and Apgar Scores in Elective Cesarean Section. *J Turk Obstet Gynecol* 2005;2:284-9.
6. Beilin Y, Halpern S. Focused review: ropivacaine versus bupivacaine for epidural labor analgesia. *Anesth Analg* 2010;111:482-7.
7. Lv BS, Wang W, Wang ZQ, Wang XW, Wang JH, Fang F, et al. Efficacy and safety of local anesthetics bupivacaine, ropivacaine and levobupivacaine in combination with sufentanil in epidural anesthesia for labor and delivery: a meta-analysis. *Curr Med Res Opin* 2014;30:2279-89.
8. McGrady E, Litchfield K. Epidural analgesia in labour. *Contin Educ Anaesth Crit Care Pain* 2004;4:114-7.
9. Anwar S, Anwar MW, Ahmad S. Effect of epidural analgesia on labor and its outcomes. *J Ayub Med Coll Abbottabad* 2015;27:146-50.
10. Comparative Obstetric Mobile Epidural Trial (COMET) Study Group UK. Effect of low-dose mobile versus traditional epidural techniques on mode of delivery: a randomised controlled trial. *Lancet* 2001;358:19-23.
11. Guo S, Li B, Gao C, Tian Y. Epidural Analgesia With Bupivacaine and Fentanyl Versus Ropivacaine and Fentanyl for Pain Relief in Labor: A Meta-Analysis. *Medicine (Baltimore)* 2015;94:e880.
12. Writer WD, Stienstra R, Eddleston JM, Gatt SP, Griffin R, Gutsche BB, et al. Neonatal outcome and mode of delivery after epidural analgesia for labour with ropivacaine and bupivacaine: a prospective meta-analysis. *Br J Anaesth* 1998;81:713-7.
13. Halpern SH, Breen TW, Campbell DC, Muir HA, Kronberg J, Nunn R, et al. A multicenter, randomized, controlled trial comparing bupivacaine with ropivacaine for labor analgesia. *Anesthesiology* 2003;98:1431-5.
14. Lee BB, Ngan Kee WD, Ng FF, Lau TK, Wong EL. Epidural infusions of ropivacaine and bupivacaine for labor analgesia: a randomized, double-blind study of obstetric outcome. *Anesth Analg* 2004;98:1145-52.
15. Owen MD, Thomas JA, Smith T, Harris LC, D'Angelo R. Ropivacaine 0.075% and bupivacaine 0.075% with fentanyl 2 microg/mL are equivalent for labor epidural analgesia. *Anesth Analg* 2002;94:179-83.
16. Finegold H, Mandell G, Ramanathan S. Comparison of ropivacaine 0.1%-fentanyl and bupivacaine 0.125%-- fentanyl infusions for epidural labour analgesia. *Can J Anaesth* 2000;47:740-5.
17. Halpern SH, Littleford JA, Brockhurst NJ, Youngs PJ, Malik N, Owen HC. The neurologic and adaptive capacity score is not a reliable method of newborn evaluation. *Anesthesiology* 2001;94:958-62.
18. Shokry M, Manaa EM, Shoukry RA, Shokeir MH, Elsedfy GQ, Abd El-Aziz Ael-S. Effects of intrapartum epidural analgesia at high altitudes: maternal, fetal, and neonatal outcomes. A randomized controlled trial of two formulations of analgesics. *Acta Obstet Gynecol Scand* 2010;89:909-15.
19. Beilin Y, Guinn NR, Bernstein HH, Zahn J, Hossain S, Bodian CA. Local anesthetics and mode of delivery: bupivacaine versus ropivacaine versus levobupivacaine. *Anesth Analg* 2007;105:756-63.
20. Bawdane KD, Magar JS, Tendolkar BA. Double blind comparison of combination of 0.1% ropivacaine and fentanyl to combination of 0.1% bupivacaine and fentanyl for extradural analgesia in labour. *J Anaesthesiol Clin Pharmacol* 2016;32:38-43.
21. Polley LS, Columb MO, Naughton NN, Wagner DS, van de Ven CJ. Relative analgesic potencies of ropivacaine and bupivacaine for epidural analgesia in labor: implications for therapeutic indexes. *Anesthesiology* 1999;90:944-50.





# Anemia prevalence at the time of pregnancy detection

## Gebeliğin tanısı ile birlikte saptanan anemi prevalansı

Mustafa Öztürk<sup>1</sup>, Özlem Öztürk<sup>2</sup>, Mustafa Ulubay<sup>3</sup>, Emre Karaşahin<sup>3</sup>, Taner Özgürtaş<sup>2</sup>, Müfit Yenen<sup>3</sup>, Aytekin Aydın<sup>3</sup>, Fahri Fıratlıgil<sup>4</sup>, Serkan Bodur<sup>3</sup>

<sup>1</sup>University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

<sup>2</sup>Gülhane Training and Research Hospital, Clinic of Medical Biochemistry, Ankara, Turkey

<sup>3</sup>Gülhane Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

<sup>4</sup>Kocaeli State Hospital, Clinic of Obstetrics and Gynecology, Kocaeli, Turkey

### Abstract

**Objective:** Anemia in the first trimester of pregnancy is the situation as described by the World Health Organization when the level of hemoglobin (Hb) is less than 11 g in 100 cc of blood. The prevalence of this problem is 18% in developed countries, whereas it is between 35-75% in developing countries. In this study, we aimed to determine the prevalence of anemia at the time of pregnancy detection.

**Materials and Methods:** A retrospective cross-sectional study was designed to determine the prevalence of anemia. A total of 5228 first trimester pregnant women were admitted to the study between 2012 and 2014. Hb levels of 11 to 9.5 g/dL, 9.5 to 8 g/dL, and less than 8 g/dL were considered as mild, moderate, and severe anemia, respectively.

**Results:** We detected mild, moderate, and severe anemia at rates of 16.64%, 3.07%, and 0.28%, respectively, in our population. The overall prevalence of anemia at the time of detection of pregnancy was 20.0%.

**Conclusion:** Anemia is a significant risk factor for maternal mortality in developing countries. The prevalence of anemia at the time of pregnancy detection was 20% and this rate is close to those indicated in developed countries.

**Keywords:** Pregnancy, anemia, prevalence

### Öz

**Amaç:** Gebelikte ilk trimesterde anemi, hemoglobin (Hb) düzeyinin 100 cc kanda 11 g'den daha düşük olduğu durumdur. Bu problemin görülme prevalansı gelişmiş ülkelerde (%18) ve gelişmekte olan ülkelerde (%35-75) olarak bildirilmiştir. Bu çalışma ile, gebe olan popülasyonda gebelik saptandığı birinci trimesterde mevcut anemi prevalansını hesaplamayı amaçladık.

**Gereç ve Yöntemler:** 2012-2014 yılları arasında adet gecikmesi nedeniyle başvuran ve gebelik tanısı konulan 5228 gebe kadında, anemi prevalansının saptanması için düzenlenmiş retrospektif kesitsel tipte bir araştırmadır. Hb değeri 11-9,5 mg/dL hafif, 9,5-8 mg/dL orta ve 8 mg/dL altında ağır anemi olarak kabul edildi.

**Bulgular:** Gebe popülasyonumuzda gebelik tespit edildiğinde hafif anemisi olan gebelerin oranı %16,64'tür. Orta anemi olan gebe oranı ise %3,07'dir. Hb değeri 8 mg/dL altında olan ağır anemi ise %0,28'dir. Genel popülasyonda gebelik tespitinde anemi prevalansı ise %20,0'dir.

**Sonuç:** Anemi gelişmekte olan ülkelerde maternal mortalite için önemli bir risk faktörüdür. Gebelik saptandığı birinci trimesterde mevcut anemi prevalansını %20 saptadık ve bu gelişmiş ülkelerin oranına yakın görünmektedir.

**Anahtar Kelimeler:** Gebelik, anemi, prevalans

Address for Correspondence/Yazışma Adresi: Mustafa Öztürk, MD,

University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Phone: +90 535 833 39 56 E-mail: drmozturk@gmail.com ORCID ID: orcid.org/0000-0002-1847-8868

Received/Geliş Tarihi: 13.03.2017 Accepted/Kabul Tarihi: 09.08.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

**PRECIS:** The prevalence of anemia at the time of pregnancy detection was 20% and this is close to the rates of developed countries.

## Introduction

It has been demonstrated that anemia in pregnancy is one of the main health problems and affects the results of pregnancy negatively<sup>(1)</sup>. The prevalence of anemia is still in question in our country<sup>(2)</sup>.

Anemia can be classified as acquired or hereditary. Deficiency anemia (iron, folate, and vitamin B12), anemias depending on blood loss, chronic disease anemias, acquired hemolytic anemias, and aplastic anemia can be considered as acquired anemias, whereas sickle cell anemia, thalassemia, and Fanconi anemias are considered as hereditary anemias<sup>(3)</sup>. Iron-deficiency anemias (IDA) are responsible for more than half of all cases in all regions worldwide (where malaria is not an endemic). In pregnancy, the most frequently encountered anemia is IDA<sup>(4)</sup>. Anemia in the 1<sup>st</sup> and 3<sup>rd</sup> trimester of pregnancy was defined by the Centers for Disease Control and Prevention in 1989 as hemoglobin (Hb) or hematocrit less than 11 g/dL or 33%, respectively, and when the level of Hb or hematocrit is less than 10.5 g/dL or 32%, respectively, in the 2<sup>nd</sup> trimester of pregnancy<sup>(1)</sup>. According to the World Health Organization (WHO), anemia in pregnancy in any trimester is considered when the level of Hb is less than 11 g/dL<sup>(4)</sup>. This definition was made in 2001 and is still valid today. When the level of Hb is less than 7 g/dL during pregnancy, it is considered as severe anemia and medical treatment is required. It has been revealed that anemia observed in the first trimester of pregnancy enhances the possibility of premature birth and low birth weight, as well as low APGAR scores<sup>(5,6)</sup>.

In our study, we aimed to identify the prevalence of anemia in patients at the time of pregnancy detection.

## Materials and Methods

This study is a retrospective cross sectional study that was designed to detect anemia prevalence of 5228 pregnant women who presented because of delayed menstrual periods and were diagnosed as being pregnant between 2012 and 2014. Hb levels of 11 to 9.5 g/dL, from 9.5 to 8 g/dL and less than 8 g/dL were considered as mild, moderate, and severe anemia, respectively<sup>(7,8)</sup>. Pregnants were classified into 4 groups according to their Hb levels as follows; group 1: severe anemia, group 2: moderate anemia, group 3 mild anemia, and group 4 as normal (Hb levels 11 g/dL or higher).

The complete blood count of the women was measured using an automated blood analyzer (Beckman-Coulter, USA). The three-year results were evaluated and classified according to their Hb levels. We did not report the risk factors and independent predictors of anemia. This study was approved by the Etimesgut Military Hospital Local Ethics Committee (approval number 8000-11-12) and all women who accepted to take part gave written informed consent before enrollment in the study.

## Statistical Analysis

The collected data were analyzed using the Statistical Package for Social Sciences version 14.0 (SPSS Inc., Chicago, USA). Continuous variables are expressed as mean  $\pm$  standard deviation, whereas categorical variables are denoted as numbers or percentages where appropriate.

## Results

Groups 1, 2, 3, and 4 comprised 15, 161, 870, and 4182 patients, respectively. The average age was  $30.2 \pm 4.75$  years and the average Hb was  $11.8 \pm 1.15$  g/dL in our population (Table 1) (Figure 1).


In groups 1, 2, 3, and 4, the average ages were  $30.4 \pm 7.14$ ,  $30.2 \pm 5.42$ ,  $30.1 \pm 4.4$ ,  $30.2 \pm 4.7$  years, respectively. The respective Hb levels in each group were  $7.5 \pm 0.35$ ,  $9.0 \pm 0.34$ ,  $10.4 \pm 0.4$ , and  $12.3 \pm 0.80$  g/dL (Table 2).

In our population, when pregnancy was diagnosed, 16.64% (n=870) were considered as having mild anemia, 3.07% (n=161) had moderate anemia, and 0.28% (n=15) had severe anemia (Table 2). The overall anemia prevalence at the time of pregnancy diagnosis was 20.0% (n=1046).

When the Hb levels were considered according to the age interval of the women, anemia prevalence was close to 20%

**Table 1.** Age and hemoglobin parameters of the participants

	n	Minimum	Maximum	Mean	Standard deviation
Hemoglobin	5228	7.07	15.56	11.88	1.15
Age	5228	17	46	30.21	4.75




**Figure 1.** Distribution of hemoglobin parameters of the pregnant women

in those aged 25-34 years (Table 3). Of the pregnant women, 7.3%, 21%, 20.5%, 19.9%, and 13.9% had anemia in the age groups 17-19 years, 20-24 years, 25-29 years, 30-34 years, and over 40 years, respectively (Table 3) (Figure 2).

## Discussion

Anemia in pregnancy is a global public health problem. The prevalence is 18% in developed countries, whereas it is between 35-75% in developing countries<sup>(9)</sup>. In developing countries, it has been estimated that 460 million women of reproductive age are anaemic, 2/3 of whom are in Asia. It is known that prevalence of anemia in pregnancy is 42% worldwide, the lowest being 6% in North America and the highest is 75% in Gambia<sup>(3)</sup>. The prevalence of anemia in pregnancy is 25.1% in Europe, and around 24.1% in America<sup>(10)</sup>. In a study performed in China with 88149 pregnant women, the prevalence of anemia in the first trimester was determined as 22%<sup>(5)</sup>.

In our country, in a study performed in 2006 in which 586 pregnant women were included, the prevalence of anemia was



**Figure 2.** Distribution of pregnant women according to age and hemoglobin parameters

**Table 2.** Age and hemoglobin parameters of the participants according severity groups

Group		n	Minimum	Maximum	Mean	Standard deviation
Severe anemia (0.24%)	Hemoglobin	15	7.07	7.97	7.56	0.356
	Age	15	19	39	30.40	7.149
Moderate anemia (3.07%)	Hemoglobin	161	8.00	9.49	9.00	0.347
	Age	161	18	44	30.02	5.42
Mild anemia (16.64%)	Hemoglobin	870	9.50	10.99	10.46	0.410
	Age	870	18	46	30.14	4.465
Higher than hemoglobin 11 g/dL (80%)	Hemoglobin	4182	11.00	15.56	12.30	0.807
	Age	4182	17	46	30.24	4.780

**Table 3.** Distribution of pregnant women with anemia according to age ranges

Age (years)		n	Minimum	Maximum	Mean	Standard deviation
17-19	Hb <11 mg/dL (7.3%)	3	7.97	9.93	9.05	0.99
	Hb >11 mg/dL (82.7%)	38	11.09	13.89	12.31	0.75
20-24	Hb <11 mg/dL (21%)	116	7.20	10.99	9.99	0.85
	Hb >11 mg/dL (79%)	433	11.00	14.47	12.21	0.74
25-29	Hb <11 mg/dL (20.5%)	372	7.07	10.99	10.21	0.69
	Hb >11 mg/dL (79.5%)	1434	11.00	15.56	12.34	0.83
30-34	Hb <11 mg/dL (19.9%)	364	7.10	10.99	10.27	0.69
	Hb >11 mg/dL (80.1%)	1463	11.00	14.79	12.30	0.79
35-39	Hb <11 mg/dL (19.9%)	172	7.63	10.99	10.18	0.75
	Hb >11 mg/dL (80.1%)	697	11.00	14.63	12.26	0.80
Over 40	Hb <11 mg/dL (13.9%)	19	8.61	10.97	9.83	0.85
	Hb >11 mg/dL (86.1%)	117	11.03	15.20	12.39	0.87

Hb: Hemoglobin

determined as 74.1%<sup>(2)</sup>. In that study, the threshold Hb level for anemia was taken as 11 g/dL<sup>(2)</sup>. This level is close to that of underdeveloped countries. The prevalence of anemia in pregnancy in Turkey was determined as 40.2% by the WHO according to data observed before 2000<sup>(3)</sup>. In some Turkish studies, the prevalence of anemia during pregnancy was identified as 29.4% in Afyon, whereas it was 42.4% in Elazığ<sup>(11,12)</sup>. In a study by Karaoglu et al.<sup>(13)</sup> with 823 pregnant women, the prevalence of anemia was detected as 27.1%. The study was performed in Malatya and the Hb level was accepted as 11 g/dL<sup>(13)</sup>.

In the present study, the prevalence of anemia in pregnancy was determined as 20% in 5228 pregnant women in Ankara. In the study performed by Karaoglu et al.<sup>(13)</sup>, it was found that 0.48% of the pregnant women had severe anemia (under 8 g/dL); this rate was 0.28% in our study. This may be due to differences between patient populations in Ankara and Malatya.

When anemia prevalence was considered according to age intervals, Karaoglu et al.<sup>(13)</sup> found that the rate was about 30% in pregnant women aged 30-39 years, whereas it was around 20% in our study for women aged 20-39 years. In a study by Pirinçci et al.<sup>(12)</sup> that included data before 2001 in 465 pregnant women in Elazığ, it was shown that 42.4% (n=197) of patients had anemia (Hb levels below 11 g/dL); 44.8% of these were observed in the first trimester. Beside this, the authors reported the incidence of anemia as 59.4% for patients aged 19 years and below, 40.8% in the 20-29 years age group, 39.5% in the 30-39 years age group, and 25.0% in the >40 years age group<sup>(12)</sup>.

In our 2011-2015 data, the anemia prevalence was detected as 7.3% in patients aged 19 years and below, 26.1% in the 20-29 years age group, 24.8% in the 30-39 years age group, and 13.9% in the >40 years age group. In our study, the prevalence of anemia "at the time of pregnancy diagnosis" was determined as 20.1% because fertility is higher between the ages of 20-39 years. When our results are compared with those of Pirinçci et al.<sup>(12)</sup>, one might conclude that the prevalence of anemia decreased by half during this 10-year period. The effect of socioeconomic differences between Elazığ and Ankara and the presence of a more conscious pregnant population could also account for this difference. It was revealed that the incidence of anemia during pregnancy increased as pregnancy advanced (1.8% in the first trimester, 8% in the second trimester, and 27% in the third trimester)<sup>(14)</sup>.

In the studies mentioned above, the measurements for determining the prevalence of anemia were performed with regard to the number of weeks' pregnancy. However, in our study, the prevalence of anemia was investigated in pregnant women in the first trimester only, and this could account for the differences between the rates observed in the indicated studies and our study.

Anemia in the first trimester of pregnancy increases the risk of preterm birth, small-for-gestational-age births, and intrauterine growth restriction<sup>(15)</sup>. For mothers, severe anemia is an important risk factor for morbidity and mortality in developing countries.

The risk of operative birth and prolonged delivery increases in cases of severe anemia<sup>(15)</sup>.

### Study Limitations

This study has a limitation, the anemia prevalence in pregnancy "at the time of pregnancy diagnosis" was detected as 20% and this was close to the rates of developed countries. However, this rate could be related to the patient population of Ankara where the socioeconomic level is higher in comparison with other regions of our country.

### Conclusion

Anemia in pregnancy is a global public health problem and early diagnosis and treatment are both maternally and perinatally important. Detecting patients with anemia in the preconceptional period and/or delaying pregnancy until optimal Hb levels are reached will lower this rate.

### Ethics

**Ethics Committee Approval:** The study was approved by the Etimesgut Military Hospital Local Ethics Committee (approval number: 8000-11-12).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: M.Ö., Ö.Ö., M.U., E.K., T.Ö., A.A., Concept: M.Ö., Ö.Ö., M.U., E.K., Design: M.Ö., Ö.Ö., M.U., E.K., T.Ö., M.Y., A.A., FF, Data Collection or Processing: M.Ö., Ö.Ö., A.A., FF, S.B., Analysis or Interpretation: M.Ö., Ö.Ö., M.U., E.K., Literature Search: M.Ö., Ö.Ö., M.U., E.K., T.Ö., M.Y., A.A., FF, S.B., Writing: M.Ö., Ö.Ö., M.U., E.K., FF

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Centers for Disease Control (CDC). CDC criteria for anemia in children and childbearing-aged women. MMWR Morb Mortal Wkly Rep 1989;38:400-4.
2. Davas I, Marangoz D, Varolan A, Akyol A, Baksu B. Gebelikte değişik seviyelerdeki anemilerde demir alınınının maternal, doğum ve perinatal sonuçlara etkileri. J Turk Soc Obstet Gynecol 2008;5:174-81.
3. World Health Organization. Worldwide prevalence of anemia 1993-2005. WHO Global Database on Anemia. Geneva: World Health Organization; 2008.
4. World Health Organization. Iron deficiency anemia assessment prevention and control: a guide for programme managers. Geneva: World Health Organization; 2001:132.
5. Ren A, Wang J, Ye RW, Li S, Liu JM, Li Z. Low first-trimester hemoglobin and low birth weight, preterm birth and small for gestational age newborns Int J Gynaecol Obstet 2007;98:124-8.
6. Sekhavat L, Davar R, Hosseini-dezoki S. Relationship between maternal hemoglobin concentration and neonatal birth weight. Hematology 2011;16:373-6.

7. Segel GB, Hirsh MG, Feig SA. Managing anemia in pediatric office practice: Part 1. *Pediatr Rev* 2002;23:75-84.
8. Wu AC, Lesperance L, Bernstein H. Screening for iron deficiency. *Pediatr Rev* 2002;23:171-8.
9. World Health Organization WHO. Maternal Health and Safe Motherhood Programme. Maternity care: what is needed for safer motherhood in the community? *Safe Mother* 1992:6-8.
10. Allen LH. Pregnancy and iron deficiency: unresolved issues. *Nutr Rev* 1997;55:91-101.
11. Bestepe G, Bilgin N. Afyon ili 2 ve 4 No'lu sađhk ocaklarındaki gebelerde anemi prevalansı ve anemiyi etkileyen bazı faktörlerin incelenmesi. *Sađlık ve Toplum* 2002;12:43-53.
12. Pirinççi E, Açık Y, Bostancı M, Eren S, Beritanlı H. Elazığ il merkezinde yaşıyan gebelerde anemi prevalansı. *FÜ.Sađ.Bil.Tıp Derg* 2001;15:449-54.
13. Karaoglu L, Pehlivan E, Egri M, Deprem C, Gunes G, Genc MF, et al. The prevalence of nutritional anemia in pregnancy in an east Anatolian province, Turkey. *BMC Public Health* 2010;10:329
14. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. *Am J Clin Nutr* 2005;81:1218-22.
15. Malhotra M, Sharma JB, Batra S, Sharma S, Murthy NS, Arora R. Maternal and perinatal outcome in varying degrees of anemia. *Int J Gynecol Obstet* 2002;79:93-100.





# A new operation technique for uterine prolapse: Vaginally-assisted laparoscopic sacrohysteropexy

## Uterin prolaps için yeni bir operasyon tekniği: Vajinal asiste laparoskopik sakrohisteropeksi

İlhan Sanverdi<sup>1</sup>, Çetin Kılıççı<sup>1</sup>, Mesut Polat<sup>1</sup>, Enis Özkaya<sup>1</sup>, Sami Gökhan Kılıç<sup>2</sup>, Merve Dizdar<sup>3</sup>, Ateş Karateke<sup>1</sup>

<sup>1</sup>University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

<sup>2</sup>The University of Texas Medical Branch, Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery/Urogynecology, Texas, USA

<sup>3</sup>University of Health Sciences, Ümraniye Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

### Abstract

**Objective:** To describe the new surgical technique and report the safety and feasibility of vaginally-assisted laparoscopic sacrohysteropexy (VALSH).

**Materials and Methods:** Thirty-three women with stage 3 or more uterine prolapse underwent VALSH operation. Patients were followed up for 12 months for mesh-related complications and improvements of symptoms. The operation had three sections; 1<sup>st</sup> laparoscopic, 2<sup>nd</sup> vaginal, 3<sup>rd</sup> laparoscopic.

**Results:** The mean age, gravidity, and parity of the study population were 46.5 years (range, 25-68 years), 4.3 (1-9), and 2.9 (1-6), respectively. The mean duration of operation was 59.5 min (range, 20-120 min). There were significant differences between the pre- and post-operative values of pelvic organ prolapse quantification parameters, which were favorable in the latter evaluation ( $p<0.001$ ); total vaginal length was preserved after surgery ( $p>0.05$ ).

**Conclusion:** VALSH is a safe and minimally-invasive procedure in uterovaginal prolapse, with favorable anatomic and functional outcomes at 12 months post-operatively.

**Keywords:** Sacrohysteropexy, laparoscopy, vaginally-assisted laparoscopic sacrohysteropexy

### Öz

**Amaç:** Yeni bir cerrahi yöntem tanımlamak ve vajinal asiste laparoskopik sakrohisteropeksi (VALSH) operasyonunun güvenilirliği ve yapılabilirliğini rapor etmektir.

**Gereç ve Yöntemler:** Evre 3 veya daha ileri düzeyde uterin prolapsusu olan 33 hasta VALSH operasyonuna alındı. Hastalar meşe bağlı komplikasyonları ve semptomları değerlendirme amaçlı 12 ay takip edildi. Operasyonun üç bölümü vardı: 1. laparoskopik, 2. vajinal, 3. laparoskopik.

**Bulgular:** Çalışma grubunda ortalama yaş, gravidite, ve parite sırası ile 46,5 yıl (25-68 yıl), 4,3 (1-9), ve 2,9 (1-6). Ortalama operasyon süresi 59,5 dk (aralık, 20-120 dk). Sonraki değerlendirmede daha iyi olmak üzere, operasyondan önceki ve sonraki pelvik organ prolapsus-sınıflaması değerlerinde anlamlı fark izlendi ( $p<0,001$ ); total vajinal uzunluk cerrahi sonrası korundu ( $p>0,05$ ).

**Sonuç:** VALSH uterovajinal prolaps tedavisinde güvenli ve minimal invaziv, anatomik ve fonksiyonel sonuçları iyi olan bir prosedürdür.

**Anahtar Kelimeler:** Sakrohisteropeksi, laparoskopi, vajinal asiste laparoskopik sakrohisteropeksi

Address for Correspondence/Yazışma Adresi: Enis Özkaya, MD,

University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Phone: +90 505 474 24 59 E-mail: enozkaya1979@gmail.com ORCID ID: orcid.org/0000-0001-6580-1237

Received/Geliş Tarihi: 22.05.2017 Accepted/Kabul Tarihi: 30.08.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

**PRECIS:** Vaginally-assisted laparoscopic sacrohysteropexy is a safe, minimally-invasive procedure in uterovaginal prolapse. Twelve months postoperatively, this procedure showed favorable anatomic and functional results.

## Introduction

Uterovaginal prolapse is a frequently encountered condition especially among older women, which may lead to disability and poor quality of life<sup>(1)</sup>, and it is a major indication for gynecologic surgery. The lifetime risk for a woman to have uterine prolapse surgery is 11%<sup>(1)</sup>. Risk of developing this kind of disorder increases with advancing age<sup>(2)</sup>. Surgery should be performed to restore anatomy with minimal morbidity and the lowest risk of recurrence. Three different approaches have been introduced to repair the pelvic floor such as abdominal, vaginal, and laparoscopic techniques. Hysterectomy is still considered to be the standard procedure for correcting uterovaginal prolapse<sup>(3)</sup>; however, in the majority of cases, hysterectomy does not overcome abnormalities associated with weakened pelvic support structures such as uterosacral and cardinal ligaments<sup>(4)</sup>. Additionally, due to the belief that the uterus plays a role in sexual satisfaction, an increasing number of women avoid undergoing hysterectomy<sup>(5)</sup>. Hysterectomy was shown to be associated with increased morbidity, blood loss, operative time, and influence post-operative recovery time<sup>(6)</sup>. Sacrospinous hysteropexy has been proposed to be an alternative approach for uterine-preserving prolapse surgery<sup>(7)</sup>. Other management alternatives include transvaginal mesh kits<sup>(8,9)</sup>, abdominal sacrohysteropexy using mesh<sup>(10)</sup>, and laparoscopic uterine suspension using a sling<sup>(11)</sup> or mesh<sup>(12)</sup>. A modified form of uterine-preserving prolapse surgery using a combined vaginal and laparoscopic approach was introduced and a series of 70 women was reported by Fayyad and Siozos<sup>(13)</sup>.

In this case series, we describe the safety, feasibility, and outcomes of a modified form of a combined vaginal and laparoscopic approach, vaginally-assisted laparoscopic sacrohysteropexy (VALSH) for treating advanced uterovaginal prolapse.

## Materials and Methods

This study is a descriptive prospective case series of 33 women with symptomatic stage 3 or 4 uterine prolapse on the pelvic organ prolapse-quantification (POP-Q) prolapse examination system<sup>(14)</sup> who underwent VALSH between 2012 and 2015 in Zeynep Kamil Women and Children's Health Training and Research Hospital. The procedure was approved by the Zeynep Kamil Women and Children's Health Training and Research Hospital Local Ethics Committee (approval number: 2015/195) and informed consent forms were obtained from each patient. This new alternative of surgical intervention was offered to women with advanced uterine prolapse.


Inclusion criteria were as follows:

(1) Symptomatic uterine prolapse > stage 3; (2) symptoms of pelvic organ prolapse such as vaginal bulge and heaviness.

Women were asked to empty their bladder before examination. All examinations were performed while the women were in the lithotomy position. The women were asked to perform a maximum Valsalva maneuver before genital examination. Stages of uterine prolapse were determined according to the POP-Q classification. Preoperatively, all patients underwent POP-Q questionnaires to assess prolapsed-related symptoms<sup>(15)</sup>. After determining the surgical indication and following preoperative preparations, the procedure was performed under general anesthesia with the patient initially in the lithotomy position. Thirty-three women with stage 3 or more uterine prolapse underwent VALSH operations. Patients were followed up over a 12-month period after surgery for mesh-related complications and improvements of symptoms.

The operation consisted of three sections; 1<sup>st</sup> laparoscopy, 2<sup>nd</sup> vaginal, 3<sup>rd</sup> laparoscopy. Laparoscopic ports were placed; one 10-mm port for umbilical and two or three 5-mm ports for lateral or suprapubic sites based upon conditions in order to achieve optimal surgical site exposure. The peritoneum over the sacral promontory was incised. A small 5-cm tunnel was made underneath the peritoneum from the sacral promontory downward to the cervix. Then, a lightweight type of mesh was placed onto the promontorium surface.

Second, the vaginal part of the surgery was performed. A semicircular incision was made at the posterior cervicovaginal junction. Curved ring forceps were placed into the retroperitoneal area via a tunnel established through blunt dissection from the vaginal part towards the promontory. At the same time, the direction of the instrument was visualized via laparoscopy (Figure 1). When the tip of the ring forceps was observed through the incision in the promontorium, the mesh was grasped and pulled downward within the tunnel with the aid of an instrument. The mesh was then fixed onto the posterior face of the uterine cervix using 3-4 non-absorbable



**Figure 1.** Laparoscopic view of curved ring forceps put into the retroperitoneal space via incision performed on the posterior wall of cervix



**Figure 2.** Cervical incision performed on the posterior wall where curved ring forceps are introduced and later mesh is fixed by 2-0 non-absorbable sutures x4

sutures via the vaginal route (Figure 2). The vaginal incision was closed by absorbable sutures.

Finally, the uterus was pushed up to the maximum level using a Rubin's cannula to obtain the required uterine suspension and mesh was tacked/sutured to the anterior longitudinal ligament at the sacral promontory and the peritoneal membrane over the promontory was sutured via the laparoscopic approach. A transobturator tape insertion procedure was applied in patients with stress urinary incontinence diagnosed before the operation through appropriate urogynecologic tests. A post-operative examination was performed in the lithotomy position using the POP-Q system. Mesh complications including mesh exposure were noted.

### Statistical Analysis

Data were analyzed using SPSS version 15.0 for Windows (SPSS Inc., Chicago, Illinois). The pre- and post-operative data were compared using the Wilcoxon t-rank test, and p values of <0.05 were considered significant.

### Results

The mean age, gravidity, and parity of the study population were 46.5 years (range, 25-68 years), 4.3 (1-9), and 2.9 (1-6), respectively (Table 1). The mean operation time was 59.5 min (range, 20-120 min). Pre- and post-operative symptoms are

**Table 1.** Summary of some demographic features of the study population

	n	Minimum	Maximum	Mean	Standard deviation
Age (years)	33	25.0	68.0	46.5	10.3
BMI (kg/m <sup>2</sup> )	33	21.00	33.00	28.5	3.5
Gravidity	33	1.0	9.0	4.3	1.8
Parity	33	1.0	6.0	2.9	1.2

BMI: Body mass index

**Table 2.** Summary of pre- and post-operative urogynecologic symptoms of the whole study population

	Symptoms				
	Pre-operative		Post-operative		p
	Frequency	Percent	Frequency	Percent	
Difficult defecation	3	9.1	1	3	
Stress urinary incontinence	1	3.0	0	0	
Stress urinary incontinence, mass protruding from vagina	4	12.2	0	0	
Stress urinary incontinence, difficult defecation	1	3.0	1	3.0	
Difficult defecation and urination	2	6.1	0	0	<0.05
Mass protruding from vagina with Valsalva	15	45.4	0	0	
Stress urinary incontinence, difficult urination	4	12.1	2	6.1	
Frequency, stress urinary incontinence	2	6.1	1	3	
Constipation, mass protruding from vagina	1	3.0	0	0	
Total	33	100.0	33	100.0	

shown in Table 2. The comparison of pre- and post-operative hemoglobin levels with the parameters of POP-Q values are summarized in Table 3. The rates of pre-operative prolapse stages were 4Ba (n=12, 36.3%), stage 4C (n=10, 30.3%), stage 3 Ba (n=3, 9.1%), stage 3C (n=3, 9.1%), stage 4 Bp (n=2, 6.1%), stage 4D (n=2, 6.1%), and stage 3 Bp (n=1, 3%). There were significant differences between the pre- and post-operative values of POP-Q parameters, which were favorable in the latter evaluation ( $p<0.001$ ); total vaginal length was preserved after surgery ( $p>0.05$ ). Among 33 women, stress urinary incontinence was determined in 12 patients by prolapse reduction testing (36.4%) managed by combined VALSH and transobturator tape insertion procedures. No perioperative complications were observed. There were five patients with cervical elongation concomitant with the uterine prolapse. At 12 months after surgery, all 33 patients reported cure of their prolapse symptoms with a subjective cure rate of 100%. None of the patients developed de novo urgency, infection or mesh erosion following surgery during the follow-up period. On assessing the patients' global impression of improvement, all 33 women reported feeling either "very much better" or "much better." No recurrence or mesh complication was observed after 12 months' follow-up.

## Discussion

In this case series, we wanted to show the feasibility of a new technique of VALSH. Data from our series show this technique to be feasible, safe, and easy to perform. It has several advantages over conventional techniques and recently introduced new vaginal-assisted laparoscopic approaches. There is still no consensus on the optimal management of advanced uterine prolapse. Vaginal hysterectomy has been proposed to be a standard procedure in these cases. In order to avoid removing a healthy organ and increasing morbidity and mortality with the hysterectomy procedure and also preserve fertility, uterine-preserving approaches were introduced a few decades ago<sup>(10-12)</sup>. With the recent advances in endoscopic surgery, some

laparoscopic uterine suspension techniques have been described<sup>(16-18)</sup>. According to the accumulated data, independent from the removal of the uterus, apical suspension is the required step for successful outcomes<sup>(19)</sup>. Recent studies showed some advantages of sacrohysteropexy including low recurrence rates, absence of mesh erosion, preserving an adequate vaginal length, and maintaining the proper physiological vaginal axis<sup>(3)</sup>. Additionally, laparoscopic hysteropexy was shown to be associated with better anatomic cure rates of higher than 90% in the majority of the studies. There was an improvement in symptoms, and cure rates of 73-100% among the patients. Reoperation rates and complication rates were generally low<sup>(20)</sup>. Furthermore, endoscopic approaches have some well-defined advantages including quicker recovery and a reduction in adhesion formation<sup>(12,13)</sup>. Additionally, current laparoscopic techniques provide better and magnified visualization of the anatomy and better hemostasis resulting from intraperitoneal gas pressure<sup>(13)</sup>. In the literature, one of the techniques of laparoscopic ventrosuspension of uterus used the rectus sheath for this purpose. However, according to the reports from the literature, it had unsatisfactory results<sup>(21)</sup>. On the other hand, uterosacral plication and suture hysteropexy were reported to have 80% success rates<sup>(19,22)</sup>. Recently, total laparoscopic hysteropexy by mesh placement from the upper part of the cervix to the sacral promontory was developed<sup>(12)</sup>. In addition, a published cohort study on the long-term outcomes of laparoscopic versus vaginal mesh hysteropexy revealed high satisfaction rates for both procedures<sup>(23)</sup>. Most hysteropexy techniques have been shown to have high satisfaction and low reoperation rates. It was reported that the type of hysteropexy and possible graft configuration may impact reoperation rates for recurrent prolapse. Furthermore, authors claimed that vaginal mesh risks and the possibility of future hysterectomy with mesh-associated risks should also be considered<sup>(24)</sup>. Moreover, relative to conventional laparoscopic sacral hysteropexy, total laparoscopic hysterectomy with laparoscopic sacrocolpopexy

**Table 3.** Comparison summary of pre- and post-operative pelvic organ prolapse-quantification classification parameters

	Pre-operative	SD	Post-operative	SD	p
Hgb (gr/dL)	12.2	1.3	11.8	1.1	>0.05
Aa (cm)	2.06	0.6	-2.3	0.4	<0.001
Ba (cm)	3.6	1.8	-2.2	1.6	<0.001
C (cm)	3.2	2.8	-6.8	0.9	<0.001
gh (cm)	3.9	0.6	1.9	0.1	<0.001
pb (cm)	1.6	0.7	2.8	0.8	<0.001
tvL (cm)	7.3	0.7	7.4	2.9	>0.05
Ap (cm)	1.6	1.2	-2.1	0.5	<0.001
Bp (cm)	2.4	1.7	-2.3	0.7	<0.001
D (cm)	1.5	2.1	-7.3	1	<0.001

SD: Standard deviation



procedures were shown to have similar anatomic results, excellent patient satisfaction, and improved quality of life scores<sup>(25)</sup>. Therefore, some modified forms of laparoscopic hysteropexy operations have been introduced.

In their series, Fayyad and Siozos<sup>(13)</sup> aimed to report the results of a novel technique of hysteropexy using vaginal dissection and mesh placement and fixation of mesh to the sacral promontory via a laparoscopic view. It had some advantages as well as efficacy, especially in patients with cervical elongation and the extra-peritoneal attachment of the mesh to the cervix eliminated the risk of compromise of uterine blood flow. On the other hand, the theoretical disadvantage of this technique is that the insertion of the mesh vaginally can result in increased infection and mesh exposure rates<sup>(13)</sup>.

In their study, Fayyad and Siozos<sup>(13)</sup> showed that their technique called "VALUES" was free from increased risk of vaginal shortening and narrowing. In addition, the procedure was shown to result in shorter hospital stay and quicker recovery<sup>(13)</sup>. Sacral colpopexy was reported to have a lower risk of recurrent prolapse on examination, redo surgery for prolapse, post-operative stress urinary incontinence, and dyspareunia than a variety of vaginal interventions. However, there is limited evidence to support the use of transvaginal mesh for apical vaginal prolapse repair. There is no consensus on the best access routes for sacral colpopexy. Moreover, there is no clear conclusion on the comparison between uterine-preserving surgery and vaginal hysterectomy for uterine prolapse<sup>(26)</sup>. Recent studies indicated the necessity of randomized controlled studies to show the benefits of laparoscopic sacrocervicopexy with or without supracervical hysterectomy in terms of surgical outcomes and reduced risk of mesh erosion compared with sacrocolpopexy and concomitant total hysterectomy<sup>(25,27)</sup>. Pelvic organ prolapses and stress urinary incontinence were reported to coexist in 80% of patients with pelvic floor dysfunction<sup>(28)</sup>. We detected coexistence of pelvic organ prolapses and stress urinary incontinence in 36.4% of cases, which was managed through transobturator tape insertion.

The most difficult part of the procedure during conventional sacrohysteropexy is to dissect the peritoneum down to the cervix. Hemorrhage during this dissection further deteriorates tissue exposure. Furthermore, this partially blinded dissection increases the risk of hypogastric nerve plexus injury. The cervical region in which the mesh is inserted is very close to the rectum, which further makes the procedure difficult. Also, it is difficult to fix the mesh low enough to the cervix in patients with cervical elongation, which results in unsatisfactory results.

### Study Limitations

This study has some limitations, one of them is small sample size and study needs longer follow-up duration.

### Conclusion

VALSH is a safe, minimally-invasive procedure in uterovaginal prolapse that preserves the uterus, enables future normal vaginal

delivery, and has shown favorable anatomic and functional outcomes at 12 months follow-up including zero recurrence rates.

### Ethics

**Ethics Committee Approval:** The study was approved by the Zeynep Kamil Women and Children's Health Training and Research Hospital Local Ethics Committee (approval number: 2015/195).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: İ.S., M.P., Concept: İ.S., Design: İ.S., Data Collection or Processing: İ.S., Ç.K., M.P., E.Ö., M.D., A.K., Analysis or Interpretation: E.Ö., İ.S., Literature Search: E.Ö., İ.S., Writing: E.Ö., İ.S., M.D., S.G.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Digesu GA, Chaliha C, Salvatore S, Hutchings A, Khullar V. The relationship of vaginal prolapse severity to symptoms and quality of life. *BJOG* 2005;112:971-6.
2. Slieker-ten Hove MC, Pool-Goudzwaard AL, Eijkemans MJ, Steegers-Theunissen RP, Burger CW, Vierhout ME. The prevalence of pelvic organ prolapse symptoms and signs and their relation with bladder and bowel disorders in a general female population. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:1037-45.
3. Rosati M, Bramante S, Bracale U, Pignata G, Azioni G. Efficacy of laparoscopic sacrocervicopexy for apical support of pelvic organ prolapse. *JSLs* 2013;17:235-44.
4. Maher CF, Cary MP, Slack MC, Murray CJ, Milligan M, Schluter P. Uterine preservation or hysterectomy at sacrospinous colpopexy for uterovaginal prolapse? *Int Urogynecol J Pelvic Floor Dysfunct* 2001;12:381-4.
5. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. *Obstet Gynecol* 1994;83:549-55.
6. Rardin CR, Erekson EA, Sung VW, Ward RM, Myers DL. Uterosacral colpopexy at the time of vaginal hysterectomy, comparison of laparoscopic and vaginal approaches. *J Reprod Med* 2009;54:273-80.
7. Dietz V, van der Vaart CH, van der Graaf Y, Heintz P, Schraffordt Koops SE. One-year follow-up after sacrospinous hysteropexy and vaginal hysterectomy for uterine descent: A randomized study. *Int Urogynecol J* 2010;21:209-16.
8. Feiner B, Jelovsek JE, Maher C. Efficacy and safety of transvaginal mesh kits in the treatment of prolapse of the vaginal apex: A systematic review. *BJOG* 2009;116:15-24.
9. Moore R, Mitchel G, Miklos J. Single-incision vaginal approach to treat cystocele and vault prolapse with an anterior wall mesh anchored apically to the sacrospinous ligaments. *Int Urogynecol J* 2012;23:85-91.
10. Costantini E, Mearini L, Bini V, Zucchi A, Mearini E, Porena M. Uterus preservation in surgical correction of uterogenital prolapse. *Eur Urol* 2005;48:642-9.



11. Cutner A, Kearney R, Vashisht A. Laparoscopic uterine sling suspension: A new technique of uterine suspension in women desiring surgical management of uterine prolapse with uterine conservation. *BJOG*. 2007;114:1159-62.
12. Price N, Slack A, Jackson SR. Laparoscopic hysteropexy: The initial results of a uterine suspension procedure for uterovaginal prolapse. *BJOG* 2010;117:62-8.
13. Fayyad AM, Siozos CS. Safety and one year outcomes following vaginally assisted laparoscopic uterine sacropexy (VALUES) for advanced uterine prolapse. *Neurourol Urodyn* 2014;33:345-9.
14. Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol* 1996;175:10-7.
15. Özengin N, Kaya S, Orhan C, Bakar Y, Duran B, Ankaralı H, et al. Turkish adaptation of the Pelvic Organ Prolapse Symptom Score and its validity and reliability. *Int Urogynecol J* 2017;28:1217-22.
16. Wu MP. Laparoscopic uterine suspension for the treatment of uterovaginal prolapse. *Int J Gynaecol Obstet* 1997;59:259-60.
17. Barranger E, Fritel X, Pigne A. Abdominal sacrohysteropexy in young women with uterovaginal prolapse: Long-term follow-up. *Am J Obstet Gynecol* 2003;189:1245-50.
18. Seracchioli R, Hourcade JA, Vianello F, Govoni F, Pollastri P, Venturoli S. Laparoscopic treatment of pelvic floor defects in women of reproductive age. *J Am Assoc Gynecol Laparosc* 2004;11:332-5.
19. Park AJ, Paraiso MF. Surgical management of uterine prolapse. *Minerva Ginecol* 2008;60:493-507.
20. Nair R, Nikolopoulos KI, Claydon LS. Clinical outcomes in women undergoing laparoscopic hysteropexy: A systematic review. *Eur J Obstet Gynecol Reprod Biol* 2017;208:71-80.
21. O'Brien PM, Ibrahim J. Failure of laparoscopic uterine suspension to provide a lasting cure for uterovaginal prolapse. *Br J Obstet Gynaecol* 1994;101:707-8.
22. Maher CF, Carey MP, Murray CJ. Laparoscopic suture hysteropexy for uterine prolapse. *Obstet Gynecol* 2001;97:1010-4.
23. Gutman RE, Rardin CR, Sokol ER, Matthews C, Park AJ, Iglesia CB, et al. Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study. *Am J Obstet Gynecol* 2017;216:38.e1-38.e11.
24. Gutman RE. Does the uterus need to be removed to correct uterovaginal prolapse? *Curr Opin Obstet Gynecol* 2016;28:435-40.
25. Pan K, Cao L, Ryan NA, Wang Y, Xu H. Laparoscopic sacral hysteropexy versus laparoscopic sacrocolpopexy with hysterectomy for pelvic organ prolapse. *Int Urogynecol J* 2016;27:93-101.
26. Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Brown J. Surgery for women with apical vaginal prolapse. *Cochrane Database Syst Rev* 2016;10:CD012376.
27. Gutman RE, Rardin CR, Sokol ER, Matthews C, Park AJ, Iglesia CB, et al. Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study. *Am J Obstet Gynecol* 2017;216:38.e1-38.e11.
28. Bai SW, Jeon MJ, Kim JY, Chung KA, Kim SK, Park KH. Relationship between stress urinary incontinence and pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct* 2002;13:256-60.



# Isolated tubal torsion: Successful preoperative diagnosis of five cases using ultrasound and management with laparoscopy

## *İzole tubal torsiyon: Beş olgunun ultrasonografi ile başarılı preoperatif tanısı ve laparoskopi ile yönetimi*

Erdem Fadiloğlu<sup>1</sup>, Rıza Dur<sup>1</sup>, Erhan Demirdağ<sup>1</sup>, Çağatayhan Öztürk<sup>1</sup>, Şeyma Fadiloğlu<sup>2</sup>, Metin Kaplan<sup>1</sup>, Ömer Lütfi Tapısız<sup>1</sup>

<sup>1</sup>University of Health Sciences, Ankara Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

<sup>2</sup>Ankara Numune Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

### Abstract

Our aim was to evaluate the presentation and diagnostic evaluation of patients with isolated tubal torsion and to evaluate the surgical approach to these patients. We also aimed to define the ultrasonographic diagnostic criteria. Five patients with isolated tubal torsion who were admitted to our gynecology department between January 2014 and January 2017 were evaluated and included in this study. All cases were diagnosed through ultrasonographic imaging alone. The preoperative findings of the patients were similar to those described in the literature. No further imaging modality was used for diagnosis and all patients were managed with laparoscopy. The clinical findings and ultrasonographic findings were consistent with literature. It may be difficult to preoperatively diagnose isolated tubal torsion, which is a rare clinical entity. Evaluation of these patients by an experienced sonographer and knowledge of the ultrasonographic findings of isolated tubal torsion may have vital preventive measures.

**Keywords:** Isolated tubal torsion, ultrasonography, whirlpool sign, case series

### Öz

İzole tubal torsiyon tanısı alan hastaların klinik prezentasyonunu, preoperatif değerlendirmesini ve bu hastalara olan cerrahi yaklaşımı değerlendirmeyi amaçladık. Ayrıca bu hastaların tanısında kullanılan ultrasonografik tanısal kriterleri değerlendirmeyi amaçladık. Ocak 2014-Ocak 2017 tarihleri arasında hastanemiz jinekoloji kliniğine başvuran ve izole tubal torsiyon tanısı alan beş hasta çalışmamız kapsamında değerlendirilmiştir. Preopatif olarak yalnızca ultrasonografi kullanarak tanı almıştır. Hastaların preoperatif bulguları literatürde tarif edilen bulgularla benzerlik göstermektedir. Bu hastaların değerlendirilmesinde başka bir görüntüleme yöntemine ihtiyaç duyulmamış ve tüm hastalar laparoskopi ile yönetilmiştir. Klinik bulgular ve ultrasonografik bulgular ise literatürde sunulan bulgularla tutarlıdır ve ultrasonografik bulgular detaylı olarak sunulmuştur. Nadir bir klinik tablo olan izole tubal torsiyonun preoperatif doğru tanı alması zor olabilir. Bu hastaların tecrübeli bir sonografist tarafından değerlendirilmesi ve izole tubal torsiyona ait ultrasonografik bulguların bilinmesi hayati öneme sahip olabilmektedir.

**Anahtar Kelimeler:** İzole tubal torsiyon, ultrasonografi, burgaç bulgusu, olgu serisi

Address for Correspondence/Yazışma Adresi: Erdem Fadiloğlu, MD,

University of Health Sciences, Ankara Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Phone: +90 546 475 01 75 E-mail: fadilogluerdem@gmail.com ORCID ID: orcid.org/0000-0001-7953-2517

Received/Geliş Tarihi: 08.04.2017 Accepted/Kabul Tarihi: 13.06.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

## Introduction

Isolated tubal torsion is a very rare entity, reported as 1 in 1.5 million women<sup>(1)</sup>. It is a challenging preoperative differential diagnosis because of its non-specific clinical findings such as lower abdominal pain, nausea, vomiting and fever, and should be kept in mind while approaching patients with abdominal pain<sup>(2)</sup>. This report presents five cases of isolated tubal torsion and their successful preoperative diagnosis using ultrasonography (USG) imaging and management with a laparoscopic approach at a tertiary health center within 2 years, and an evaluation of literature findings.

## Case Report


Patients diagnosed as having isolated tubal torsion between January 2014 and January 2017 were included in this presentation after acquiring informed consent from all patients. Five patients with lower abdominal pain at different intensities were diagnosed as having tubal torsion using USG imaging. All five patients had significant acute lower abdominal pain. The patients described a sudden onset of symptoms, and four patients had slightly increased white blood cell counts (WBC). Only case 5 had a normal WBC count. Three of five patients had nausea and vomiting as other symptoms. The decision was made for all patients to undergo surgery with a preoperative diagnosis of tubal torsion with or without coexisting adnexal masses. No other imaging modality beyond USG was used for the preoperative diagnosis. All diagnoses were confirmed under laparoscopy, but coexisting risk factors were misdiagnosed in case 1 and 2, as listed at Table 1. Four of the five patients were managed with salpingectomy, and detorsion was performed in only one patient who desired future fertility. None of the patients had postoperative complications and all were discharged within 48 hours. The important feature of these five patients was the correct preoperative diagnosis acquired using just USG, which was confirmed during the operation, and also through postoperative pathologic examination of specimens.

## Discussion


The potential risk factors for isolated tubal torsion are tubal pathologies such as hydrosalpinx, paratubal cysts or ovarian masses, and altered tubal function. However, normal tubal appearance was mostly found in cases of isolated tubal

torsion<sup>(3)</sup>. One of our five cases had normal tubal structure, two had paratubal cysts, and one had hydrosalpinx, consistent with the literature.

The USG features of tubal torsion may vary widely. Preoperative suspicion may rise with an image of elongated, convoluted cystic mass, tapering as it nears the uterine cornua<sup>(4)</sup>. An increased



**Figure 1.** \*"Whirlpool" sign, \*\*hydrosalpinx at the distal side of tubal torsion, #ovarian tissue



**Figure 2.** Ongoing circulation within the "whirlpool" sign showing circular pattern


**Table 1.** Summary of five cases with preoperative diagnosis and postoperative pathologic results

	Age (years)	Preoperative diagnosis	Surgery	Pathology result
Case 1	38	Tubal torsion + hydrosalpinx	Laparoscopic detorsion + paratubal cyst excision	Benign serous cyst
Case 2	49	Tubal torsion + paratubal cyst	Laparoscopic salpingectomy	Hydrosalpinx
Case 3	30	Tubal torsion	Laparoscopic salpingectomy	Dilated fallopian tube
Case 4	32	Tubal torsion + paratubal cyst	Laparoscopic salpingectomy	Paratubal benign cyst
Case 5	28	Tubal torsion + paratubal cyst	Laparoscopic salpingectomy	Hematosalpinx + paratubal benign cyst



resistance index due to decreased blood flow determined using Doppler USG may also strengthen the suspicion of torsion<sup>(5)</sup>. Nevertheless, abnormal Doppler findings are not a necessity for the diagnosis of torsion. Identifying a normal ipsilateral ovary may strongly suggest tubal torsion.

As in other torsion cases, a systematic evaluation of the adnexal areas is needed in order to be able to identify isolated tubal torsion cases with USG. A systematic evaluation of symptomatic patients should always include evaluation of tubal segments. In the correct evaluation of the adnexal area, the starting point should be the interstitial tubal segment, which is the starting point of the adnexa, and from here onwards, the entire tuba continues to medial to the fimbrial tip. Neighboring structures should also be evaluated at the same sections. The interstitial and trunk part of the uterine tube, the proper ovary ligament (ligamentum ovarii proprium) and the round ligament are located in the cornual area near the uterus. Over-torsions in this region are mostly around the



**Figure 3.** Isolated tubal torsion captured during laparoscopy without any other adnexal pathologies (case 3)



**Figure 4.** Isolated tubal torsion with concurrent paratubal cyst (case 5)

proprium ligament axis, and tubal torsion mostly occurs by rotating around its own axis.

In isolated tubal torsion cases, torsional twist is directly observed on USG imaging (Figure 1). This finding must be seen and seen absolutely for the exact diagnosis of any kind of torsion in all cases. This finding is enough for the diagnosis of torsion because it is the physical image of torsion. Due to circulation problems, the tuba seems edematous and swollen and it is easily distinguishable from the overdose around the hypoechoic irregular soft tissue mass formed by the adnexal inferior tubal edema. When the “whirlpool” finding is evaluated with power Doppler, the venous circulation may be observed in a circular pattern (Figure 2). However, with the deterioration of the arterial circulation by the progress of the tubal torsion, this Doppler “whirlpool” image may disappear, but the sonographic image sign of turning around the axis remains. As the event progresses, the walls of the tuba become thicker with the edema and findings of hydrosalpinx and hematosalpinx in the lumen of the tuba begin to show themselves. Tubal torsion of this size may ultimately be regarded as ovarian torsion because the hematosalpinx is very enlarged and it is difficult to monitor the ovary when it starts to form incomplete septations.

The progression of torsion causes hematosalpinx, tubal rupture, and peritubal hematomas, which become more complicated and harder to diagnose. If the heterogeneous mass forming in the adnexal area is not carefully evaluated, it can easily be confused with a ruptured ectopic pregnancy.

The primary approach to tubal and ovarian torsion should be laparoscopy and recommended as primary approach<sup>(2)</sup>. Torsions are mostly treated with this approach owing to the advanced accessibility with laparoscopy. We prefer the laparoscopic approach for both ovarian and tubal torsions, as in these 4 cases, which were successfully managed using laparoscopy (Figure 3, 4).

In conclusion, tubal torsion is an emergency condition and a correct preoperative diagnosis should be acquired immediately. Ultrasound criteria for tubal torsion diagnosis require careful evaluation, thus it should only be performed by an experienced practitioner, and laparoscopy should be the primary choice of treatment.

### Literature review

Isolated tubal torsion is a very rare clinical entity. Correct diagnosis requires great caution and experience because of its rarity and non-specific symptoms. The most common symptoms were listed as abdominal pain, vomiting, and fever in pediatric case series<sup>(6)</sup>. Also, bowel and bladder problems, lower abdominal mass diagnosed during examination, and elevated WBCs may be other symptoms<sup>(7)</sup>. The etiology remains unclear, but anatomic changes, positional changes, trauma, previous surgeries or gravid uterus are listed as potential risk factors<sup>(8)</sup>. There is also a higher probability for right tubal torsion than left due to the position of the sigmoid colon and

slow venous drainage of the right tuba<sup>(9)</sup>. Paratubal or adherent cysts may also play an important role in the etiology according to literature and our findings<sup>(10)</sup>. This situation may be seen in pregnant patients; isolated tubal torsion should be considered as a diagnosis because of difficulties in imaging<sup>(11)</sup>. Magnetic resonance imaging (MRI) may be used with clinical suspicion both in pregnant and non-pregnant patients for differential diagnosis<sup>(9,12)</sup>. MRI may also show the “whirlpool” sign, which is the image of physical torsion of tubas<sup>(13)</sup>.

Diagnosing torsion correctly using USG is also challenging, but very important because of its speed and easy accessibility. Ultrasonographic findings listed in the literature are mostly the same as the criteria used at our clinic. MRI or computed tomography scans may play role in diagnosis, but have disadvantages such as cost, radiation exposure, and potential hazards during pregnancy<sup>(14)</sup>. Prompt diagnosis is also very important due to the possible results of delay such as necrosis<sup>(15)</sup>. Management of tubal torsion mostly requires surgical intervention. Salpingectomy may be performed if there is no further desire for fertility, but the proper approach should be detorsion of tuba for preserving fertility<sup>(14)</sup>. Urgent intervention should be performed in symptomatic patients and rare results of chronic tubal torsion such as tubal autoamputation should be known<sup>(16)</sup>.

Isolated tubal torsion is a very rare entity and may be misdiagnosed due to its non-specific symptoms. All physicians must know the diagnostic criteria for prompt diagnosis and a proper evaluations should always include the adnexal area and tubas. A systematic approach to the adnexal area as mentioned may diagnose most tubal torsion cases. After proper preoperative diagnosis, tubal torsions may be managed via laparoscopy. In conclusion, the most important point in managing these patients is a correct and rapid diagnosis.

## Ethics

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: R.D., M.K., Concept: E.D., Ç.Ö., Design: R.D., Ö.L.T., Data Collection or Processing: E.F., E.D., Analysis or Interpretation: E.D., Ç.Ö., Literature Search: E.F., Ş.F., Writing: E.F., Ş.F.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Ferrera PC, Kass LE, Verdile VP. Torsion of the fallopian tube. *Am J Emerg Med* 1995;13:312-4.
2. Krissi H, Shalev J, Bar-Hava I, Langer R, Herman A, Kaplan B. Fallopian tube torsion: laparoscopic evaluation and treatment of a rare gynecological entity. *J Am Board Fam Pract* 2001;14:274-7.
3. Regad J. Etude anatomo-pathologique de la torsion des trompettes uterines. *Gynecol Obstet* 1933;27:519.
4. Harmon JC, Binkovitz LA, Binkovitz LE. Isolated fallopian tube torsion: sonographic and CT features. *Pediatr Radiol* 2008;38:175-9.
5. Andreotti RF, Harvey SM. Sonographic evaluation of acute pelvic pain. *J Ultrasound Med* 2012;31:1713-8.
6. Schuh AM, Klein EJ, Allred RJ, Christensen A, Brown JC. Pediatric Adnexal Torsion: Not Just a Postmenarchal Problem. *J Emerg Med* 2017;52:169-75.
7. Varghese U, Fajardo A, Gomathinayagam T. Isolated fallopian tube torsion with pregnancy- a case report. *Oman Med J* 2009;24:128-30.
8. Renjit S, Morale EU, Mathew M. Isolated torsion of a tubal ectopic pregnancy- a rare event. *Oman Med J* 2008;23:289-90.
9. Erdemoglu M, Kuyumcuoglu U, Kale A. Pregnancy and adnexal torsion: Analysis of 20 cases. *Clin Exp Obstet Gynecol* 2010;37:224-5.
10. Pansky M, Smorgick N, Lotan G, Herman A, Schneider D, Halperin R. Adnexal torsion involving hydatids of Morgagni: a rare cause of acute abdominal pain in adolescents. *Obstet Gynecol* 2006;108:100-2.
11. Ten Cate A, Han S, Vliegen AS, Lewi L, Verhaeghe J, Claus F. Conservative surgery for left-sided isolated tubal torsion in pregnancy. *JBR-BTR* 2011;94:212-3.
12. Sun Y, Liu L, Di J. Isolated tubal torsion in the third trimester of pregnancy: A case report and review of the literature. *J Res Med Sci* 2014;19:1106-9.
13. Aydin R, Bildircin D, Polat AV. Isolated torsion of the fallopian tube with hydrosalpinx mimicking a multiloculated ovarian cyst: whirlpool sign on preoperative sonography and MRI. *J Clin Ultrasound* 2014;42:45-8.
14. Mueller C, Tomita S. Fallopian Tube Torsion as a Cause of Acute Pelvic Pain in Adolescent Females. *Case Rep Pediatr* 2016;2016:8707386.
15. Boukaidi SA, Delotte J, Steyaert H, Valla JS, Sattonet C, Bouaziz J, et al. Thirteen cases of isolated tubal torsions associated with hydrosalpinx in children and adolescents, proposal for conservative management: retrospective review and literature survey. *J Pediatr Surg* 2011;46:1425-31.
16. Sankaran S, Shahid A, Odejinmi F. Autoamputation of the fallopian tube after chronic adnexal torsion. *J Minim Invasive Gynecol* 2009;16:219-21.





# Laparoscopic repair of ureter damaged during laparoscopic hysterectomy: Presentation of two cases

## Laparoskopik histerektomide yaralanan üreterin laparoskopik tamiri: İki olgunun sunumu

Murat Api<sup>1</sup>, Ayşen Boza<sup>2</sup>, Semra Kayataş<sup>3</sup>, Barış Boza<sup>3</sup>

<sup>1</sup>Istanbul Medipol University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul, Turkey

<sup>2</sup>Vehbi Koç Foundation American Hospital, Women's Health Center Assisted Reproduction Unit, Istanbul, Turkey

<sup>3</sup>University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Istanbul, Turkey

### Abstract

Ureter injuries are uncommon but dreaded complications in gynecologic surgery and a frequent cause of conversion to laparotomy. Recently, a few papers reported the repair of gynecologic ureteral injuries using laparoscopy with encouraging results. In these case reports, we aimed to present two laparoscopically repaired ureter injuries during total laparoscopic hysterectomies (TLH). In the first case, the ureter was transected during the dissection of the cardinal ligament, approximately 7 to 8 cm distal to the ureterovesical junction (UVJ), and in the second case, it was damaged approximately 10 cm distal to the UVJ. Both transections were identified during surgery. The injured ureter was repaired without converting to laparotomy or additional trocar insertion. Ureteroureterostomy was performed in both cases uneventfully. Although ureteric injury is a rare complication during TLH, it can be managed by the same surgeon laparoscopically during the same procedure.

**Keywords:** Ureter, injury, complication, laparoscopy

### Öz

Üreter hasarı, jinekolojik cerrahilerde nadir görülen ancak korkulan bir komplikasyondur ve tamiri için sıklıkla laparotomiye ihtiyaç duyulur. Yakın zamanda, jinekolojik üreter hasarının laparoskopik tamiri ile ilgili cesaretlendirici birkaç makale yayınlanmıştır. Amacımız total laparoskopik histerektomide (TLH) hasarlanan ve laparoskopik olarak başarılı bir şekilde tamir edilen iki olguyu sunmaktır. İlk olguda, sağ kardinal ligament (KL) hizasına kadar sorunsuz devam eden operasyonda, KL diseksiyonu sırasında üreterovezikal bileşkenin (UVB) 7-8 cm distalinde üreter hasarı oluştu. İkinci olguda, UVB'nin yaklaşık 10 cm distalinden üreter hasarlandı. Her iki üreter hasarı da cerrahi sırasında fark edildi. Hasarlanan üreterler laparotomiye dönmeden ve ek trokar girişi yapılmadan sorunsuz bir şekilde onarıldı. Her iki olguda da mid-üretral hasar olduğundan üreteroureterostomi tercih edildi. Üreter hasarı her ne kadar TLH sırasında nadir gelişen bir komplikasyon olsa da, eğer mümkünse, laparoskopik sütür ve düğüm teknikleri konusunda deneyimli bir jinekolog veya ürolog tarafından, laparoskopik olarak tamir edilmelidir.


**Anahtar Kelimeler:** Üreter, yaralanma, komplikasyon, laparoskopi

## Introduction

Urologic complications during gynecologic surgery are uncommon but dreadful. The reported incidence of ureteral injury related to gynecologic surgery varies between 2.5% and 12.1%<sup>(1)</sup>. Pelvic ureters are retroperitoneal structures that run from the renal pelvis to the bladder that can be injured during pelvic surgery at any point along their distal course. However, the approach of hysterectomy plays a role in the variation of incidence in total laparoscopic hysterectomies (LHs) (TLHs) compared with the abdominal and vaginal approach; the reported odds ratio for urinary tract injuries was 2.41 and 3.69, respectively<sup>(2)</sup>. Although the risk of ureter injury significantly decreases with the increasing experience of surgeons, ureter injuries also occur in the hands of experienced gynecologists because the indication for TLH is expanding and the difficulty of the operation is increasing. The question is whether complications of laparoscopic procedures such as ureteral injury could be managed successfully and effectively without converting to laparotomy. We report successful immediate primary laparoscopic repair of two cases of ureter transection during TLH and discuss possible causes that lead to ureter injury and make recommendations for prevention.

## Case Report

A patient aged 48 years underwent TLH and bilateral salpingo-oophorectomy (BSO) due to abnormal uterine bleeding that was unresponsive to medical therapy. She had no previous history of abdominal surgery or any kind of disease causing pelvic adhesions. On exploration, the uterus was of 8 weeks' pregnancy in size, the bilateral adnexa were normal, and no pelvic adhesions or distortion of anatomy was observed. A four-trocar technique (out of main trocar, two at the left side and one at the right side) and Hohl manipulator (manufactured by Karl Storz, Germany) was used. The TLH was uneventful until the area of the cardinal ligaments (CLs). The ureter was transected with the Ligasure™ (Valleylab, Boulder, CO, USA) during the dissection of the right CL, 7 to 8 cm distant from the ureterovesical junction (UVJ) (Figure 1a). The transection was identified during the dissection and immediate repair was performed peroperatively without converting to laparotomy. The proximal and distal ureteral segments were identified, then sutured at the 6 o'clock position for approximation (Figure 1b). A double J ureteral stent was taken to the abdomen through the 5-mm lateral trocar and inserted in the ureter (Figure 1c). After the stent application, 3/0 Vicryl sutures were placed at the 9, 12, and 3 o'clock positions (Figure 1d). A Foley catheter



**Figure 1.** The surgical technique of laparoscopic ureter injury is shown. The transected edges of the ureter at the area of cardinal ligament are seen (a). First, the proximal and distal ureter edges are sutured at the 6 o'clock position (b), then the ureteral stent is inserted in the ureter (c) and the anastomosis is completed using sutures placed at the 9, 12 and 3 o'clock positions (d)

remained in the bladder and a drainage tube in the abdomen to prevent possible urinoma formation and to control bleeding. In the second case, a woman aged 59 years underwent TLH and BSO due to simple endometrial hyperplasia with atypia. TLH, BSO, and frozen pathology were planned with the suspicion of malignancy. Laparoscopy was performed using the same technique as in the first case. Frozen section was reported in favor of benign pathology. During the dissection of the left CL, the ureter was damaged approximately 10 cm distant from UVJ with the Halo™ bipolar cutting forceps (Gyrus ACMI, Olympus) (Figure 2). The injured ureter was noticed during the dissection and repaired without converting to laparotomy or additional trocar insertion, similar to the first case. The duration of the ureteral repairs from the time of the injury to the end of the last anastomosis suture were 55 and 40 minutes for the first and second cases, respectively. Estimated blood loss during the ureteral repairs was negligible. The vesical catheters were withdrawn on 7 days postoperatively and the ureteral stents were removed cystoscopically on the 21<sup>st</sup> day. We did not use prophylactic antibiotics due to prolonged catheterization. Patients were closely monitored after discharge weekly for the first three weeks, then monthly up to 10-12 months using serial urinary system ultrasonography. Neither patient had any pelvicalyceal ectasia or visible ureters. The patients' recoveries were uneventful with normal kidney and urinary function. Written informed consent was obtained by both patients.

## Discussion

Ureter injuries can result from pelvic dissection or due to thermal injury by excessive use of energy adjacent to the ureter. In a retrospective review of 165 patients with iatrogenic ureteral injuries over a 20-year span, endourologic procedures


were responsible for most iatrogenic injuries with 42%, and gynecologic and general surgery procedures were 34% and 24%, respectively<sup>(3)</sup>. Urinary tract injuries during LH are reported to be more frequent than in abdominal or vaginal hysterectomies. The higher risk in LH compared with the abdominal approach is due to the use of electrocoagulation of uterine vessels during laparoscopic procedures<sup>(4)</sup>. Extensive electrocoagulation of uterine vessels and CLs near the ureter increases the risk of ureter injuries.

Intraoperative detection of ureter injuries has been reported in only 5-13% of cases<sup>(3,4)</sup>. Among the acute injuries of the urinary tract, ureter injuries are most difficult to recognize as there often may be few or with no symptoms<sup>(1)</sup>. Intraoperative iatrogenic ureteral injuries, if recognized during the procedure, should be repaired at that setting<sup>(5)</sup>. In our cases, the transected edges of the ureter were seen without any urine leakage during the dissection of the CLs.

Approximately 90% of the trauma to the ureter occurs in the lower portion, which extends from the inferior border of the sacroiliac joint to the UVJ<sup>(6)</sup>. Transection injuries are repaired depending on the severity of the injury and approximation to the UVJ. If the ureteral injury is more than 6 cm distant from the UVJ, a primary ureteral anastomosis is performed. Primary ureteroureterostomy is the optimal technique when the anastomosis can be performed without tension and if the initial approach was laparoscopic<sup>(7)</sup>. Laparoscopic ureteroureterostomy was preferred in our cases because the mid-ureter was transected approximately 8 cm and 10 cm distant from the UVJ, respectively.

Laparoscopic ureteral repair is technically feasible and an alternative to open repair for immediate, early, and delayed diagnosis of ureteral injury. In the literature, although long-term outcome of laparoscopic repair is limited to small series and case reports, the results are excellent if the diagnosis and repair is performed at the time of injury<sup>(8)</sup>. A delay in diagnosis worsens prognosis because of infection, hydronephrosis, abscess, and fistula formation. No postoperative complication occurred in our cases, the patients have continued their lives with normal kidney function and no urinary incontinence for 10 and 12 months follow-up, respectively.

Recommended techniques for reducing the risk of urinary tract injuries were agreed upon by experts in a Delphi consensus procedure: routine use of uterine manipulator, coagulation of uterine vessels close to the uterus with a perpendicular approach from the ipsilateral side, and visualization or dissection of the ureter in the case of distorted anatomy<sup>(9)</sup>. Intraoperative routine use of cystoscopy was proposed to assess the ureter flow as a part of all TLHs. Cystoscopy during TLH is well tolerated and can reassure surgeons of immediate urinary tract injuries; however, it is an additional time-consuming procedure that is not required in most patients. Cystoscopy during TLHs was postulated to be cost effective if the rate of ureter injury exceeded 2%<sup>(10)</sup>.



**Figure 2.** The transected edges of the ureter at the level of left cardinal ligament were seen

Urt: Ureter, Bl: Bladder

In the case of ureteral injury during laparoscopic gynecologic surgery, either a gynecologist or urologist who is experienced in suturing and knot-tying techniques can successfully perform a primary laparoscopic repair of the ureter. Visualization of the course of ureters at the beginning or end of the operation may prevent complications of the urinary tract and possible delayed diagnosis of ureteral injuries.

### Ethics

**Informed Consent:** Written informed consents were obtained from the patients for publication of these case reports and accompanying images.

**Peer-review:** External and internal peer-reviewed.

### Authorship Contributions

Surgical and Medical Practices: M.A., A.B., Concept: M.A., A.B., Design: M.A., A.B., Data Collection or Processing: B.B., Analysis or Interpretation: M.A., A.B., B.B., Literature Search: B.B., S.K., Writing: M.A., A.B., B.B., S.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Teeluckdharry B, Gilmour D, Flowerdew G. Urinary Tract Injury at Benign Gynecologic Surgery and the Role of Cystoscopy: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2015;126:1161-9.
2. Nieboer TE, Johnson N, Lethaby A, Tavender E, Curr E, Garry R, et al. Surgical approach to hysterectomy for benign gynaecological disease. *Cochrane Database Syst Rev* 2009;CD003677.
3. Delacroix SE Jr, Winters JC. Urinary tract injuries: recognition and management. *Clin Colon Rectal Surg* 2010;23:104-12.
4. Donnez O, Jadoul P, Squifflet J, Donnez J. A series of 3190 laparoscopic hysterectomies for benign disease from 1990 to 2006: evaluation of complications compared with vaginal and abdominal procedures. *BJOG* 2009;116:492-500.
5. Redan JA, McCarus SD. Protect the ureters. *JSL* 2009;13:139-41.
6. Brummer TH, Jalkanen J, Fraser J, Heikkinen AM, Kauko M, Makinen J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. *Hum Reprod* 2011;26:1741-51.
7. McAninch Jack W. Injuries to the Genitourinary Tract, Injuries to the Ureter. In: Tanagho EA, McAninch JW, editors. *Smith's General Urology*, 17th Ed, United States of America (USA): Mc Garw Hill Companies; 2011. p. 291-311.
8. Brandes S, Coburn M, Armenakas N, McAninch J. Diagnosis and management of ureteric injury: an evidence-based analysis. *BJU Int* 2004;94:277-89.
9. Janssen PF, Brolmann HAM, Huirne JAF. Recommendations to prevent urinary tract injuries during laparoscopic hysterectomy: a systematic Delphi procedure among experts. *J Minim Invasive Gynecol* 2011;18:314-32.
10. Visco AG, Taber KH, Weidner AC, Barber MD, Myers ER. Cost-effectiveness of universal cystoscopy to identify ureteral injury at hysterectomy. *Obstet Gynecol* 2001;685-92.





# Ovarian metastasis of Müllerian adenocarcinoma of the cervix with sarcomatous overgrowth

## Serviksin sarkomatöz gelişim gösteren Müllerian adenosarkomunda over metastazı

Meral Koyuncuoğlu<sup>1</sup>, Bahadır Saatli<sup>2</sup>, Nuri Yıldırım<sup>3</sup>

<sup>1</sup>Dokuz Eylül University Faculty of Medicine, Department of Pathology, İzmir, Turkey

<sup>2</sup>Dokuz Eylül University Faculty of Medicine, Department of Obstetrics and Gynecology, İzmir, Turkey

<sup>3</sup>Ege University Faculty of Medicine, Department of Obstetrics and Gynecology, İzmir, Turkey

### Abstract

The aim of this study is to present a rare case of Müllerian adenocarcinoma of the cervix with ovarian metastasis and sarcomatous overgrowth. A gravida 2, para 2 woman aged 32 years with vaginal bleeding was admitted to the gynecology department. A 3-4 cm polypoid mass protruding from the cervix was detected in a pelvic examination. Total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed because of metastatic implants on the right ovary. The pathologic evaluation revealed Müllerian adenocarcinoma of the cervix with sarcomatous overgrowth and ovarian metastasis. After surgery, the patient was planned to undergo chemo- and radiotherapy. This is the first cervical Müllerian adenocarcinoma case mentioned in the literature with metastasis to the ovary in a young woman. There is no optimal management option for cervical adenocarcinomas due to the rarity of this phenomenon. Nevertheless, even if the patient is young and imaging techniques do not elucidate metastatic disease, surgeons should evaluate the ovaries for the spread of tumor, especially if histology reveals sarcomatous overgrowth.

**Keywords:** Cervix, Müllerian adenocarcinoma, ovarian metastasis

### Öz

Bu çalışmanın amacı, nadir görülen ve over metastazı ile birlikte olan sarkomatöz gelişim gösteren serviks adenosarkom olgusunu sunmaktır. Otuz iki yaşında gravida 2, para 2 olan olgu, vajinal kanama yakınması ile jinekoloji bölümüne başvurmuştur. Pelvik bakıda, serviksten vajene protrüde olmuş 3-4 cm polipoid yapıda kitle izlenmiştir. Total abdominal histerektomi ve over üzerindeki metastatik odaklar nedeniyle de bilateral salpingo-ooferektomi uygulanmıştır. Patolojik değerlendirme, over metastazının eşlik ettiği serviksin sarkomatöz gelişim gösteren Müllerian adenosarkomu olarak raporlanmıştır. Operasyon sonrası hastaya kemoterapi ve radyoterapi planlanmıştır. Bu olgu, literatürde genç hastada overe metastaz yaptığı gösterilmiş ilk serviksin Müllerian adenosarkom olgusudur. Olgunun nadir görülmesinden dolayı, uygun tedavi yaklaşımı ile ilgili yeterli bilgi yoktur. Ancak olgu genç ve görüntüleme yöntemlerinin sonucunda overlerin normal dahi olduğu belirtilsin, sarkomatöz gelişim gösterdiği bildirilen olgularda, cerrah over metastazı riskini göz önünde bulundurmalıdır.

**Anahtar Kelimeler:** Serviks, Müllerian adenosarkom, over metastazı

Address for Correspondence/Yazışma Adresi: Nuri Yıldırım, MD, PhD,

Ege University Faculty of Medicine, Department of Obstetrics and Gynecology, İzmir, Turkey

Phone: +90 232 390 17 00 E-mail: nuri-yildirim@hotmail.com ORCID ID: orcid.org/0000-0002-0605-4750

Received/Geliş Tarihi: 17.04.2017 Accepted/Kabul Tarihi: 27.07.2017

Presented in: 25<sup>th</sup> European Congress of Pathology on 31 August-4 September 2013 in Lisbon, Portugal.

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.



## Introduction

Müllerian adenosarcoma (MA) is relatively a rare type of mixed epithelial and mesenchymal tumor of the uterus. It is usually composed of a benign epithelial component and a low-grade stromal-sarcomatous component. Occasionally, the epithelial component may be atypical and sarcomatous overgrowth may be seen in the stromal component<sup>(1-3)</sup>. MA mostly occurs in the uterus but also in extra-uterine sites, particularly in the ovary.

The tumors generally originate from the uterine corpus/endometrium, and less frequently from the uterine cervix. Adenosarcoma usually presents with abnormal vaginal bleeding. If the tumor originates from the cervix, the tumor is commonly seen as a polypoid tissue protruding from the external cervical ostium like a cervical polyp on gross evaluation<sup>(3,4)</sup>. Cervical adenosarcoma, especially with sarcomatous overgrowth, is extremely rare. Distant metastasis is also extremely rare because the epithelial component is usually benign and the stromal component is generally low-grade<sup>(1)</sup>. In this report, we present a MA originating from the endocervical canal with sarcomatous overgrowth including heterologous elements and ovarian metastasis in a young woman.


## Case Report

A gravida 2, para 2 woman aged 32 years with vaginal bleeding was admitted to the gynecology department. She reported having abnormal vaginal bleeding for a couple of years and a benign endometrial biopsy in another gynecology center 6 months ago. The pelvic examination revealed a 3-4 cm polypoid mass protruding from the cervix to the vagina. The uterus and the ovaries were normal in size. Transvaginal sonography revealed an irregular-shaped polypoid structure lying from the internal cervical ostium level to the vagina whose thickness was 16 mm. Magnetic resonance imaging (MRI) revealed a lesion starting from the endocervical canal lying to the vagina and there were no pathologic lymph nodes. Her serum CA125 and CA19-9 levels were within normal limits. A biopsy from the polypoid lesion revealed MA with sarcomatous overgrowth.


During surgery, metastatic implants were observed over the right ovary and the left ovary was solid in appearance. The outer surface of the uterus was normal. Total abdominal hysterectomy and bilateral salpingoopherectomy was performed. Three polyps were seen in the endocervical canal, which measured between 0.6x0.5x0.3 and 2x0.8x0.5 cm. The cut surfaces of the polyps were solid and grey-white in appearance. Hemorrhage was seen because of previous biopsy. The tumor had invaded the outer half of the myometrium macroscopically (Figure 1a, 1b).

The final report confirmed that the tumor originated from the endocervical canal. It invaded the lower uterine segment and the myometrium, less than the outer half, and consisted of elongated spindle cells with a myxoid background and few benign glandular formations. The sarcomatous stroma made up 80% of the tumor. In these areas, paucicellular and

hypercellular morphology with myxoid stroma were seen. Low-grade and high-grade stromal components were mixed. Mitotic activity was 4 per 10 high-power fields (HPFs) and 2 per 10 HPFs in paucicellular and hypercellular areas, respectively. Immunohistochemistry showed positive immunoreactivity with vimentin and desmin, and negative immunoreactivity to actin, s-100, and CD99. The glandular epithelium was primarily of endocervical type without atypia and mitotic activity. Large foci of benign cartilage were seen in the sarcomatous areas (Figure 1c, 1d, 1e). There was no endometrial involvement (Figure 1f). The tumor invaded the ovaries and there were no lymphovascular space invasion. The ovarian metastasis showed the same morphology (Figure 2). Intraoperative peritoneal lavage cytology was positive for malignant cells. The patient was discussed in the gynecologic oncology board and at the present time she has been taking a chemotherapy regimen of ifosfamide and doxorubicin. Then she is planned to have both pelvic and vault radiotherapy.



**Figure 1.** The tumor was seen as polyps (a) and invaded the outer third of the myometrium macroscopically (b). The tumor originated from the cervix, and sarcomatous component was over 25% (c, d). Large foci of benign cartilage (inset) were seen as heterologous element (e). The non-tumoral endometrium was seen (f)



**Figure 2.** The ovarian metastasis showed sarcomatous component with myxoid background and foci of benign cartilage

## Discussion

MA is an infrequent type of sarcoma of the female genital system. It mostly comprises a low-grade malignant stromal component and benign epithelial component. It commonly arises from the uterine corpus/endometrium. Cervical adenosarcoma is seen in 2-9% of all MAs<sup>(5-8)</sup>. The age at clinical presentation in cervical adenosarcoma is lower than that with uterine corpus, which is about 27 years<sup>(3-6)</sup>. This is concordant with our patient whose age was 32 years. Chin et al.<sup>(9)</sup> also showed that 89% of patients were premenopausal. The most frequent symptom is abnormal vaginal bleeding, as in our case<sup>(9)</sup>. Generally, the most common finding in physical examination is cervical polypoid lesion protruding from external cervical ostium to the vagina. The diagnosis can be made through biopsy from the lesion.

Sarcomatous overgrowth is defined as overgrowth of the neoplasm by a pure sarcomatous component occupying at least 25% of the lesion<sup>(1)</sup>. This subtype has a more malignant behavior than the classic adenosarcoma<sup>(10)</sup>. The rate of myometrial invasion and extension to the serosal surface, recurrence rate, and death because of tumor progression are all higher in adenosarcomas with sarcomatous overgrowth<sup>(10,11)</sup>.

Heterologous elements are rarely reported, accounting for 8-42% of cervical adenosarcoma<sup>(3-4)</sup>. Mostly, these elements are cartilage or striated muscle. Charfi et al.<sup>(12)</sup> also reported a patient with adenosarcoma of the cervix with sarcomatous overgrowth and heterologous elements that contained cartilage and presented as a recurrent cervical polyp.

Cervical adenosarcomas with sarcomatous overgrowth in young patients are very rare. In particular, ovarian metastasis at the time of diagnosis is almost not mentioned in the literature. A recent study by Tanner et al.<sup>(13)</sup> reported that ovarian metastases were not identified in any patients undergoing bilateral salpingoopherectomy in 16 patients with MA. The present case

is one of the first with cervical adenosarcoma metastases to the ovary.

The optimal therapy and the prognostic factors for these are still unclear because the reports of these cases are insufficient and long-term follow-up data are absent. The extensiveness of surgery may differ from patient to patient. Chin et al.<sup>(9)</sup>, reported 9 cases of cervical adenosarcoma. They performed a cervical wedge resection for a patient who desired to preserve fertility. Hysterectomy, bilateral salpingoopherectomy, and lymphadenectomy were performed for other patients, none of whom had sarcomatous overgrowth. Park et al.<sup>(14)</sup> performed hysterectomy, bilateral salpingoopherectomy, and lymphadenectomy for a 37-year-old woman with adenosarcoma of the cervix with sarcomatous overgrowth. However, there was no tumor in the ovaries and no lymph node metastasis<sup>(14)</sup>. Manoharan et al.<sup>(15)</sup> reported three patients with cervical adenosarcoma. The first one was a 28-year-old woman with sarcomatous overgrowth. She underwent radical hysterectomy with preservation of the ovaries. The histology revealed lymphovascular space and right parametrial invasion, so she had chemotherapy followed by both pelvic radiotherapy and brachytherapy. The second case was a 26-year-old woman who had cervical MA with spindle cell stroma and benign glands. Vaginal hysterectomy with preservation of the ovaries and laparoscopic lymph node dissection was performed. The lymph nodes were free of tumor. She was given adjuvant pelvic radiotherapy because of deep stromal infiltration and high-grade tumor. The third case was a 41-year-old woman who had cervical adenosarcoma with mild-to-moderate stromal cytological atypia and underwent abdominal hysterectomy with preservation of ovaries. She received no adjuvant therapy because the tumor was localized to the polyp. Our patient was also a young woman and we were planning to preserve the ovaries before surgery. However, we came across the metastatic implants on the right ovary intraoperatively. MRI and ultrasonography did not facilitate the management preoperatively.

As previously mentioned, this is a very rare case and there is no consensus on either surgical or adjuvant treatment strategy. The first point that physicians should keep in mind is the number of mitotic figures in the mesenchymal part because the epithelial part is benign. Secondly, sarcomatous overgrowth may determine the behavior of the disease, as it was in our patient. If there is sarcomatous overgrowth, surgeons should carefully evaluate the patient for distant or locoregional spread. As a result, there is no optimal management option for cervical adenosarcomas due to the rarity of this phenomenon. Nevertheless, even if the patient is young and imaging techniques fail to reveal metastatic disease, surgeons should evaluate the ovaries for the spread of tumor, especially if the histology reveals sarcomatous overgrowth.

## Ethics

**Informed Consent:** Consent form was filled out by the patient.

**Peer-review:** Externally peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: M.K., B.S., N.Y., Concept: M.K., N.Y., Design: M.K., B.S., N.Y., Data Collection or Processing: N.Y., Analysis or Interpretation: M.K., B.S., N.Y., Literature Search: N.Y., Writing: M.K., B.S., N.Y.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. *Hum Pathol* 1990;21:363-81.
2. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a gynecologic oncologic group clinicopathologic study of 31 cases. *Int J Gynecol Pathol* 1992;11:75-88.
3. Jones MW, Lefkowitz M. Adenosarcoma of the uterine cervix. A clinicopathological study of 12 cases. *Int J Gynecol Pathol* 1995;14:223-9.
4. Kerner H, Lichtig C. Mullerian adenosarcoma presenting as cervical polyps: a report of seven cases and review of the literature. *Obstet Gynecol* 1993;81:655-9.
5. Ramos P, Ruiz A, Carabias E, Piñero I, Garzon A, Alvarez I. Müllerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature. *Gynecol Oncol* 2002;84:161-6.
6. Patrelli TS, Gizzo S, Di Gangi S, Guidi G, Rondinelli M, Nardelli GB. Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature. *BMC Cancer* 2011;11:236.
7. Duggal R, Nijhawan R, Aggarwal N, Sikka P. Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature. *J Gynecol Oncol* 2010;21:125-8.
8. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C, et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. *Oncol Rep* 1998;5:939-44.
9. Chin PS, Chia YN, Lim YK, Yam KL. Diagnosis and management of Müllerian adenosarcoma of the uterine cervix. *Int J Gynaecol Obstet* 2013;121:229-32.
10. Clement PB. Müllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. *Am J Surg Pathol* 1989;13:28-38.
11. Rovirosa A, Ascaso C, Ordi J, Abellana R, Arenas M, Lejarcegui JA, et al. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. *Int J Radiat Oncol Biol Phys* 2002;52:1320-9.
12. Charfi S, Kallel R, Mnif H, Ellouze S, Dhouib M, Guermazi M, et al. Mullerian adenosarcoma of the cervix with sarcomatous overgrowth and heterologous elements presenting as a recurrent cervical polyp. *Case Rep Obstet Gynecol* 2012;2012:358302.
13. Tanner EJ, Toussaint T, Leitaio MM Jr, Hensley ML, Soslow RA, Gardner GJ, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. *Gynecol Oncol* 2013;129:140-4.
14. Park HM, Park MH, Kim YJ, Chun SH, Ahn JJ, Kim CI, et al. Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature. *Int J Gynecol Cancer* 2004;14:1024-9.
15. Manoharan M, Azmi MA, Soosay G, Mould T, Weekes AR. Mullerian adenosarcoma of uterine cervix: report of three cases and review of literature. *Gynecol Oncol* 2007;105:256-60.